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gC1qR was originally discovered as a C1q receptor specific to the globular head domain of C1q, 
the first subcomponent of the classical pathway of complement activation. During the same 
period, calreticulin (CRT), formerly called as cC1qR, was described as a receptor for the collagen 
region of C1q and collectins. Although much work has been carried out with relation to CRT-
CD91 complex, the biological implications and structure-function studies of C1q-gC1qR 
interaction has not been further explored. With passage of time since 1994, it has become 
evident that gC1qR is also a multi-functional pattern recognition receptor that can recognise 
pathogens in addition to acting as a modulator of inflammation at the site of injury or infection. 
In this thesis, a recombinant form of gC1qR using a T7 promotor expression system was 
expressed and examined for its interaction with individual globular head modules of C1q A, B 
and C chains (ghA, ghB and ghC, respectively). A number of single residue substitution mutants 
of ghA, ghB and ghC modules were also analysed for their interaction with gC1qR in order to 
map complementary binding sites. Concomitant expression of gC1qR and C1q in the adherent 
monocytes with, and without proinflammatory stimuli was analysed by qPCR in order to 
establish autocrine/paracrine basis of C1q-gC1qR interaction. In addition, experiments were 
carried out to examine if C1q-mediated anti-lymphoproliferative effect can be altered by 
gC1qR. Subsequently, using the wild type and mutants of ghA, ghB and ghC modules, the 
interaction of DC-SIGN and SIGN-R, a newly discovered partner of C1q and gC1qR on the 
dendritic cell surface, was examined. Experiments are underway to understand how a 
trimolecular complex involving C1q, gC1qR and DC-SIGN participate during HIV-1 infection. 
Structure-function studies involving gC1qR and HCV core protein and HIV-1 gp41 have also 
been carried out to localise domains of gC1qR responsible for viral pathogenesis. The last 
chapter dwells on a newly discovered ability of gC1qR to upregulate bradykinin 1 receptor on 
the endothelial cell surface, thus its role in altering vascular permeability and the contact 
system. 
The thesis describes (1) localisation of interacting sites between C1q and gC1qR and their 
togetherness in co-expression under pro-inflammatory conditions and possibly suppression of 
v 
 
immune cell proliferative response; (2) localisation of complementary binding sites between 
DC-SIGN, gC1qR and C1q and its possible implications in HIV-1 infection and antigen presenting 
cells such as dendritic cells; (3) localisation of interacting sites between gC1qR and HCV core 
protein as well as HIV-1 gp41 peptides with potential to propose a therapeutic peptide; and (4) 
ability of gC1qR to upregulate bradykinin 1 and 2 receptors on endothelial cells and its newly 
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1.1 Innate and Adaptive Immune system 
The immune system essentially functions to actively remove infectious non-self microbes 
invading the body. The immune system is split into two major components, each with its 
own critical function in response to infection and disease. The first is known as the innate 
immune system which includes sensors to detect the invading pathogen through Pattern 
Recognition Receptors (PRRs) expressed on innate immune cells.  These PRRs recognize 
specific microbial motifs known as pathogen associated molecular patterns (PAMPs). This 
recognition leads to the secretion of various cytokines to bring upon necessary immune 
responses which make up the second component known as the adaptive immune system. 
This system is highly specific and diverse in discriminating between different PAMPs and 
essentially carries out specific antibody and cell mediated responses performed by B cells 
and T cells.  The innate immune system serves as the body’s first line of defence, whereas 
the adaptive system behaves as a secondary response system where it comes into force to 
eliminate pathogens that have overcome initial innate immune responses. Adaptive 
immunity is also ‘adapted’ to respond against previously encountered pathogens due to its 
persistent memory. In spite of these differences, adaptive immunity is bought upon by the 
innate immune response due to a range of cellular and humoral factors. 
1.2 Components of Innate Immune System 
Cells of the innate immune system include leucocytes which are made up of phagocytes and 
lymphocytes. Phagocytic cells are macrophages, neutrophils and dendritic cells (DC). 
Neutrophils circulate the blood stream and arrive at sites of inflammation to encounter 
invading microbes by a process called phagocytosis. This occurs through the plasma 
membrane of the neutrophil extending (known as pseudopodia) around the foreign 
particle to enclose it into a phagosome inside the cell. Killing of the phagosome is carried 
out by the neutrophil through the release of cytotoxic chemicals and enzymes. A non- 
mitochondrial oxidase enzyme is activated which generates toxic oxygen species (Segal and 
Jones 1978) to digest the particle. Neutrophil granules are also capable of releasing their 
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contents such as acid hydrolase, an enzyme that digests and degrades the engulfed 
pathogen.  
Neutrophils are the primary cells responsible for the immune response.  Macrophages are 
abundant in every tissue of the body and result from the differentiation of monocytes. They 
are involved in apoptosis. Along with neutrophils, macrophages also play a role in 
phagocytosis where they are able to secrete toxic peroxide chemicals to kill the foreign 
invader within the phagosome. Aside from this, macrophages also play a role in activating 
immune effector molecules where its role is highlighted in linking adaptive immunity.  The 
main function of DCs is to present antigen material on their surface to other cells of the 
immune system, hence their term ‘Antigen presenting cells’ (APC). Immature DCs (iDCs) 
have high antigen capturing activity and low T cell activation properties. In this immature 
state, they function to sample the body’s environment and recognize bacteria and viruses 
through PRRs expressed on their surface known as Toll like receptors (TLRs) (Janeway and 
Medzhitov, 2002). These iDCs serve to phagocytose the pathogen and degrade the antigen 
into small pieces and present them on their cell surface using Major Histocompatibility 
Complex II (MHC). This process enables the DC to undergo maturation and the mature DC 
migrates to the lymph node (Bell et al., 1999) where it presents the antigen to naïve T cells 
of the adaptive immune system and activates them. In this regard they are very important 
























Plasma B cells are capable of producing antibodies which 
attach onto microbes. This antibody/antigen complex is able 
to lead to a range of processes to abolish the antigen 
including phagocytosis or activation of the complement 
system. 
Memory B cells tend to live for a longer time and 
respond quickly to the same antigen convened 
during the previous primary immune response 
T-Cells 
T-helper (Th) cells, also known as CD4+ T cells 
are activated when presented foreign antigens by 
macrophages. Once bound to the antigen, this Th 
cell differentiates into several Th subtypes which 
secrete signals known as cytokines to trigger 
various immune responses.  
Th1 response produces interferon gamma, IL-2 
and TNF-β which activate macrophages and are 
important for cell mediated immunity 
Th2 response produces IL-4, IL-5, IL-10 and IL-13, 
responsible for strong antibody production and 
eosinophil activation. 
Cytotoxic T-Cells bind antigens on cells that are 
altered or infected by viruses. These killer T cells 
interact with the peptide via MHC class I molecule 
which presents the antigen to cytotoxic T cells 
allowing them to directly destroy the cell.  Such 
cytotoxic cells are essential in eliminating virus 





















Figure 1.1: Cellular components of the adaptive system: The two main types of lymphocytes are 
B cells and T Cells. B cells are involved in humoral immunity and have antibodies (immunoglobin) 
attached on their surface which binds to its own specific antigen to mark the invading pathogen for 
removal. This in turn stimulates the B cell to differentiate into a plasma cell or a memory cell. MHC 
molecules are found on the surface of APCs. Infected cells are able to use MHC II to display antigenic 
peptides on their surface to attract a compatible T cell via its T Cell Receptor (TCR). However co-
stimulatory molecules on both the T-Cell and APC are required to initiate further immune 
responses. Upon interaction between these co-stimulatory molecules, the T-Cell can take several 
routes such as T- Cell activation, tolerance or T-Cell death (Abbas et al., 2004).  
T-Cells 
The initial encounter of a naïve T cell with an antigen also causes it to 
proliferate and differentiate into a memory T cell which remains in the 
host for an extended amount of time to recognize previous invading 
antigens such as viruses, bacteria or cancer cells. 
T reg cells control cellular activity and are another subset of T 
lymphocytes also known as suppressor T cells. Such cells 
modulate the immune system by suppressing the immune 
response of other cells to prevent excess reactions upon 
elimination of unwanted pathogens. This control is vital in 
avoiding diseases such as lymphoproliferative disease and 
immunopathologic sequellae (Schultz and Grieder, 1987) that are 
bought upon by excessive Immune responses. 
NK Cells 
Natural Killer cells (NK) are a type of lymphocyte that are 
cytotoxic, they contain granules in their cytoplasm that 
contain proteins called perforin and proteases called 
granzymes. When in contact with an infected cell, perforin 
injects holes into the cell membrane of the target cell which 




The primary lymphoid organs involved in the immune system include the bone marrow 
and the thymus. The bone marrow is critical to the immune system as it is this organ where 
all cells including red blood cells, white blood cells and lymphocytes are derived. Immature 
thymocytes migrate from the bone marrow into the thymus. The thymus is essential in 
providing an environment for the maturation of T- lymphocytes with the help of the 
hormones thymopoietin and thymosin. During this process T cells are able to differentiate 
between the body’s cells and foreign antigens and are released into the blood stream.  
Secondary lymphoid organs include the spleen and lymph nodes. Both B and T 
lymphocytes are found in the lymph nodes with T cells residing in the paracortical area and 
B cells in the primary and secondary lymphoid follicles. T cells and B cells are also 
contained in the spleen.   
1.4 Components linking Innate and Adaptive immunity 
1.4.1 Cytokines and Toll Like Receptors 
Essentially the innate immune system works to recognize microbes known as PAMPS 
(Janeway et al., 1989) via PRR germ line receptors. PRRs are abundant in several groups 
with their own specific role such as opsonisation, activating the complement cascade or 
phagocytosis. TLR are a subset of PRRs expressed on macrophages and DCs and are critical 
to innate immunity as they allow host cells to recognize PAMPS and are able to breach 
immune responses through cytokine activation (Janeway and Medzhitov, 2002). Humans 
express 13 TLR with each TLR able to recognize its own set of PAMPs. For example, TLR4 
recognises lipopolysaccharide (LPS) (Poltorak et al., 1998) a ligand unique to gram 
negative bacteria, whereas TLR2 recognises peptidoglycan (Takeuchi et al., 1999). TLR1 
and TLR6 form heteromeric complexes with TLR2 which enhances the amount of TLR2 
signaling that occurs due to the increased types of PAMPs the TLR can attract (Beutler, 
2004a). 
TLR are currently widely known for being the primary sensors to pathogens to activate 
innate host defenses, their recruitment and activation of phagocytes can directly kill 
microbes (Takeda et al., 2003). In light of this, an important role for TLR is to bridge innate 
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and adaptive immunity through inducing DC maturation to prime naïve T cells. There is 
accumulating evidence that innate immune recognition by TLR shapes activation of the 
adaptive immune response in this manner. As described previously, a naïve T cell is able to 
differentiate once activated through its TCR. However a fully mature DC is required to bind 
to a TLR ligand to achieve upregulation of MHC and co-stimulatory molecules (Banchereau 
and Steinman, 1998) which will in turn allow the APC to bind and activate naïve T cells. 
Literature to support this has come from experiments performed involving MYD88, an 
essential signaling protein used by TLRs. Mycobacterial extracts containing TLR ligands 
were injected into mice (Schnare et al., 2001) with results demonstrating elevated levels of 
T cell activation. However mycobacterial extracts immunized into MYD88 deficient mice 
failed to induce DC maturation, thereby inhibiting T-Cell activation. This experiment 
highlights that TLR and PAMP engagement is essential in priming adaptive immunity to 
bring about T-cell differentiation and activation.  
Experiments performed with DCs and TLRs have revealed that T reg cells also control 
activation of pathogen specific T cells. Binding of TLR4 to LPS allow DCs to mature even 
without the presence of MYd88 (Kaisho et al., 2001). However, this upregulates MHC and 
co-stimulatory molecules, but no induction of cytokines. Interestingly in spite of activating 
this co-stimulatory pathway, these molecules alone have been shown to be incapable of 
activating T cell priming. The secretion of cytokine IL-6 released as a result of TLR binding 
to microbial products is essentially required to block T-cell suppression, thereby allowing 
activation of T-cell specific adaptive responses (Pasare and Medzhitov, 2003). This is 
advantageous as sustained function of T reg cells prevents self-reactive T cells to activate 
during an immune response to infection (Abbas et al 2006). 
1.4.2 Cellular Components 
The cellular components of the innate immune system (Figure 1.2) include NK cells, 
macrophages, neutrophils and DCs (Beutler, 2004b). Macrophages are derived from 
monocytes and are well distributed throughout the body’s major organs such as the heart, 
brain and lungs, thereby ensuring they are readily available to counter invading organisms. 
Although key in engulfing and killing microbes, macrophages are also important in 
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releasing cytokines to recruit polymorphonuclear phagocytes such as neutrophils. 
Macrophages, along with mature DCs, present antigens to naive T cells which initiate the 
adaptive system. Although the innate immune system was evolved much earlier, the 
activation of the adaptive immune system is dependent upon the myloid cellular innate 
components. For instance, the abolishment of neutrophils which are key players in 
combating infection would result in an immunodeficiency state. Moreover without the 
antigen presenting function of DCs and innate immunity cells  triggered cytokine 
production, adaptive immune responses would be unsuccessful due to pro inflammatory 
cytokines also involved in recruiting and activating T-Cells (Lacy and Stow, 2011)  
B cells of the adaptive system are also activated by the innate system. B cells that produce 
autoantibodies known as Rheumatoid factor (RF) are activated by chromatin ICs  
(Leadbetter et al., 2002) which bind to B cell receptors (BCRs) on the surface of B cells and 
are delivered to TLR9. TLR9 recognizes bacterial genomes and DNA viruses, therefore 
interaction of these chromatin complexes to TLR9 initiates TLR9 signaling which activates 
B cells and allows them to differentiate and secrete specific antibodies to chromatin 
antigens. This can lead to pathological consequences and autoimmunity due to B cells 
activating non-specifically and generating self-reactive antibodies which are implicated in 
the pathogenesis of auto immune diseases. This establishes an evident link between the 
innate and adaptive immune system in the development of autoimmune diseases. 
Cytokines are released upon complement activation, a key pathway of innate immunity, or 
as just mentioned, by TLRs (McGettrick and O'Neill, 2007). IL-12 (Interleukin 12) is a 
cytokine produced by APCs and links adaptive immunity by playing a role in the 
differentiation of T-cells into Th cells, as well as enhancing cytotoxic activity of CD8+ T cells 
(Iwasaki and Medzhitov, 2010). TNF is another cytokine produced by macrophages and is 
involved in inflammation, (Hernandezpando and Rook, 1994). It is able to induce fever and 
apoptotic cell death through production of IL-1 and IL-6. Another important group of 
cytokines are type I interferons, this family is comprised of 13 proteins that contribute to 
the innate immune response against viral infection. Release of these pro-inflammatory 





Figure 1.2: Cells and components of Innate and Adaptive immunity:  The innate immune 
system consists of plasma proteins and cells circulating the blood and ready to fight microbes at the 
site of infection such as epithelial barriers, leucocytes, DCs, and NK cells. The adaptive system gets 
into action when pathogens evade initial innate immune responses. Components of the adaptive 
immune system include B-Cells that produce antibodies known as humoral immunity and T-
lymphocytes (CD4+ and CD8*) that exert their function through cytotoxicity known as the cell 
mediated response (Abbas et al, 2006) 
1.5 Key Innate Immune System Is The Complement System 
The complement system (figure 1.3) is a key part of the innate immune system which 
works to remove antigen/antibody complexes known as ICs. This process is initiated by 
C1q, the first component of the classical pathway which latches onto the Fc portion of the 
antibody and triggers the activation of a range of plasma proteins, eventually leading to 
Membrane Attack Complex (MAC) complex which destroys the cell. 
The complement pathway is made up of over 40 plasma proteins and receptors which 
serve as the major primary defence in innate immunity. Most of these proteins are 
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proteases and react with one another by proteolytic cleavage to activate themselves into 
their enzymatic form. Therefore, the complement system is activated via a triggered 
enzyme cascade. They then work to opsonize pathogens and produce inflammatory 
responses in response to fight infections. Eventually this amplified complement response 
leads to a series of events on the surface of the pathogen which works to kill the pathogen 
and eliminate the infection. 
The complement system can be activated by both the innate and adaptive system which 
branch further into activating three main complement pathways (figure 1.3), the classical, 
alternative and mannon binding lectin (MBL) pathway (Janeway et al 2001). The innate 
immune activation involves the binding of mannan binding lectin, a protein that binds to 
mannose containing carbohydrates on the surface of bacteria. The classical pathway 
activation takes place when antibodies IgG or IgM bind to the antigen which exposes the Fc 
region of the antibody enabling the first component of the classical pathway C1q to bind to 
this Fc portion (Duncan et al 1988). Finally the alternative pathway is activated 
spontaneously when a complement protein binds to the surface of the pathogen. Although 
each pathway is triggered by a different mechanism, they all converge at the C3 convertase 





Figure 1.3: The Complement pathway:  The complement pathway is activated through three 
pathways, the classical, Lectin and alternative. Activation of the classical pathway occurs when C1q 
attaches onto an antigen-antibody complex which activates C1r and C1s leading to the cleavage of 
C4 and C2. Lectin pathway activation occurs when MBL binds to a carbohydrate on the surface of 
pathogens which leads to the activation of the serine proteases MASP-1 and MASP-2, again cleaving 
C2 and C4. Cleavage of C2 and C4 form C4bC2a which cleaves C3 into C3b and C3a known as the C3 
convertase  of the classical and lectin pathway. C3b then attaches to C4bC2a to form the C5 
convertase C4bC2aC3b. The alternative pathway is activated due to spontaneous hydrolysis and 
forms the C3 convertase C3Bb. Factor B and D lead to additional C3 cleavage forming C3bBb, the 
additional C3 convertase and the C5 convertase C3bBbC3b. All three pathways converge at the C3 
convertase which activate the anaphylatoxins C4a, C3a, C5a and the MAC complex. Anapylatoxins 
are potent inflammatory molecules resulting from cleavage of C4, C3 and C5. The MAC complex 
consists of the complement components C5b to C9 which form an assembley around the surface of 
pathogens to induce lysis (Dunkelberger et al, 2010) 
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The C3 convertase (figure 1.4) is the most crucial stage of the complement pathway where 
all three pathways converge. The protease C3 convertase activates C3 which gets cleaved 
into C3a and C3b. C3b binds to the surface of the pathogen and is a powerful opsonin as it 
mediates binding of the pathogen to phagocytic cells to target it for destruction. Initiation 
of the classical complement cascade begins with the binding of antibody-antigen 
complexes. Upon binding to the antigen, the Fc portion of the antibody is exposed allowing 
it to bind to the macromolecule C1 (Reid and Porter, 1976) via its globular domain. The C1 
complex is 790kDa and consists of 3 subunit, C1q, C1r and C1s (Arlaud et al., 2001; Cooper, 
1985)  This activates the two serine proteases C1r and C1s which along with C1q make up 
the C1 macromolecule complex. Activation of C1r and C1s leads to the cleavage of C4 and 
C2 forming C4b2a, the C3 convertase. Activation of the alternative pathway arises when C3 
slowly hydrolyses in solution which forms C3 (H20). This forms a complex with Factor B 
and is activated by Factor D to form the C3 convertase C3Bb. C3b binds randomly and 
covalently to the surface of pathogens and is stablilised by Properdin. The next stage 
involves the generation of the C5 convertase which cleaves C5 to produce C5a and C5b. C5b 
binds to C6, C7, C8 and C9 to create the C5b-9 complex known as MAC. This complex 
punctures pores into the surface of the pathogen and inserts into the lipid bilayer to initiate 
cell lysis. C3a, C4a and C5a are chemotactic factors involved in inflammation known as 
anaphylatoxins. These potent inflammatory molecules bring upon their effects through 
binding to the receptors C3aR and C5aR on monocytes/macrophages and 
polymorphonuclear cells to recruit the cells to the site of inflammation. C5a is the most 
potent anaphylatoxin and is involved in a wide range of activities including the promotion 
of superoxide radical production from eosinophils and the release of hydrolic enzymes 
from neutrophils. C3a is involved in mast cell chemotaxis (Legler et al., 1996), eosinophils 
(Daffern et al., 1995) and contraction of smooth muscle cells. C3aR is also known to be 
expressed on activated CD4+ T-Cells (Wefel 2000) and B-Cells. Therefore this C3a-C3aR 
interaction could also be involved in activating adaptive immune responses through the 
activation of T-Cells (Werfel et al., 2000). The deposition of C3b on complement activating 
fragments leads to its cleavage to produce iC3b and C3dg. These proteins are recognized by 
various receptors including on a range of cell types leading to the binding of the 
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complement particles onto the cell. The complement receptor CR1 recognises C3b and C4b. 
CR2 binds to C3dg/C3d and CR3 and CR4 bind to iC3b and CR1g. 
The lectin pathway is activated when the protein MBL binds to Mannose residues which 
are exposed on various pathogens. Upon the binding of MBL to a pathogen, two serine 
proteases known as MASP-1 and MASP-2 are activated.  Although MASP-1 was initially 
known to cleave C2 and C4 (Matsushita and Fujita, 1992), its role had been question and it 
has recently emerged that MASP-1 cannot initiate the lectin pathway (Rossi et al., 2001). 
Instead, MASP-1 has been identified to cleave zymogen MASP-2 to activate MASP-1 and C2 
in the proconvertase C4b2, creating the C3 convertase C4b2a (Megyeri et al., 2013). 
1.6 Complement protein C1q 
C1q, the first recognition subcomponent of the classical complement pathway, is a 460-kDa 
protein composed of 18 polypeptide chains (figure 1.5) (6A, 6B and 6C)  (Sellar et al., 1991; 
Sellar et al 1992). The A chain (233 residues), B chain (226 residues and C chain (226 
residues) (figure 1.5) are composed of a N-terminal region consisting of a half-cysteine 
residue that is involved in the formation of disulphide bonds, a collagen-like region (CLR),  
(81 residues) and a  C-terminal globular region, called the gC1q domain (135 residues) 
(Kishore and Reid 1999). There are four conserved cysteines present in each chain at 
position 4, 135, 154 and 171. At position 4, the cysteines present are responsible for 
creating the A-B and C-C dimers (figure 1.5), whereas the other three cysteine residues are 
involved in producing one interchain disulphide bond and one free thiol group per gC1q 
domain. The interchain disulphide bond is involved in creating the 6A-B dimer and the 3C-
C dimer subunits (figure 1.5) (Reid and Porter 1976;Kishore and Reid, 2000). The CLR of 
this A-B dimer and the C-C dimer join together to give rise to a triple helical structure with 
the composition ABC-CBA (figure 1.5) which are held together by both covalent and non-
covalent bonds. The gC1q domains contains a exposed calcium ion located near the apex 
(figure 1.7) which is important in target binding of its ligands such as IgM and IgG 










Figure1.4: C3 convertase: Spontaneous hydrolysis of C3 causes C3b to bind to the surface of the 
pathogen Properdin which cleaves more C3 to C3b amplifying the process. Surface bound C3b binds 
to Factor B and is then cleaved by Factor D to form C3bBb. This C3bBb is known as the C3 
convertase of the alternative pathway. C3bBb is stabilized by Properdin (Kouser et al, 2013). 
C1q is essentially a versatile charge pattern recognition molecule that binds to a number of 
ligands and triggers biological and cellular responses.  This versatility of this complement 



























Figure 1.5: Structure of C1q: C1q is composed of 18 polypeptide chains, six C1qA chains, six C1qB 
chains and six C1Qc chains. Each chain comprises of a N-Terminal collagen domain which 
resembles a stalk, and a C-Terminal globular domain. The chains are aligned as six heterotrimers 
which come together to create a ‘bouquet of tulip’ configuration. A) The globular head domain is 
made up of three different types of chains, ghA, ghB and ghC. Each chain posseses a CLR region and 
a C-terminal globular domain. B) The three heads are assembled to form disulphide linked A-B and 
C-C dimers. C) A-B-C chain. The length of each chain as well as the length of the gC1q and CLR 
region given in parenthesis D) The A-B dimer is non-covalently linked to another C chain forming 
A-B-C. The C chain is then linked to another C chain by disulphide bonds giving rise to A-B C-C B-A. 
These three doublets are linked by non-covalent bonds which gives rise to C1q’s bouquet link 
structure (Kishore et al 1994).   E)    Ribbon representation of globular head showing ghA, ghB and 


























































The gC1q domain binds the Fc portion of IgG (figure 1.6) through ionic 
interactions on immune complexes (IC). Binding of this gC1q domain to 
IgG induces a conformal change in the CLR region which activates C1r 
and brings upon activation of the classical pathway. The avidity of this 
interaction is greatly strengthened when C1q binds to many Fc regions 
on aggregated IgG, as opposed to non-aggregated IgG (figure 1.6). The 
ghB module of gC1q is implicated in this binding with arginine and 
histidine residues mainly involved in assisting this complex.  
 
The complementary 
binding site on IgG has 
been localised within 
the C-terminal region 
of the Cγ2 domain, 
specificially to the 
amino acids Glu318, 
Lys320, Lys322 
 
(Kishore et al, 
2003; 
Kojouharova 
et al., 2004; 












Along with IgG, C1q also binds to IgM to activate complement. However, 
the extent of classical activation is largely dependent on the binding 
affinity between these two proteins. For instance, hexameric IgM binds 
the strongest to C1q (figure 1.6), hence activates complement to a greater 
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C1q has also been implicated in the pathogenesis of cardiovascular 
diseases due to its contribution to inflammation via complement 
activation. C1q binds to the surface of endothelial cells via its gC1q 
domain leading to inflammation of the endothelium due to the buildup of 
ICs. The accumulation of ICs occur when patients are deficient in 
complement proteins leading to the their inability to remove immune 
complexes.  This build up in turn creates tissue damage, progressing to 
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LDL gC1q The pathogenesis of atherosclerosis has also been speculated to arise 
from C1q initiating complement activation on Low Density Lipoproteins 
(LDL) deposits. Enzymatically modified LDL deposits with protease and 
cholesterol esterase bind to C1q with high affinity and trigger C1 
activation. The rationale for enzymatically modifying these lesions is to 
represent atheroscloric lesions in the physiological condition of patients, 
as cholesterol rich particles of LDL are formed. Therefore, treatment of 
cholesterol esterase in an in vitro setting would expose similar 
cholesterol molecules that would correspond to the cholesterol rich 
particles of LDL, hence mimicking the physiological settings of 
atherosclerosis. It is this attachment of cholesterol molecules that is 




















gC1q Deficiency of C1q leads to the development of Systemic Lupus 
Erythematosus (SLE) due to the inability to remove apoptotic bodies 
leading to their accumulation. C1q is able to bind to apoptotic blebs and 
apoptotic cells through its globular head domain which effectively 
activates the classical pathway leading to the clearance of dying cells due 
to  the opsonin C3b binding to the surface of the pathogen, and targeting 
it for destruction by phagocytes bearing the C3b receptor. Failure leads 
to the accumulation of apoptotic cells, marking the C1q deficiency 
disease, Systemic Lupus Erythematosus. A ‘waste disposal’ hypothesis 
has been descrbed to explain the link between complement deficiency 
and the pathogenesis of SLE. This proposes that the deficiency of 
complement proteins prevents waste ICs and dyng cells from being 
removed from the body. This in turn leads to structural modification in 
IC/dying cells DNA creating autoantigens that drive the production of 
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Blood platelets have been shown to bind to C1q via gC1qR and activate 









CRP  Another example of how complement activation contributes to 
inflammation is through the protein CRP. This protein behaves as a 
marker of inflammation by binding to phosphotidylcholine (PS) on the 
surface of dying cells. This exposes its binding sites for C1q activating 
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Initiation of the classical pathway has also been demonstrated on 
adiponectin, the adipose specific tissue. The binding of C1q to 
adiponectin leading to complement activation suggests this complex 
could tag adiponectin target molecules such as damaged endothelium 













 Long pentraxin 3 (PTX3) is a PRR that binds to C1q via its gC1q domain 
to initiate complement. However whereas immobilized PTX3 lead to C1q 
dependent classical pathway activation, fluid phase conditions inhibited 
binding of C1q with PTX due to C1q bound to IgG. This ability of PTX3 to 
activate and inhibit the classical pathway suggests a role for this protein 















The globular domain of C1q recognizes LPS on gram negative bacteria 
with this interaction largely specified to the B chain and demonstrates 
classical pathway activation. In addition to this, both LPS and IgG binding 
sites are observed to be overlapping on the gC1q domain 
LPS is 
mainly via the 
phosphate groups 














Several viral proteins also bind C1q with one of them identified as the 
human astrovirus coat protein (HAst V-1 CP) (Bonaparte et al., 2008). 
However, this interaction suppresses complement as studies have 
shown that classical pathway was inhibited at its first component 
C1with HAst V-1 CP specifically recognizing the A chain of C1q. Since 
complement has great inflammatory potential, inhibiting this pathway 
would support the rationale behind the lack of inflammation observed 



















Rhumatoid arthritis (RA) and Osteoarthiritis also involve contribution 
from complement activation giving rise to chronic inflammation. This 
is bought upon by short leucine rich glycoproteins (SLRP) such as 
fibromodulin, osteoadherin and chondroadherin binding to C1q. The 
cartilage component fibromodulin recognizes C1q with a high affinity 
which could potentially account for the inflammation seen in joint 
disease. Osteroadherin found in the territorial matrix of articular 
cartilage is also known to be a very potent activator of complement; 
however chondroitan initiates complement to lesser complement as it 






       Not known 
 
 
(Sjoberg et al., 
2009; 






Complement activation also follows binding of C1q to A1-42, the fibril 
peptide found in brains of patients with Alzheimer’s Disease (AD).This 
is evident in the presence and absence of C1 inhibitor. The biological 
relevance of this C1 complex to activate the classical pathway supports 
the notion that complement activation may also be a component of 
neurodegenerative disease pathology by contributing to the 




























 Aside from activating the classical pathway, C1q’s role in targeting and 
scavenging altered self substances is further highlighted through its 
function in binding to the pathological form of the prion protein (PrP). 
Prp is a alpha helix rich 35 kDa glycoprotein found in neuronal tissue. 
Upon conversion into an abnormal isoform, prion diseases develop 
which represent neurodegenerative disorders. It has been speculated 
that complement activation occurring in prion diseases facilitates both 
the pathogenesis of the diseases as well as the neuronal damage. As 
well as this, it has been shown that the three genes for C1q are highly 
upregulated in the brain of mouse prion diseases. Characterization 
between the Prp and C1q interaction has indicated that C1q binds to 
the Prp through its globular head only under the condition of the Prp 
converted into Beta rich oligomers leading to activation of the classical 
pathway. More recently it has been discovered that small sized Prp 
oligomers of 8-15 molecules are specific to interacting with C1q and 
these sites initiate the highest complement activation  Moreover, C1q 
has also been discovered to promote Prp aggregation leading to the 




(Bailly et al., 
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(Gehlenborg 
et al., 2009) 
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Figure 1.6: IgM and IgG antigen binding: A) Soluble hexameric IgM in its planer form. B) C1q is 
able to bind to hexameric IgM  via its gC1q domain and activate the classical pathway, as opposed to 
momomeric IgM. C) Soluble aggregated IgG. D) C1q binds to aggregated IgG resulting in activation 
of the classical pathway. 
21 
 
Table 1.2: Non Complement Activating Functions of C1q 
However, C1q also participates in a range of processes that are not dependent on complement activation (table 1.2) (Nayak et 















Although apoptotic cell clearance is facilitated by the 
activation of complement, it is also dependent on C1q 
without the classical pathway. C1q has been shown to bind 
to PS exposed on the surface of apoptotic cells and targets 
them for clearance by phagocytes. C1q also possesses the 
ability to bind to self DNA on apoptotic cells, hence targeting 



















The notion that C1q is a multi-potent molecule is also 
reinforced due to its involvement in the maturation of DCs. 
Experiments have shown that immature DCs cultured on 
C1q activate and produce elevated levels of the cytokines IL-
12 and Tumour Necrosis Factor (TNF) -alpha, as well as 
triggering translocation of NFkB, all components that are 
required for DC-maturation and T cell stimulation. 
Furthermore, C1q matured DCs direct a Th1 response. 
Immature DC start expressing CD83, CD86, MHCII and CCR7 
in the presence of C1q, the upregulation of these markers of 
DC maturation and T cell activation suggest that immature 
DC that produce functionally active C1q may bind to the cell 
membrane once released and contribute to DC maturation. 
This functional role of C1q in DC biology provides an insight 
into how this complement protein shapes adaptive 










Csomor et al., 
2007;Castellano 
et al., 2004) 
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absence of C1q could possibly lead to impaired functioning 
of DCs. Together, the idea of C1q behaving as an opsonin for 
apoptotic cells, and additionally regulating DC function 
emphasizes the concept that C1 containing ICs could also 
















Opsonised apoptotic cells use multiple ‘eat me’ signals to 
mark themselves for removal. This hypothesis is supported 
by C1q recognizing Calreticulin (CRT) the candidate 
receptor for its CLR region on apoptotic cell surfaces which 
in turn attracts phagocytes to subject apoptotic cells for 
phagocytosis through CD91-induced macropinocytosis  
Therefore the prospect of the C1q globular region binding to 
PS and its collagen region binding to CRT elicits the idea of 
C1q being a multi potent protein able to collect structural 
features and sense multiple signals as a major player in 









(Paidassi et al., 
2008) 








C1q’s non complement associated functions is also apparent 
in pregnancy. Heparin (Low Molecular Mass Heparin) binds 
to C1q via its collagen region and inhibits complement 
activity which entails C1q’s protective role in pregnancy to 






















Although C1q has been linked with the neurodegenerative 
pathology of AD via activating complement through 
interacting with fibrillar amyloid peptide, evidence has also 
stated that C1q produces a neuroprotective role , 
independent of its complement functions  due to no 
complement cascade proteins being detected in conditions 

































C1q is produced after injury which suggests a beneficial role 
of this complement protein. In light of this statement, 
experiments have shown that Amyloid-beta (A- beta) 
induced neurotoxicity, signals through caspase and calpain, 
and incubation of C1q with A-beta only slightly inhibited 
caspase activation. 
C1q has also shown to suppress the production of 
proinflammatory cytokines IL-6 and TNF-alpha when 
treated with apoptotic neurons and microglia cells which 
again supports the idea of C1q acquiring a protective role. 
The upregulation of C1q following neuronal injury triggers a 
large abundance of the phagocytic cells, microglial cells in 
the CNS. Their function is to phagocytose the buildup of 
opsonised targets which in this case are amyloid peptides 
and apoptotic neurons that have been deposited. The 
mechanism employed to achieve this involves these 
phagocytic cells producing C1q. However, the activation of 
these microglia cells has been shown to be dependant on 
extrinsic C1q. Therefore, extrinsic C1q activates microglia 
cells to work similar to other phagocytes by enhancing the 
uptake of apoptotic neurons and suppressing inflammatory 
cytokine production of TNF-alpha and IL-6 in macrophages 
and DCs in the complete absence of activation of the  
 
complement cascade which enforces C1q’s protective role in 





























 In addition to this, SAP does not induce its pathological 
effects through caspase signaling and binding of C1q to SAP 
inhibited SAP induced neurotoxicity which highlights a 
neuroprotective role for C1q independent of these signaling 







investigated that would reveal the route C1q employs to 






C1q has also shown to suppress the production of 
proinflammatory cytokines IL-6 and TNF-alpha when 
treated with apoptotic neurons and microglia cells 
supporting the idea of C1q acquiring a protective role. 












Platelet aggregation in response to C1q follows expression 
of P-Selectin and alphaII beta/beta 3 integrin. P-Selectin is 
involved in recruiting immune cells to the site of injury and 


















PTX3 involvement with C1q also plays a part in inhibiting 
the classical pathway and arbitrating the clearance of 
apoptotic cells. In physiological conditions, mature DC also 
produces these innate molecules PTX3 and C1q.  This PTX3 
binds to C1q in the fluid phase of DC microenvironment and 
inhibits complement activation on apoptotic cells as well as 
suppressing C1q’s opsonin functions by inhibiting 
phagocytosis by DC. 
  






Figure 1.7: Structure of C1q: A) Top view of globular head domain, red: ghA, green: ghB, blue: 
ghC. Yellow circle represents Calcium ion. B) Lateral view. C) Lateral view of C1q showing 






Figure 1.8: Structural basis of the versatility of C1q. The ghB module within the 
heterotrimeric structure of the gC1q domain is apically positioned to make contact with the Fc 









1.7 Interaction between C1q and Immune Cells:  
1.7.1 Neutrophils 
The nature of the interaction between C1q and a number of immune cells has been 
explored with results stating the enhancement of several important immune functions. 
These effects are bought upon through C1q binding to either its globular head receptor 
gC1qR or CRT which recognizes the CLR.  With regards to this, the role of C1q with 
neutrophils to assess chemotactic properties has been studied (Leigh et al., 1998). 
Experiments revealed that the CLR region of C1q mediated neutrophil chemotaxis, and 
interestingly the chemotactic potency of C1q increased greatly in the presence of its 
globular head receptor gC1qR. This states that C1q functions as a potent 
chemoattractant via both its globular head and CLR region. In addition to this, C1q 
acquires the ability to trigger superoxide production in neutrophils (Goodman et al., 
1995). However further studies have shown that whereas C1q’s chemotactic properties 
function through g-protein signaling, this multi ligand protein does not utilize g protein 
signaling to bring upon its respiratory burst effects in neutrophils, implying different 
signaling mechanisms for C1q in these two functions. In addition to this neutrophils 
have also shown to inhibit classical pathway activation through the Defensin molecule 
human neutrophil peptide-1 (HNP-1) (Groeneveld et al., 2007). Defensins are 
antimicrobial peptides and play an essential role in antimicrobial response to 
microorganisms. HNP-1 is present in the granules of neutrophils and are released by 
stimulated neutrophils. The ability of HNP-1 and C1q to inhibit classical activation may 
point towards a protective role against tissue injury in inflammatory conditions.  
1.7.2 Fibroblasts 
C1q’s chemotactic and adhesive properties have also been noted in the biological 
activity of fibroblasts (Bordin et al., 1990) . The adhesion capability of fibroblasts was 
shown to be greatly promoted when treated with C1q, with this enhanced adhesion 
dependant on the CLR of C1q. As C1q is known to bind to cells of the extracellular 
matrix, its participation in cell adhesion may highlight a mechanism of how fibroblasts 
adhere to molecules of the extracellular matrix. Chemotaxis of fibroblasts is also 
induced via the CLR (Oiki and Okada, 1988) and is dependent upon an influx of Ca2+ 
ions. As fibroblasts are known to be essentially involved in wound healing, it is 
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hypothesized that C1q binds to fibroblasts through a C1q receptor specified to the CLR 
region and triggers fibroblast chemotaxis in response to tissue injury to the site of the 
wound. Mast cell chemotaxis is also mediated by C1q (Ghebrehiwet et al., 1995) with 
the migratory response to C1q carried out in two distinct phases, a chemotactic 
response followed by a chemokinetic response. This could be accounted for by the 
presence of two separate receptors , where by the CLR binds to CRT and is then further 
enhanced by the binding of gC1q to gC1qR (Ghebrehiwet et al., 1995). C1q’s 
chemokinesis properties have been further highlighted through its role in inducing 
migration of eosinophills(Kuna et al., 1996) through both candidate receptors gC1qR 
and CRT. C1q is also associated with modulating T-cell activity.  
1.7.3 T-cells and DCs 
C1q has also been shown to enhance IFN-production through T-cells as studies show 
that C1q produced by DC generate a Th1 response which is supported by the production 
of the essential defense cytokine IFN- (Baruah et al., 2009). This cytokine is key in 
driving Th1 cell mediated immune responses. In addition to this, C1q’s enhanced 
differentiation of T-cells has been demonstrated through the mechanism of triggering 
CD40 ligation on DCs. As mentioned previously, C1q produced by DCs is able to bind 
back on DC surface. When antigen specific T-Cells recognize antigens on DC, they 
become activated and express CD40L. These CD40L molecules connect CD40 expressed 
by DCs. This leads to the upregulation of CD40 on DC which co-localise with C1q to form 
a signaling complex leading to enhanced T-Cell differentiation and IFN-γ production. 
Human DCs deficient in C1q have been shown to have an impaired response to CD40 
ligation, emphasizing that C1q is required for greater T-cell differentiation.  
1.7.4 B-cells 
C1q stimulates the production of IgG by B-lymphocytes (Young et al., 1991) by binding 
to both small resting and large activated B cells. C1q also plays a role in the negative 
selection of autoreactive B cells (Ferry et al., 2007), C1q deficiency increases the 
positive selection of B1 cells and decreases the negative selection of autoreactive 
conventional B cells through the same intracellular antigen. This highlights a role for 
C1q in tolerance, in both the clearance of antigens and positive and negative selection of 
autoreactive B cells. Moreover, studies have shown that B cells maintain their tolerance 
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in the absence of C1q showing that C1q deficient cell tolerance is not a primary 
mechanism leading to autoimmunity, through inactivation of the classical pathway in 
the clearance of dying cells (Cutler et al., 2001) Another feature of this complement 
protein is presented through a functional role in regulating the expression of the tumor 
suppressor gene WOX1 in prostate cancer (Hong et al., 2009). C1q enhanced WOX1 
induced apoptosis and growth suppression of prostate cancer cells through 
destabilizing cell adhesion. This observation has been supported through low levels of 
C1q promoting prostate cancer formation due to impaired activation of WOX1. 
C1q also binds to the small leucine rich glycoproteins decorin, biglycan, lumican, 
laminin and fibronectin through its CLR. Decorin and biglycan are involved in matrix 
assembly and bone mineralization and bind C1q with high affinity to inhibit classical 
activation (Krumdieck et al., 1992; Groeneveld et al., 2005) which could have relevance 
in downregulating the pro inflammatory effects caused by C1q. On the other hand, 
Lumican, Laminin and fibronectin bind to C1q at a lower affinity and hinder 
complement activation (Bohnsack et al., 1985) Laminin is a large basement membrane 
glycoprotein, and as C1q is known to bind ICs in the basement membrane, it is 
hypothesized that this binding is facilitated through laminine. Therefore, within this 
structure, C1q could play a role in the deposition and retention of ICs. 
Reflecting on these complement and non-complement functions of C1q, it is noticeable 
that C1q ligand interactions involving the gC1q domain usually leads to the activation of 
the classical pathway, whereas engagement of the CLR usually exhibits other biological 
functions of C1q.  
1.8 Structure and Function of Human C1q 
As stated earlier, the binding of C1q to multiple Fc regions on aggregated IgG as seen in 
ICs leads to activation of the classical pathway. In terms of IgM binding, classical 
activation is proportional to the binding affinity between these two proteins. In terms of 
mapping these immunoglobulin binding sites on the gC1q domain, mutational 
constructs of each ghA, ghB and ghC chain containing a single amino acid substitution 
have been generated which has allowed identification of key residues on the gC1q 
domain of C1q in ligand binding (Kojouharova et al., 2004; Ghai et al 2007). These 
mutants have supported an essential role for the B chain residues Arginine 114 and 
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Arginine 129 in facilitating C1q-IgG interaction, consistant with previous findings 
(Burton et al., 1980; Marques et al., 1993) Crystal structure data shows that the surface 
of ghB is mostly positively charged with a stretch of these important residues Arg114 
and Arg129 present on the outside edge of the ghB module (Gaboriaud et al 2003). It is 
postulated that once IgG engages with C1q, the two molecules line up to allow the 
residues Asp 270 and Lys 322 of IgG to form salt bridges with Arg 129 and Glu 162 of 
ghB, with ArgB114 and Arg B161 stabilizing the complex (Ghai et al., 2007). On the other 
hand, the gC1q binding sites for IgM have been identified as Arg B108, Arg B109 and Tyr 
B175 (figure 1.9) (Kojouharova et al., 2004). Crystal structure analysis illustrates that 
C1q interacts with IgG at the top of the gC1q domain due to the location of these three 
residues. Therefore, the organisiation of the gC1q domain allows recognition of IgG and 
IgM through different residues (figure 1.9), highlighting the structural versitality of C1q. 
In comparison to how the individual globular head behave when in contact with IgG and 
IgM, results by Kishore et al have shown the following; ghA binds IgG and IgM equally, 
whereas ghB binds IgG preferentially over IgM, and ghC showed better binding affinity 
to IgM. The difference in this functional behavior of each globular head suggest that the 
gC1q domain is organized in such a way that each module is structurally and 
functionally different (Kishore et al, 2003) 
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Binding of substitution mutants of ghA, ghB and ghC modules to IgG and IgM 
 
Figure 1.9: Comparison of binding decreases obtained with IgG and IgM: A scatter plot 
showing the % decrease in binding obtained with IgG and IgM is shown for all mutants in the 
study. The points on the plot are colored according to the gC1q subunit (ghA, ghB or ghC). 
Clearly, the ArgB108Glu and ArgB109Glu mutants (along with LysB136Glu) show highest 
binding decreases both with IgG and IgM, suggesting the possibility of an overlapping binding 
site for both on gC1q.  
1.9 C1q Family 
The C-terminal of C1q is also found in many other proteins, both collagenous and non- 
collagenous, and are recognized as ‘C1q family members’ (figure 1.9) (Kishore et al 
2004). This C1q family is further split into two groups, a family of C1q like and 





Figure 1.10:  Pytogenetic tree to show C1q family members, 32 gC1q domains have been 
found in the human genome. C1qTNF4 is the only protein found with two gC1q domains (Ghai et 
al 2007) 
The C1q like proteins consist of C1qA, C1qB, C1qC, COL8A1, COL8A2, COL10A1, C1QL1, 
C1QL2, C1QL3, C1QL4 and Adiponectin. Adiponectin is produced by adipocytes (Scherer 
et al., 1995) and low levels of this protein is associated with type II diabetes (Kondo et 
al., 2002), with Insulin greatly boosting its levels. The Cerebellin proteins are known as 
Cbln1, Cbln2, Cbln3 and Cbln 4 (Shimono et al., 2010) and are expressed in the CNS 
system. Cbln1 plays an essential role in the formation and maintenance of synapses 
(Matsuda and Yuzaki, 2011) whereas Cbln 2-4 are involved in the developing and 
maturing of brains. Out of the C1q like proteins, C1QL3 also has neuronal relevance as it 
is highly expressed in glial cells in areas of the brain involved in motor function (Berube 
et al., 1999) The C1q like collagens COL8A1 and COL8A2 are expressed in tissues 
undergoing active remodeling and play a role in vascular tissue development (Hopfer et 
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al., 2005). COL10A is localized in chondrocytes and encodes the alpha chain of type 10 
collagen. Defects in the gC1q domain in COL10A1 leads to Schmids Metaphyseal 
Chondrodyplasia (SMCD) which is a disorder of the skeletal structure (Dublet et al., 
1999) Moving to the second subset of the C1q family members, EMLIN1 is an 
extracellular matrix glycoprotein expressed in elastic fibres and blood vessels, and is 
therefore considered to play a role in adhesion of smooth muscle cells to elastic fibres. 
Interestingly this function is thought to be mediated via its gC1q domain at the C-
terminal (Doliana et al., 1999) EMLIN-2 is identified to be involved in the development 
of heart chambers (Doliana et al., 2001) and also possess both a gC1q and CLR (figure 
1.11). Multimerin 1 is a large protein abundant in platelets and endothelial cell bodies, 
and upon exposure, binds to the cell surface of these plateles and endothelial cells to 
mediate platelet storage and stability (Hayward and Kelton, 1995). Multimerin 2 on the 
other hand is involved in vasculogenesis and angiogenesis.  
 
Figure 1.11: C1q like proteins representing different domains present within them in the 
human genome: The diagram reveals that most of the proteins have a collagenous region that 
appears before the gC1q domain. Each protein has a homotrimeric or heterotrimeric structure 
which assists in forming the trimeric structure. Multimerin 1, CBLN1, 2, 4, C1QTNF4, 5 and 
C1qDC1 lack collagen repeats in their domains. (Ghai et al 2007) 
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A new group of proteins known as C1q and TNF related proteins (C1QTNF1-9) have 
recently emerged to show functions similar to that of C1q and TNF members (Kishore et 
al 2002). C1TNF1 is highly expressed in the heart as well as the liver and skeletal 
muscle and plays a role in platelet aggregation (Lasser et al., 2006) C1TNF3 is expressed 
on fibroblasts and adipose tissue and is involved in angiogenesis and smooth muscle 
proliferation. Mutations in the gC1q domain of C1qTNF5 results in abnormal adhesion 
between the retinal pigment epithelium Bruchs membrane leading to severe vision loss. 
Binding studies performed using individual ghA, ghB and ghC chains advocate that each 
module functions independently in binding ligands (Kishore et al., 1998). Analysis of the 
crystal structure shows that each gC1q domain is a spherical heterotrimer with a three-
fold symmetry. Each globular head unit has a jelly roll topology consisting of two five 
strand anti parallel beta sheets to form a 10 stranded β sandwich (Gaboriaud et al., 
2003). The interactions that contribute to holding the gC1q domain include mainly non 
polar interactions, followed by hydrogen bonds and main chain polar interactions. A Ca+ 
is also exposed at the apex of the gC1q domain and is implicated in assisting C1q-ligand 
interactions. Additional hydrophobic residues at the base, and polar and hydrophilic 
near the apex further contribute to holding the heterotrimeric assembly. The charged 
distribution of each globular head surface clearly vary from one another with ghA and 
ghC showing a spread of basic and acid residues on their surface and ghB appearing to 
be greatly positively charged (Gaborioud et al 2003). 
The structural similarity between C1q family members within the gC1q domain has 
found C1qTNF9 and LOC387911 to show 96% sequence similarity (Ghai et al., 2007). 
An attractive feature of the gC1q domain show that nearly all members of the C1q 
family posess eight conserved residues which are crucial in maintaining the structural 
integrity of this globular structure. Along with C1q, four other configurations of the 
gC1q domain have been revealed in mouse ACRP30 (Shapiro and Scherer, 1998), human 
collagen X (Bogin et al., 2002)and mouse collagen (Kvansakul et al., 2003). Each of these 
structures reveal the same three fold symmetry, with the N and C terminal of each 
module positioned lateral to one another on the same side of the trimer. The collagen X 
structure displays a buried cluster of three Ca+ ions which enclose one located on the 
axis of the trimer. Acidic residues form a network of ionic bonds important in 
maintaining the high stability of the gC1q collagen X trimer. The Ca+ present in ACRP30 
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contributes to stabilizing the gC1q domain. The C1q Ca+ is well exposed at the apex and 
is crucial for ligand binding and complement activation (Roumenina et al., 2005). 
Interestingly, the ACRP30 structure reveals the same C-terminal structural scaffold as 
seen in the C-terminal homology domain of the TNF family. The beta stands between 
ACRP30 and TNF-α show identical lengths and positions (Shapiro and Scherer, 1998). 
The versatility of the gC1q domain is further highlighted through its binding to CRP 
(Volanakis, 1982). 
1.10 Mutational Studies 
CRP is an acute phase proteins that binds to PS on dying cells to activate complement 
via C1q. However, upon CRP binding to C1q, complement activation is bought to a halt 
after C3 convertase. The inability to form a C5 convertase  prevents pro-inflammatory 
cytokines such as C5a and MAC complex to be generated (Volanakis, 2001). Therefore 
antigens bound by CRP are opsonised by C3b and tagged for phagocytosis by 
macrophages. Mutant studies have initially labeled residues Asp112 and Lys114 on CRP 
to be involved in the CRP-C1q interaction (Agrawal and Volanakis, 1994) CRP has five 
identical subunits held together by non-covalent interactions and arranged in a 
pentramic symmetry around a pore. Crystal structure analysis illustrates a cleft which 
protrudes from the centre of each subunit and extends to the central pore of the 
petramer to where Asp112 is situated and indicated as the C1q binding site. CRP being 
pentameric in nature suggests that only one gC1q domain can bind to each CRP 
pentamer through one of the binding sites available out of the five subunits. 
Furthermore modeling of the structure of C1q and CRP has revealed a complimentary 
shape between the top of the gC1q domain and the pore of the pentramic ring which 
puts forward the idea of ghA, ghB and ghC interacting with CRP Arg112 and Tyr175 
(Gaboriaud et al., 2003) LPS is another ligand that shows of the independent versitality 
of the gC1q domain (Roumenina et al., 2008). LPS is lipoglycan made up of a lipid and 
polysaccharide and is mainly found on the outer membrane of gram negative bacteria. It 
behaves as an endotoxin to ellict pro inflammatory responses. The ghB module of gC1q 
has been shown to be primarily involved in this interaction with LPS as seen with IgM. It 
appears that a few C1q ligands share binding sites or overlap, this is evident in IgG and 
CRP (Roumenina et al., 2006) and PTX3 and CRP (Nauta et al., 2003). Mutational 
analysis to map the specific binding residues in ghB that is complimentary to LPS 
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indicated that Tyr175 is essential in this interaction which clearly shows that the IgM 
and LPS binding sites are shared on the same gC1q domain. 
1.11 Biosynthesis of C1q 
C1q is synthesized by a range of cell types including macrophages (Petry et al., 1991), 
DCs (Vegh et al., 2003), decidual endothelial cells (Bulla et al., 2008) and microglia cells. 
Although C1q is produced in the liver, adherent monocytes and macrophages appear to 
predominantly express C1q (Loos et al., 1983). It has been found that formation of a 
functional C1q molecule on macrophages depends upon three mRNA species each 
coding for the A, B and C chains (Petry et al., 1991). Experiments have demonstrated 
that membrane C1q (mC1q) is synthesized in a developmental phase by monocyte 
derived macrophages. In addition to this it has also been explored whether the 
activation of these macrophages producing C1q affect the function of this protein. Data 
has highlighted a strong link between IFN-γ production in macrophages and the 
expression and function of mC1q, as IFN-γ increased the expression of C1q and 
amplified mC1q mediated phagocytosis. Peripheral blood monocytes have also shown 
expression of surface C1q (Hosszu et al., 2008) with this monocytic supply of C1q 
contributing to monocyte derived DC differentiation (Vegh et al., 2003).  
C1q production is also evident in monocyte derived DCs. However, once DC seem to 
differ into mature DCs, C1q expression is abrogated. The differentiation of monocytes 
into activating DC mediated through the immunostimulatory cytokine IFN-α illustrates 
an inability of these mature DCs to synthesise C1q. This reinforces the idea of IFN-alpha 
playing a pathogenic role in SLE where low levels of C1q observed could be due to this 
cytokine (Ronnblom and Alm, 2001; Castellano et al., 2004). The production of 
functionally active C1q by immature DC (iDCs) provides an additional role for C1q in 
apoptotic cell clearance, as iDC show enhanced uptake of apoptotic cells through their 
C1q. Interstitial DC and Langerhan cells are subsets of DC and at precursor levels also 
produce low amounts of C1q. However, once differentiated into DC, interstitial cells 
appear to produce a considerably higher amount of C1q (Castellano et al., 2004). 
Recently, it has emerged that C1q is locally produced in the kidney by myloid DCs 
(Castellano et al., 2010). This has implications in the pathogenesis of lupus nephritis as 
it has been found that SLE patients with severe lupus nephritis showed C1q positive 
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myloid DC infiltrating into the tubule interstial which may contribute to local tissue 
damage seen in SLE via complement. Expression of C1q has also been detected in 
arterial wall DCs (Cao et al., 2003), which suggests a role for DC abundant in 
atherosclerosis lesions suggesting that the C1q they produce may play a role in trapping 
ICs as seen in the pathogenesis of atherosclerosis. Unlike other complement proteins, 
this APC cell origin of C1q by macrophages and DCs puts forward a role for C1q in 
regulating APC mediated adaptive immunity which is linked to the pathogenesis of 
several diseases. 
Interestingly, decidual endothelial cells (DEC) have been shown to synthesise and 
express C1q (Bulla et al., 2008) unlike other endothelial cells of blood vessels. This 
surface bound C1q to DEC has been shown to act as a molecular bridge between the 
decidual endothelium and endovascular trophoblasts. In relation to this, migrating 
extravillious trophoblasts have also been shown to synthesise and secrete C1q 
(Agostinis et al., 2010) with their C1q promoting trophoblast invation of the decidua 
through C1q interacting with Integrin α4 of the decidual extracellular matrix. 
Interestingly, mice studies have revealed that C1q deficiency led to increased fetal 
resorption, reduced fetal weight and impaired decidual vessel remodeling which 
suggests that defective production of local C1q can lead to pregnancy disorders. As 
mentioned previously, neurons and microglia in the CNS are also known to synthesis 
C1q. More recently it has emerged that astrocytes also induce the production of C1q in 
neurons through a mechanism that is yet to be identified (Stephan et al., 2012). Thus, 
the local synthesis of C1q can lead to regulation of the inflammatory processes. 
1.12 gC1q binding receptors 
1.12.1 gC1qR  
gC1qR (33kDa) and CRT (previously known as cC1qR) are two well-studied and most 
ubiquitous C1q receptors involved in mediating a range of C1q mediated biological 
processes. The 33kDa protein gC1qR was first isolated from Raji cells (figure 1.12) and 
is found on fibroblasts, neutrophills and endothelial cells. gC1qR has been shown to 
bind to the globular head region of C1q (gC1q domain) (Ghebrehiwet et al., 1994). In 
addition to binding to C1q, gC1qR has also been shown to bind other various plasma 
proteins such as thrombin, prothrombin and vitronectin (Lim et al., 1996). Although 
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expressed on the cell surface, gC1qR interacts with β-integrin to allow transmission of 
signals to the cell surface (Eggleton et al., 1995). In terms of secretion, different studies 
have challenged various findings of how gC1qR is secreted. Peterson et al demonstrated 
that gC1qR is secreted in a soluble form from cytoplasmic vesicles on the plasma 
membrane of Raji cells and Peripheral blood lymphocytes). However, Dedio et al has 
shown that gC1qR is localised in the vesicular compartment of endothelial cells 
concluding that its primary location is intracellular with only a minority located on the 
surface.  The underlying mechanism of gC1qR secretion is yet unknown (Peterson et al., 
1997)  
1.12.2 gC1qR Structure and Function 
gC1qR is shown to bind to the gC1q domain of C1q via high affinity interactions 
(Ghebrehiwet et al., 1994). It has also been shown to interact with proteins of the 
intrinsic coagulation/ Bradykinin cascade such as HK (High molecular weight 
Kininogen), fibrinogen, thrombin and multimeric vitronectin (Joseph et al., 1999) 
Binding of gC1qR to C1q has been shown to bring upon a number of biological 
responses including procoagulant activity on platelets (Peerschke et al., 2001) and anti-
proliferative responses on B and T cells. C1q is shown to bind to gC1qR expressed on 
platelets bringing upon initiation of complement, which leads to inflammation. 
Experiments have shown that platelets exposed to stress led to the largest amount of 









Figure 1.12: Surface expression of gC1qR on Raji cells: Antibodies 60.11 which binds to 
residues 74-96 and pAb 74.5.2 which interacts with residues 204-218 have been used to detect 
expression of gC1qR. (Ghebrehiwet et al 1994) 
C4 deposition. This suggests that platelets may drive classical activation in this manner 
to sites of vascular injury to enhance the inflammatory response to repair wound 
healing. 
Alongside this, C1q’s non complement functions are also underlined in the activation 
and adhesion of platelets through binding to both CRT and gC1qR (globular head 
receptor) expressed on platelets Studies have shown that platelet aggregation in 
response to C1q follows expression of P-Selectin and alphaII beta/beta 3 integrin With 
P-Selectin playing an essential role in recruiting immune cells to the site of injury and 
alphaII beta 3 crucial in platelet aggregation in thrombosis, C1q activating platelets and 
inducing procoagulant activity may contribute to the pathology associated with 
thrombosis. Binding of the Hepatitis C Virus (HCV) core to gC1qR expressed on the 
surface of T-cells weakens the activation of the lymphocyte’s intracellular signaling 
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proteins, Lck and ZAP-70, thereby effectively suppressing T cell proliferation (Yao et al., 
2004). The binding of gC1qR to HK brings upon the formation of Kalekrein, which 
generates Bradykinin, a peptide that increases the vascular permeability of the vessel 
wall leading to the infiltration of pro-inflammatory tissue (Kaplan et al., 2001). 
gC1qR, being a cell surface protein brings to our interest the properties of its two faces; 
the membrane face which is basic and interacts with the cell surface, and its solution 
face which is highly acidic and recognizes ligands (figure 1.16) (Ghebrehiwet et al., 
1994). The C1q binding site on gC1qR was identified on residues 76-93 (figure 1.17), 
whereas the HK binding side resides on residues 205-218 (figure 1.17) (Joseph et al., 
1996). Since C1q binds gC1qR when it is bound to the cell surface, the C1q binding site 





Figure 1.13: Surface expression of gC1qR in permeabilised and non-permeabilised cells. 
2-D microscopic studies reveal surface expression of gC1qR as well-defined patches. 
 
gC1qR is synthesized as a pre-pro protein of 282 residues. It was initially thought that residues 
74-282 were expressed on the cell surface membrane, postulating that the pre-pro residues 1-
73 are cleaved off, expressing only the ‘mature’ form. However, it has recently been shown that 
the full length protein comprising of residues 1-282 do in fact exist on the cell surface (Hosszu 
et al., 2010). The three – dimensional crystal structure of gC1qR resembles a trimeric ‘doughnut’ 
(figure 1.14) composed of 3 identical chains (Ghebrehiwet et al 2002). The spacefill residues 
between each monomer are known as the amino terminal Met, and carboxy terminal, Gln, 
(Ghebrehiwet et al., 2002) and between each monomer the amino and carboxy terminals are in 
contact with each other (figure 1.14). The crystal structure shows gC1qR folds with seven 



















Figure 1.14: Structure of gC1qR: The configuration of gC1qR appears as a homotrimeric 
structure composed of three momomers. The spacefill residues are the amino terminal Met 
(red), the Carboxy terminal Met (green) and the carboxy terminal Gln (yellow). In each 
monomer the amino terminal and the carboxy terminal are in contact with each other 
(Ghebrehiwet et al., 2002) 
As mentioned previously, an interesting feature of gC1qR is that it is devoid of a 
transmembrane domain, therefore, how it is anchored to the cell surface is not known. 
It is speculated that gC1qR transduces its signal through a docking/signaling complex 
via membrane spanning proteins such as β1 integrins (Yin et al., 2007). This has been 
demonstrated on endothelial cells, where binding of gC1qR to its ligand (gC1q) leads to 
the assembly of these membrane proteins, which have direct means of expression to 








able to convey its message across the membrane and bring upon biological responses 
such as inflammation (Feng et al., 2002)  
 
 
Figure 1.15: Folding topology of gC1qR monomer: Ribbon representation of gC1qR showing 
seven antiparallel β-strands with a C-terminal and N-terminal α-helical strands at the edge.  
Although gC1qR binds to the globular head region of C1q, it is not yet identified as to 
which chain of the gC1q domain this interaction is specific too. To date it has been 
shown that C1q binding to gC1qR on platelets and endothelial cells induces complement 
activity independent of IgG (Peerschke et al., 2006), as well as an anti-proliferative 
response on B and T lymphocytes (Ghebrehiwet et al., 1990). Recently it has been found 
that gC1qR is associated with C1q on the surface of immature DC, along with DC-SIGN to 
form a trimolecular complex (Hosszu et al., 2012). As C1q is already known to modulate 
the differentiation of monocytic derived DCs, this provides a potential role for C1q to 
bind to gC1qR-DC-SIGN complex and initiate DC-SIGN mediated cellular signaling to 
regulate DC differentiation. 
Residues 1-73 which consist of the precursor sequence have been found to hold a signal 
sequence MLPLLRCVPRVLG at its N terminus which is targeted to the mitochondria 
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(Dedio et al, 1998) but could also be a signal sequence to anchor gC1qR to the cell 
surface. It appears that the sequence CGSLHT that forms the mature protein is identical 
in mitochondrial and cell surface gC1qR which hypothesizes that the signal pathway 
that processes intracellular gC1qR may also target gC1qR to the cell surface (Van 
Leuwen and O’ Hare 2001) 
Mature gC1qR is very acidic with a calculated p.i of 4.15. Unlike the prepro sequence 
which holds an abundance of Cys residues, the mature sequence holds only one Cys at 
position 186 so is void of intrachain disulphide bonds (Ghebrehiwet et al 2001).  
The cDNA of gC1qR reveals 97% sequence homology between rat and mouse, whereas 
comparison between both these sequences and human shows 89% similarity ((Lynch et 
al., 1997). The gC1qR gene is located on chromosome 17p13.3 and is composed of 6 





                                                  
Figure 1.16: Faces of gC1qR: gC1qR consists of two faces, the solution face (S) and the 
membrane face (M). Residue Trp283 protrudes from the solution face. Sequences 189-190 and 
197-201 are only located in the A chain. The rotation of gC1qR 90◦ from the S face shows 









Figure 1.17: Ligand binding sites on gC1qR: Crystal structure analysis has enabled the 
modeling of gC1qR to identify ligand binding sites. The diagram represents the soluble (S) face 
and membrane face (M) when the protein is rotated 180°. The binding sites for the gC1qR 
ligands, C1q and HK have been identified and represented in blue according to antibody 
recognition. The mAb 60.11 recognizes the C1q binding site (residues 76-94), indicated in blue 
on S face and M face. The mAb 74.5.2 recognises the HK binding site (204-218) indicated in blue 






Table 1.3: gC1qR is a Pattern Recognition Receptor: Viral ligands gC1qR binds to 
and subsequent effector functions  
 
 
gC1qR is a pattern recognition receptor due to its ability to bind to a range of viral ligands. The 
gC1qR amino acid residues complementary in interacting with the respective ligand are 
provided, along with the exon the residues are found on. Along with binding to such ligands, this 
interaction with gC1qR is able to exert physiological effects to bring about relevant functions 





Table 1.4: Functions of gC1qR 
 
 
1.12.3 gC1qR in Inflammation 
The role of gC1qR in inflammation has been highlighted through its ability to bind 
plasma proteins such as C1q and HK (table 1.4). Studies have shown that both native 
and recombinant gC1qR are able to activate the classical pathway (Ghebrehiwet et al, 
1994).  The binding site for gC1qR and IgG on C1q could potentially overlap since gC1qR 






gC1qR binds to HK and activates the coagulation cascade leading to 
the generation of the vasoactive peptide Bradykinin which causes 
vasodialation. Recently additional binding sites have been identified 
on gC1qR that are complementary to HK and are implicated to be 
targets for vascular permeability and inflammation. 
 
Joseph et al 1994 
Ghebrehiwet et al 2012 
 
gC1qR binds to endothelial to activate the classical pathway 
 
Joseph et al 1999 
 
gC1qR is able to bind to T and B lymphocytes and initiate an anti-
proliferative response 
 
Ghebrehiwet et al 1990 
 
Platelet gC1qR contains a binding site for staphylococcal protein A 
and plays a role in bacterial cell adhesion to sites of vascular injury 
and thrombosis. 
 
Nguyen et al 2000 
 
gC1qR forms a complex with C1q and DC-SIGN on the surface of iDCs 
to regulate DC differentiation 
 
Hosszu et al 2012 
 
gC1qR binding to platelets leads to the adhesion and activation of 
platelets  
 
Peerschke et al 2003 
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SRBCs. Structural data to support this has revealed that gC1qR interacts specifically 
within residues 155-164 of the A chain, which is also predicted to interact with IgG 
(Marques et al 1993). Given that gC1qR has complement inducing activity on 
endothelial cells and platelets (Peerschke et al 2004) appears to indicate that at sites of 
inflammation, gC1qR is a possible activator of the classical pathway. 
Aside from the complement system, gC1qR is able to activate the Kallikrein/Kinin 
system (KKS) through its interaction with HK. HK interacts with gC1qR through its C 
terminal region on residues 204-218 (Joseph et al 1994) and is zinc dependent (Kaplan 
et al 2004). High affinity interaction between gC1qR and HK begins the assembly of the 
contact system where Kallikrein is formed and leads to the generation of the vasoactive 
peptide Bradykinin (BK). BK then exhibits its effects by binding to its B2 receptor 
(Regoli and Barabe, 1980) on the surface of endothelial cells. These cause vasodilatation 
and is enhanced through the production of vasodilators such as nitric oxide. BK’s 
inflammatory properties are evident in the disease angioedema where it is responisible 
for the swelling observed. 
1.12.4 DC-SIGN 
Very recently, DC-SIGN (Dendritic Cell Specific ICAM3 grabbing Non Integrin) has been 
shown to be a ligand of C1q (Hosszu et al., 2012). DC-SIGN is a C-type lectin expressed 
on DCs (Geijtenbeek et al., 2000) that functions to mediate interactions between DCs 
and T-cells via ICAM3 (Intracellular adhesion molecule). The binding of DC-SIGN to its 
ligands such as ICAM-3, mannose and mannan is mediated through its carbohydrate 
recognition domain (CRD) and is calcium dependant (Curtis et al., 1992) which 
hypothesizes that DC-SIGN binding is carbohydrate dependant with high affinity to 
oligosaccharides which are present in both ICAM3 and gp120. C1q has been shown to 
co-localise with DC-SIGN and gC1qR on immature DC which has raised the idea that this 
complex of C1q with its receptor and ligand could be involved in DC differentiation 
through the binding of C1q with DC-SIGN signaling through the NF-kB pathway (Hosszu 
et al 2012). Evidence from Hosszu et al has shown that the binding of C1q to DC-SIGN 
has been inhibited by Ca+ and mannan suggesting that C1q binds to DC-SIGN via its Ca+ 
binding site through its globular domain. In light of this statement, it has been 
speculated that DC-SIGN shares the same binding site with C1q as IgG (Hosszu et al., 
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2012) which puts forward the possibility of DC-SIGN-C1q being an initiator of the 
classical pathway. Additional significance of this interaction could be applied in an 
infection model where the interaction of these two proteins could somehow play a role 
in pathogen entry due to accumulating evidence of C1q receptors and ligands becoming 
key players in binding viral pathogens (Fausther-Bovendo et al., 2010) and infection 
transmission. DC-SIGN has also  been shown to play a role in  HIV infection where it 
binds to the HIV1 envelope protein gp120 (Masso, 2003). However DC-SIGN does not 
behave as a receptor on DC for viral entry, instead it acts as a reservoir by carrying DC 
cells with this viral infection through the lymphatics into the peripheral mucosa where 
it transmits HIV-1 to CD4+ T-cells leading to their infection and depletion as observed in 
the disease. This is evident on both immature and mature DC expressing DC-SIGN. The 
interaction of DC-SIGN with gp120 has been further elucidated by Sarker et al 2013 who 
has shown that the binding of DC-SIGN with gp120 leads to gp120 downregulating IL-6 
release by Nef, another viral regulatory protein. The mechanism of this is bought upon 
by gp120 interacting with DC-SIGN which activates Ras-GTPase to induce Raf-1 which 
activates the NfKappaB pathway by translocating the p65 fragment of NfKappaB in the 
nucleus, and triggers IL-10 release. This IL-10 induction leads to the cytokine 
suppressor SOCS-3 being activated which initiates the downregulatory effect of IL-6 on 
Nef through gp120 on iDC. This clearly reflects on the DC-SIGN-gp120 induced signaling 
contributing to HIV pathogenesis. 
1.12.5 DC-SIGN-R 
DC-SIGN-R (DC-SIGN-Related) is a homolog of DC-SIGN that binds C1q (Kang et al., 
2006). Both these C-type lectins share 77% sequence homology and binding is proposed 
to be calcium dependant. DC-SIGN-R is expressed on endothelium including liver 
sinusoidal, lymph node sinuses and placental capillary (Mitchell et al., 2001). Functions 
of DC-SIGN-R have been shown to lie with also binding ICAM-3 as well as gp120 to 
facilitate HIV viral infection (Bashirova et al., 2001). This C-type lectin has been 
previously noted to be the receptor for bacterial dextrans (Kang et al., 2003) and 
capsular pneumococcal polysaccharide (CPS) of S. pneumoniac. DC-SIGN-R binding to 
CPS has shown to lead to the proteolysis of C3 and binding of C3 opsonins to CPS (Kang 
et al 2006) which led to the discovery that SIGN-R binds directly to C1q upon 
interacting with the polysaccharide independent of an antibody. DC-SIGN-R is shown to 
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be highly expressed by spleen marginal zone macrophages (MZM) and lymph node 
macrophages (Leavy, 2006). It has very recently emerged that SIGN-R1 produced by 
MZM interact with C1q in the spleen and enhance apoptotic cell clearance through 
interacting with C1q and activating the SIGN-R mediated classical complement pathway. 
This newly discovered complement pathway uses macrophages expressed DC-SIGN-R to 
capture microbial polysaccharides in the spleen by directly binding to the bacterial 
surface which then allows C1q to engage with SIGN-R and activate the classical pathway 
(Prabagar et al., 2013). This illustrates that SIGN-R plays a role in apoptotic cell 
clearance and immune tolerance through mediating the classical pathway. 
1.13 Collagen Binding receptors 
1.13.1 Calreticulin 
CRT is also referred to as the ‘collectin receptor’ (cC1qR) due to its ability to bind to 
various other collagenous domains of MBL (Mannan Binding Lectin) and Surfactant 
Protein A (SP-A) and SP-D (Malhotra et al., 1993). CRT is comprised of 3 domains, N, C 
and P (Figure 1.18), and studies have shown specific C1q binding domains in the N-
terminal domain of CRT (Kishore et al., 1997). This domain essentially plays a role in 
interacting with glycoproteins and regulating the chaperone function of the protein. 
Alongiside this, the N-terminal domain of CRT shows sequence similarity to IgG and its 
binding site has been shown to compete with IgG for C1q binding. Several studies have 
shown that such peptides inhibit complement activation by occupying the IgG binding 
site on C1q (Kovacs et al., 1998). As stated earlier, CRT and C1q has also been shown to 
play a role in apoptotic cell clearance via macrophages due to C1q being present on the 
surface of apoptotic cells and CRT linked to CD91 (Srivastava, 2002) at the monocyte 
cell surface (Gregory and Devitt, 2004; Kishore et al 1997) has shown that the globular 
head region of C1q also has the ability to bind to CRT and furthermore CRT deficiency 
showed an increase in C1q binding to apoptotic cells which revealed to be due to 
phosphatidylserine on apoptotic cells sharing the same binding site with CRT on C1q. 
This states an insight into the role of CRT and C1q in the removal of apoptotic cells 
through their involvement with PS which allows macrophages to connect with apoptotic 
cells. The chemotactic properties of gC1qR and CRT have also been observed by 
researchers who showed that DC cells treated with anti-gC1qR and anti-CRT reduced 
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chemotactic responses to C1q (Vegh et al., 2006). It was shown that the DC cells treated 
with anti-CRT entirely abolished DC chemotaxis, whereas anti-gC1qR treatment 
reduced cell migration highlighting that each of these receptors holds different 
chemotactic propertie 
 
Figure 1.18: Structure of Calreticulin: CRT has a molecular weight of 55-60 kDa and is divided 
into 3 domains; the N-terminal (N), Proline- rich domain (P) and a C-terminal (C). The N 
terminal plays a role in interacting with glycoproteins and regulating the chaperone function of 
the proteins. It also binds Ca2+ with high and low affinity. The C- domain has high affinity for 
binding Ca2+ and helps regulate Ca2+ storage in the ER. The P-domain pays an important role in 
binding to ERp57 to aid disulphide exchange reactions in incorrect folded proteins in the ER  
(Mendlovic et al, 2011;Ellgaard et al., 2001). 
Although CRT has been proposed to function as a receptor complex with CRT where 
CD91 acts as the phagocytic transmembrane molecule (Basu et al., 2001) and CRT 
engages directly with apoptotic cells, data has emerged to expose that C1q is capable of 
recognizing CD91 directly, independent of CRT (Duus et al., 2010). Experiments have 
shown that C1q binds to cells from a CD91 expressing monocytic cell line as well as 
monocytes from human blood with this binding corresponding with CD91 expression. 
Inhibition studies have reported that 45% inhibition was observed where CRT was used 
to interfere with C1q and CD91 binding, which suggests that only part of C1q is shared 
as a binding site for both these receptors (Duus et al., 2010). This identifies CD91 as a 
clear receptor for C1q and proposes that CD91 is a phagocytic receptor capable of 




C1qRp in another putative receptor for C1q (Nepomuceno et al., 1997). This C1q 
receptor is an heavily glycosylated 97kDa protein expressed on myeloid cells, 
endothelial cells and platelets (Nepomuceno et al., 1999). C1qRp also known as CD93 
has been found to bind to the collagen region of C1q as well as a number of other 
collectins such as Surfactant Protein A (SpA) and MBL. Structurally, C1qRp is composed 
of a C-type lectin domain, an array of epidermal growth factor like domains, a single 
transmembrane domain and a short cytoplasmic tail (Nepomuceno et al., 1999). Its role 
within C1q has been initially demonstrated to lie with C1q mediated enhancement of 
phagocytosis, as the binding of C1qRp and C1q resulted in increased phagocytic 
function with this enhancement dramatically reduced to 80% with anti C1qRp antibody. 
However, the functional role of C1q with this candidate receptor has raised a great deal 
of controversy as to how this molecule interacts with C1q on the cell surface to trigger 
biological responses. For instance, C1qRp-C1q interaction has been speculated by 
McGreal et al 2002 who showed under physiological conditions that cells infected with 
C1qRp failed to bind C1q. This puts forward the idea that C1qRp augments C1q 
mediated phagocytosis by monocytes as a co receptor as opposed to direct binding. 
However, this notion has been further challenged as Norsworthy et al 2004 have 
provided evidence using C1qRp deficient mice to indicate that CD93 deficiency in 
peritoneal macrophages has no impact on C1q mediated phagocytosis and instead 
illustrated an impaired ability to uptake apoptotic cells, thereby postulating a role for 
CD93 in the removal of dying cells. CD93 has also been hypothesized to play a role in 
cellular adhesion (McGreal and Gasque, 2002), due to its ability to bind vascular 
endothelial cells and its abundance of motifs common to other intracellular adhesion 
molecules. Nevertheless, further work based on this hypothesis (Norsworthy et al., 
2004) states that CD93 deficiency has no effect in leading to cellular changes in 
distribution and adherence of peripheral blood cells. Quite recently, soluble CD93 
expression has been known to be elevated in response to inflammation (Greenlee et al., 
2009). Experiments undertaken by Greenlee et al 2009 to elucidate the molecular 
mechanism behind this CD93 dependant regulation of inflammation and any association 
with C1q have revealed using a thioglycollate induced peritonitis infection model that 
CD93 deficient mice after induction of peritonitis confirmed deregulation of C1q 
hemolytic activity which was correlated with increased leucocyte recruitment which 
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clearly highlights a connection between CD93 and the classical complement function of 
C1q. 
1.13.3 α1β2 Integrin  
α2β1 Integrin is an collagen binding receptor also capable of binding to laminins, 
decorins and several viruses (Zutter and Edelson, 2003). It is expressed on several cell 
types including epithelial cells, fibroblasts, endothelial cells and platelets. α2β1integrin 
has been suggested to hold a number of roles in inflammation (de Fougerolles et al., 
2000), such as the deficiency of α2β1 integrin in mice failing to elicit inflammatory 
responses to the Gram negative bacteria Listeria monocytogenes as well as high 
expression of this integrin expressed on peritoneal mast calls which are needed for 
inducing inflammatory reactions in response to infection in the peritoneal cavity 
(Echtenacher et al., 1996). In light of this statement C1q has been identified as a ligand 
for α1β2 Integrin with this interaction specific to the a2 integrin domain where C1q is 
shown to mediate PMC adhesion (Edelson et al., 2006). The capability of mast cells 
expressing a2 b1 Integrin to bind to C1q bound ICs and stimulate mast cell activation 
provides a favorable role for 21 Integrin in modulating the immune response. 
Alongside this, it has been shown that 21 Integrin-IC interaction is capable of 
providing signals to secrete cytokines by mast cells in response to various stimuli, and 
hypothesizes a role for α2β1Integrin in regulating autoimmune and allergic disorders. As 
a2 b1 Integrin serves as a collagen receptor on platelets, initial studies have identified 
this protein expressed on platelets involved to play a role in C1q binding (Peerschke 
and Ghebrehiwet, 1997b). However, antibody inhibition studies concluded a small 
decrease of 17% in platelet adherence to C1q which diminished the idea of a2 b1 Integrin 
involved in C1q- platelet adherence. The function of 21 Integrin in the activation of 
mast cells could be explained through the indirect activation of the classical pathway. 
For instance, the binding of this receptor to C1q on ICs could trigger the complement 
cascade which leads to the deposition of C3b in turn generating C3a or C5a thereby 
activating mast cells. 
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1.13.4 Complement receptor 1 (CR1) 
Complement Receptor 1 (CR1) is another protein identified as a C1q receptor specific to 
the CLR  (Medof et al., 1982) and is expressed on esoniphills, neutrophils, monocytes, B 
and T lymphocytes and erythrocytes. Its role involving C1q lies within CR1 binding to 
C1q bound ICs and targeting them for clearance. Due to CR1 holding a major role on 
phagocytic cells in regulating the phagocytosis of complement opsonised pathogens 
(Gigli et al 1968), it is also capable of binding to the opsonins C3b and C4b (Tas et al., 
1999) which attach onto ICs to enhance their clearance. The cellular function of CR1 
widely differs depending upon the type of cell it is expressed on. For example it has 
recently been found that CR1 expression levels hold implications in RA (Kremlitzka et 
al., 2013) due to its downregulation on B cells observed in the disease. However despite 
this low expression of CR1, it has been shown to have no effect on the inhibitory 
function of B cells as data has illustrated CR1 clustering by its ligand to result in major 
inhibition of B cell proliferation in correlation to what is seen in healthy individuals 
which raises the point that CR1 hold alternate roles as a possible therapeutic target in 
arthritis. CR1 has also been shown to inhibit the differentiation of B cells to 
plasmoblasts, as well as inhibit their antibody production highlighting a role in B cell 
activation. The role of this complement receptor expressed on erythrocytes has been 
revealed to bind to C1q and mediate erythrocyte adhesion (Tas et al., 1999).  Moreover, 
experimental evidence on erythrocytes has confirmed that CR1 plays the role of an 
immune adherence receptor by being able to bind to the opsonic ligands C3b and C4b 
and mediate adhesion. The fact that C1q has been shown to enhance C4b mediated 
adhesion to CR1 is of great beneficiary in cases with lower levels of C4b. interestingly, 
CR1 dependant phagocytosis of complement opsonised pathogens is decreased in SLE 
patients (Mir et al., 1988)  which suggests that this impaired function of CR1 on 
phagocytes could somehow give rise to these autoimmune disease. Although C1q also 
opsonises ICs (IC), research has shown that CR1 failed to remove IC in patients deficient 
for C3b and C4b which emphasizes that the interaction between C1q and this receptor is 




C1qR02 is a C1q receptor that has been identified to trigger superoxide in 
polymorphonuclear leucocytes (Tenner, 1998). The generation of superoxide is a 
protective mechanism produced by immune cells to help destroy pathogens. The 
activation of superoxide leads to degranualation of the cell due to secretion of 
proteolytic enzymes from the granules. However, C1q mediated activation of 02- does 
not lead to degranulation of the leucocyte. Alongside this, C1q regulated respiratory 
burst does not require increased cell adherence, a feature which is accompanied by 
oxidative burst (Goodman et al., 1995)This holds implications in diseases such as SLE 
where the non-specific host tissue damage could be due to activation of the oxide 
produced by C1q (Schur, 1982). Evidence for the C1qR02 specificity for C1q comes from 
antibodies that bind C1qRp on neutrophils failing to inhibit C1q induced production of 
02 by neutrophils (Guan et al., 1994). Structural studies within this C1q and this 
receptor have shown that the C1qR02 binding site on C1q required triple helical 
secondary structure in for functional activity to take place (Ruiz et al., 1995). In addition 
to this, the kink region of C1q is also hypothesized to be essential for functional binding 
between C1q and C1qR02. The active site on C1q accountable for generating 02 
production has been recognized as amino acids 42-61 of the C chain of the CLR. 
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In this thesis we have addressed the nature of interaction between gC1qR and some of 
its known biologically relevant ligands. Thus,  
Chapter 3 examines the interaction between recombinant gC1qR and recombinant 
globular head modules of human C1q. in order to further characterize the interaction, a 
number of substitution point mutations were examined for their affinity to gC1qR. Since 
C1q expression is upregulated in adherent monocytes, we also examined concomitant 
expression of C1q and gC1qR in adherent monocytes with and without challenge with a 
pro inflammatory stimuli such as lipopolysaccharide (LPS). C1q is known to have an 
anti-proliferative effect, thus, the ability of globular head modules and gC1qR to 
modulate C1q functions on mitogen stimulated PBMCs is also a subject of investigation 
and discussion. 
Chapter 4 examines interaction between gC1qR and its newly discovered adaptor 
molecule on the cell surface DC-SIGN whose interaction is likely to have profound 
implications on HIV-1 infection of Dendritic Cells. Using recombinant forms of 
monomeric and tetrameric DC-SIGN and SIGN-R we have extensively characterized the 
interaction between the tripatipe interaction between globular head modules, gC1qR 
and DC-SIGN. These studies are now ripe for further understanding the modulation of 
HIV infection which is currently underway. 
Chapter 5 examines gC1qR ability to act as pattern recognition receptor for HIV-1 gp41 
and HCV core protein. The structure function relationships between gC1qR and its viral 
ligands have been extensively studied using recombinant proteins and synthetic 
peptides. 
Chapter 6 identifies the ability of gC1qR to bind to endothelial cells via fibrinogen and 
upregulate the surface expression of bradykinin 1 receptor using a range of binding and 
microscopic experiments, this chapter provides an excellent model of how gC1qR can 











CHAPTER 2:  

















2.1 Purification of Human C1q 
C1 was purified from freshly-thawed serum. Briefly, freshly thawed serum was made 
5mM EDTA and centrifuged to remove aggregated lipids. The serum was then incubated 
with non-immune IgG coupled to CnBr-activated sepharose (GE Healthcare, UK) for 1 
hour at 4degrees. The plasma with IgG-sepharose was filtered through a scintered glass 
funnel, ensuring that no air bubbles are formed. The C1q-bound sepharose is then 
washed extensively with 10mM HEPES, 140mM NaCl, 0.5mM EDTA, pH 7.0 and C1q is 
eluted with CAPS buffer (100mM CAPS, 1M NaCl, 0.5mM EDTA, pH 11.0). The eluted C1q 
is then passed through a HiTrap ProteinG column (PierceNet, USA) to remove IgG 
contaminants and dialysed against the washing buffer.  
2.2 Constructs expressing Wild Type and substitution mutants of ghA, ghB and 
ghC modules of C1q 
The C-terminal globular region of human C1q A (ghA), B (ghB) and C (ghC) chains were 
expressed as maltose binding fusion proteins using the expression vector pMal-c2 
(figure 2.1) as described by earlier (Kishore et al 2003). Each mutant has been altered 
by substituting a single amino acid involving either Arginine (R) to Alanine (A), 
Glutamate (E), or Glutamine (Q) substitutions, or Histidine (H) to Alanine (A) or 
Aspartate (D) substitutions, and Leucine (L) to Glutamate (E). The following mutants 
were purified: ghA mutants were Arg162E, Arg162A, ghB mutants were Arg114Q, Tyr175L, 
Arg114A, Arg129A, Arg129E, Arg163E, Arg163A and His117D. ghC mutants were Arg156Q, Arg156E, 
His101A and Leu170E. The generation of various mutants has been described previously by 










Figure 2.1: pMalc vector:  
The pMal-c2 vector was used to express the ghA, ghB and ghC globular head substitution 
fusion proteins. The gene was cloned downstream to the malE gene of E.coli which codes for 




















Figure 2.2:  pT5t vector: The cDNA for DC-SIGN tetramer, DC-SIGN monomer, SIGN-R tetramer 













Figure 2.3: pGEX vector: Map of the glutathione S-transferase fusion vector used for 














2.3 Bacterial Transformation  
Various expression constructs used for making the recombinant proteins were 
transformed in BL21, the host strain of E. coli and selected on Ampicillin (100µg/ml) LB 
agar plates, with the exception of the transformant expressing the monomeric form of 
SIGN-R, which was selected for kanamycin resistant (50µg/ml). 
 A single colony of BL21 (DE3) was inoculated in 5ml of LB (Lauria Broth) medium and 
grown overnight in a 37° shaker.  The next morning 500µl of this overnight culture was 
inoculated in 25ml LB and grown at 37°C, A600 was read every hour until the cells 
reached a value of 0.3. The cells were then pelleted by centrifugation at 3000rpm for 10 
minutes and the supernatant discarded. The cell pellet was then gently re-suspended in 
12.5ml of 0.1M CaCl2. This was then left on ice for an hour and centrifuged again. The 
cells were resuspended in 2ml of ice cold 0.1M CaCl2 (Competent cells). 200µl of 
competent cells were added to an eppendorf tube containing 2µl of the plasmid. This 
mixture was left on ice for an hour. The mixture was then heat shocked at 42°C for 90 
seconds. 800µl of LB medium was added to the mix and left in the 37°C incubator for 40 
minutes. 150µl of this culture was then plated out on the antibiotic containing plate (LB-
Ampicillin or LB-Kanamycin) and left to grow overnight at 37°C. 
2.4 Pilot scale testing for the recombinant Protein Expression using IPTG 
A single transformed colony was selected from its transformed plate and incubated in 
5µl of its resistant antibiotic and 5ml of LB overnight in a 37°C shaker. The next 
morning, 200µl of the overnight culture was added to 10ml of LB with 10µl of its 
antibiotic and left to grow in the 37°C shaker until it reached a reading of 0.6. 1ml 
sample was then removed to test for uninduced expression and IPTG (isopropyl-ß-D-
thiogalactopyranoside ) was added to the sample and left in the 37°C shaker for 3 hours. 
Once induction time was over, 1 ml sample was collected to assess the induction of the 
expression. Both uninduced and induced samples were spun down at 13,000rpm for 10 
minutes using a micro-centrifuge and the supernatant was discarded. 100µl of 
treatment buffer was added to the samples and they were heated at 100°C for 10 
minutes. Expression for uninduced and induced samples was tested on an SDS-PAGE 
gel. Once the best colony for expression was established the next step was to upscale it. 
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2.5 Upscale of the wild-type and substitution mutants of the globular regions of 
C1q A, B and C chains (ghA, ghB and ghC, respectively) 
A single colony was inoculated individually in 5ml of LB and 5µl of Ampicillin and left to 
grow overnight in a shaking 37°C shaker. The next morning, the overnight inoculum 
was transferred into 200ml of LB with 200µl of ampicillin and left to grow in the 37°C 
for 2-3 hours until the cells reached an OD (600 nm) of 0.6. 1ml of the culture was 
transferred into an eppendorf tube to use as an uninduced sample. The rest of the 
culture was induced with 0.5mM IPTG and both un-induced and induced samples were 
further incubated for 3 hours in a 37°C shaking incubator. After induction was complete, 
1ml of the induced sample was transferred into an eppendorf tube and along with the 
un-induced sample, the samples were centrifuged at 13,000rpm for 10 minutes and the 
supernatant discarded. The pellet was resuspended in 100µl of treatment buffer and 
heated on a heat block at 100°C for 10 minutes. Expression was tested on a 10% SDS-
PAGE gel by loading 15µl of each sample and running the gel at 120v. The 200ml culture 
was harvested by centrifugation at 4500rpm for 10 minutes and the pellets were stored 
at -20°C until required for further processing. 
2.6 Purification of the wild-type and substitution mutants of the globular regions 
of C1q A, B and C chains (ghA, ghB and ghC, respectively) 
The cell pellet obtained after IPTG induction was thawed at 37°C and resuspended in 
lysis buffer (containing 0.1g lysozyme, 20mM  Tris pH 8.0, 0.5M NaCl, 1mM EDTA, 0.2% 
Tween 20, 5% glycerol and 0.1mM PMSF). This was left on a rocker in the cold room for 
1 hour. Following this, the sample was sonicated on ice, (8 cycles at 30 seconds each 
with 2 minute gaps where the sample was placed on ice). The samples were then 
aliquoted into eppendorf tubes and spun down at 13,000 for 15 minutes. The 
supernatant was collected and run on a 15% SDS gel to confirm the presence of target 
protein in the soluble fraction. ghA, ghB and ghC and its mutants were purified by 
running them through Amylose resin columns with a bed volume of 30ml.   MPB being a 
maltose binding protein, therefore an Amylose resin was used which would bind the 
MBP fused to the globular head from the unpurified soluble fraction of the total E.Coli 




2.7 Preparation of Amylose Resin and DEAE Sepharose columns 
Amylose Resin was purchased from New England biolab cat number: E8021L and DEAE 
Sepharose from GE Healthcare Life Sciences cat number: 17-0709-01. 5ml of the resin 
was washed in autoclaved dH20 in a beaker by gently shaking and discarding the water. 
This was repeated 3 times. The resin was then packed into a disposable plastic column 
with a polyethylene filter disc (Pierce, Cat no: 299920) allowing the water to pass and 
leaving the resin intact in the column.   
2.8 Purification using Amylose Resin Column 
The columns were first washed with 0.1% SDS three times, autoclaved dH20 three times 
and buffer I (20mM Tris pH 8.0, 100mM NaCl, 0.2% Tween 20, 1mM EDTA and 5% 
glycerol) three times. 30ml of Buffer I was loaded on the column following the 
supernatant of the protein which was mixed with Buffer I on a ratio of 1:5. This followed 
two 30ml bed volumes of buffer II( 250ml of buffer I (without Tween 20) made up to a 
litre with water). The column was then eluted with 10mM maltose (100ml of buffer II 
with 10mM Maltose) and collected in 15 fractions of 2ml eppendorf tubes and frozen at 
-20.. As MBP has its highest affinity for maltose, it would compete with the amylose 
resin and attach to Maltose, enabling the fusion protein to be eluted from the column 
where it was collected.    
2.9 Cloning, Expression and Purification of human gC1qR 
Recombinant mature gC1qR consisting of sequences 74-282 were expressed in E.coli 
BL21.  Colonies selected from the transformed cells were incolulated in 5ml LB and 5µl 
of Ampicillin overnight at 37°C. The next morning, the overnight inoculum was added in 
250ml of LB and 250µl of Ampicillin and grown at 37°C until an OD of 0.6 was reached. 
The cell culture was then induced with 100ug/ml of IPTG. Following a further 
incubation for 3 hours, the cell culture was spun down (4500rpm for 15minutes). The 
cell pellet was treated with lysis buffer (0.5M NaCl, 20mM Tris pH 8.0, 1mM EDTA, 0.2% 
Tween, 5% glycerol, 0.1g lysozyme) and incubated for 1 hour at +4 shaking. The cell 
lysate was sonicated for 10 cycles for 30 seconds with 2 minute intervals. Following this 




2.10 Ion Exchange of gC1qR 
The supernatant was dialysed using dialysis tubing for 2 hours against 1 litre of 100mM 
NaCl and 20mM Tris at +4°C. The dialysed protein was subjected to ion exchange using 
a 5ml DEAE Sepharose column. The column was first equilibrated by washing with 5 
bed volumes of dialysis buffer. Next the protein sample was passed through the column. 
Purified gC1qR was eluted at a peak concentration of 0.45M NaCl and collected  in 1ml 
fractions. Each sample was then run on a 15% SDS-PAGE gel to assess purity and 
samples were pooled to give a final concentration. 
2.11 Construction of gC1qR deletion mutants 
The gC1qR deletion mutants were expressed and purified using the pGEX vector (figure 
2.3) and kindly provided to us by Ghebrehiwet et al. The rationale was generating these 
mutants was to confirm previously identified binding sites or to discover new ones. The 
deletion sequences were chosen by deleting those sequences predicted to have either a 
membrane attachment or ligand binding site. The residues to be deleted were selected 
by analysing the crystal structure and identifying residues involved in ligand binding. 
The deletions were generated using complementary sense and antisense primers that 
bridge the deleted region. Maxiumum of mutagenesis was achieved by bringing the 
melting temperature on each side of the deleted sequence to 60°C. Primers were 
extended using Pfu Turbo polymerase and the mutant constructs were enriched by 
digestion of the methylated template with Dp1 and transformed into E.coli. A single 
residue mutation was performed on Trp233 which is the only domain that projects out 
on the solution phase side of gC1qR in the crystal structure. Encoded by the codon TGG, 
this residue was mutated by a single base change to GGG (Gly) using double strand 
mutagenesis.  Due to its conspicuous projection, this site is considered to be a wide 
target for plasma or pathogen associated ligands. 
2.12 SDS-PAGE  
SDS-PAGE was used to separate protein samples according to their molecular weight. 
The size of the protein was estimated using a molecular weight marker. The gel 
comprised of two parts, a stacking and a resolving gel. The composition of the stacking 
gel was the same regardless of the percentage of the gel. A separating comb for samples 
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to be loaded into these wells was placed in the stacking gel as soon as it was loaded 
above the resolving gel. After the gel was polymerized, it was placed in a tank and 1 X 
running buffer was poured into the tank over the gel and the separating comb was 
removed. The protein samples were mixed with an equal volume of bromophenol blue 
loading dye and denatured by heating at 100°C for 10 minutes before being briefly 
centrifuged prior to loading  in the wells. A molecular weight protein marker was also 
loaded at approximately 3 μl and the gels were run at 120V for 1.5 hours. The gel was 
then stained with staining solution (50% Methanol, 40% acetic acid with 0.1% 
Coomassie blue). This was left on a rotating rocker for 4hours minimum for proteins to 
incorporate the dye before the de-staining process. After destaining the gel, only the 
proteins stained with Coomassie blue were visible as well as the protein marker to 
estimate the size of the protein. The gel images were taken using the Molecular Imager 
Gel Doc (Peqlab, Sarisbury Green, UK). 
For most purposes a 12% v/v SDS-PAGE gel was made by making a resolving gel 
followed by a stacking gel. The 10ml resolving gel was made up using the following 
reagents: 
Table 2.1: Components of Resolving gel 
Component (12% Resolving 
Gel)  
 
 Volume     
 dH20   3.3ml    
 30% Acrylamide  4ml   
 1.5M Tris-HCL, pH8.8   2.5ml   
 10% sodium dodecyl sulfate 
(SDS)  
 100µl    
 Ammonium persulfate (APS)   100µl   
 TEMED   15 µl   
 
The resolving gel was left to polymerise at room temperature. Once polymerised the 
stacking gel was made and loaded above the resolving gel with a separating comb 




Table 2.2: Components of stacking gel 
Component (Stacking Gel)  
 
Volume  
dH20  3.4ml 
30% Acrylamide 830µl 
1.5M Tris-HCL, pH8.8  630µl  
10% sodium dodecyl sulfate 
(SDS)  
50µl  
Ammonium persulfate (APS)  50µl  
TEMED  15 µl 
2.13 BCA Protein Estimation 
The Pierce BCA Protein was used to quantitate the protein. This assay is based on a 
colormetric method. Firstly, diluted bovine serum albumin (BSA) standards and BCA 
working reagent was prepared. The working reagent was made by mixing 50 parts of 
BCA reagent A with 1 part BCA Reagent B (50:1). 0.1 ml of each standard and unknown 
sample replicate was pipetted into a test tube, and 2 ml of the working reagent was 
added to each tube followed by thorough mixing. The tubes were then incubated at 37°C 
for 30 minutes and then brought to room temperature. The absorbance of each tube 
was measured at 562nm and a standard curve was prepared by plotting the average of 
the OD values for each BSA standard versus its concentration in µg/ml. The protein 






Figure 2.4: BCA standard curve: Typical standard curves for bovine serum albumin (BSA) and 
bovine gamma globulin (BGG) in the BCA Protein Assay.  
2.14 ELISA (Enzyme Linked Immuno Sensitive Assay) 
2.14.1 Direct Binding ELISA 
A 96 well plate was used for all ELISAs and each sample was tested in duplicates. Poly-
L-lysine wells were coated with different concentration of protein in serial dilutions 
(µg/well) in 100µl/well carbonate/bicarbonate buffer pH 9.3 and left overnight at 4°C. 
Following morning the buffer and unbound proteins were discarded and wells were 
blocked with 100µl of 2% w/v BSA in PBS for 2h at 37°C. The wells were then washed 
three times using PBS + 0.05%v/w Tween 20. The desired protein was diluted in 
Calcium buffer (10mM Tris-HCL pH 8, 5mM CaCl2, 50mM NaCl) and added at a constant 
concentration (µg/well) of 100µl. The microtitre plate was incubated at 37°C for 1.5 
hours and 4°C for 1.5 hours. Next, the microtitre wells were again washed three times 
with PBS + 0.05% Tween and 100µl per well of polyclonal antibody (pAb) or 
monoclonal antibody (mAb) in PBS at the relevant concentration was added and 
incubated for a further 1 hour. Three washes were then repeated and 100µl of the 
secondary antibody, either rabbit anti mouse IgG-Horseradish peroxidase (HRP) binds 
to mAb) or Protein A (PA)-HRP (binds to pAb) at a dilution of 1:5000 in PBS was added 
to each well. Wells were then washed again. Finally, the reaction was developed using 
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OPD substrate which reacted with the HRP conjugated protein A and optical density was 
determined under a plate reader at 450 nm. The OPD tablets were diluted in 10 ml of water 
and 100 μl of OPD was added to each well to develop a colour from the enzyme-substrate 
reaction. The optical density of the plate was read under a plate reader at 450 nm. 
2.14.2  Competitive ELISA 
The protein of interest was coated on microtitre wells at a constant concentration 
(µg/well) in bi-carbonate/carbonate buffer pH 9.6 and left overnight at 4°C. The 
following morning blocked was performed as described above. The microtitre wells 
were then washed three times in PBS + 0.05% Tween. The two competitors of proteins 
were added together in a total volume of 100µl buffer per well with one protein at a 
constant concentration and the other competitor at a range of serial dilutions. The plate 
was then incubated for 1.5 hours at 37°C and 1.5 hours at 4°C. Following repeated wash, 
the protein added at a constant concentration was probed using its primary antibody 
approximately diluted in PBS, and then incubated for an additional hour at 37°C. The 
secondary antibody conjugated to HRP was added in PBS to the wells and incubated for 
1 hour at 37°C. Following repeated washing, the plate was read at 492 nm after addition 
of OPD. 
2.15 Far Western Blot 
A SDS-PAGE was prepared using the biorad rainbow marker (Cat no #161-0375). The 
protein(s) were diluted in an equal amount of treatment buffer and heated for 10 
minutes at 100°C. Following a quick centrifuge the sample(s) were loaded into the 
well(s) and the gel was run at 120V. 
After the protein sample had passed through the gel for separation, it was ready to be 
transferred to PVDF membrane. Initially, The gel and western blot material consisting of 
4x 2.5mm Whatman paper, 2x fibropads and PVDF membrane were equilibrated in 
transfer buffer (80% v/w Methanol, 5.8 g Tris Base, 2.9 g Glycine and 0.37 g SDS) for 15 
minutes. The apparatus was set up in the following order: black side- fibropad- 
whatman paper-gel-nitrocellulose membrane-Whatman paper-fibropad-white side, in 
the transfer buffer. As each layer was applied, a serological tip was used to smooth out 
all air bubbles which would alter sufficient transfer of the bands. The western blot 
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sandwich was then placed in the holder ensuring the black side was facing the black, 
and once in the tank, the transfer buffer was poured and the lid was secured well. The 
transfer took place at 320mA for 1 hour with a magnetic stirrer and ice pack in place to 
prevent overheating.  
Once the protein transfer was finished, the PVDF membrane was carefully transferred 
into a plastic cassette using tweezers and blocked for 1 hour at room temperature in the 
blocking solution made up of 3% Non-fat milk powder in PBS. Following this, the 
membrane was incubated overnight at 4°C in the probing protein in the binding buffer 
(50mM Tris-HCL pH 8.0, 100mM NaCl, 5mM CaCl2). The membrane was then washed 5x 
in PBS + 0.02% v/w Tween 20 for 10 minutes each to ensure removal of any non 
specific protein binding. Next, the primary antibody was added at the relevant 
concentration in 10ml of 1% non-fat milk powder in PBS and incubated for 2 hours at 
37°C. The membrane was then washed as described above and the secondary antibody 
conjugated to HRP was diluted in 10ml 1% v/w non fat milk powder in PBS at the 
relevant concentration. This was incubated for 1 hour at room temperature. Repeated 
washes followed this and the membrane was developed using diaminobenzidine 
peroxidase (DAB). 
2.16 Plasmid Preparation 
Competent cells were prepared as mentioned above using TOPO 10 strain of E. coli. The 
plasmid required to be made was transformed in TOPO10 as described in 2.3.  The 
following evening a single transformed colony was inoculated in 5ml LB and left to grow 
shaking at 37°C overnight. The next morning 3 ml of the overnight culture was spun at 
13,000 for 2 minutes. Quigen kit (Cat no: 27104) was used to extract plasmid. The 
supernatant was discarded and 250µl of Resuspension buffer (P1) was added, followed 
by 250µl of lysis buffer (P2) and left at room temperature for 2 minutes. Next, 350µl of 
neutralization buffer was added and the sample was mixed immediately by repeatedly 
and gently inverting the eppendorf tube upside down. The sample was then left on ice 
for 5-10 minutes. Following this, the eppendorf tube was spun at 13,000 for 10 minutes 
and the supernatant was carefully transferred onto the mini spin column. Once the 
sample had flown through, the column was spun at 13,000 for 1 minute and the flow 
through was discarded as the DNA would have been bound to the column. Next, 500µl of 
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binding buffer was added to the column and spun at 13,000 for 1 minute, the flow 
through was discarded. 750µl of wash buffer was then added to the column and spun at 
13,000 for 1 minute. The flowthrough was discarded and the column was spun for 
another 1 minute to ensure elimination of all the buffers. The column was then 
transferred onto another eppendorf tube and 50µl of elution buffer was added and left 
to flowthrough for 2-3 minutes. Following this, the column was spun at 13,000 for 
10minutes and the supernatant (plasmid) was collected and frozen at -20. 
2.17 Agarose Gel Preparation 
To ensure the correct plasmid was extracted, the sample was run on an agarose gel. 
Firstly, 0.5g of agarose was weighed out and added to 75ml of 1x TBE (Tris Boric acid, 
EDTA) buffer which was made by diluting 100ml of the 10x stock (108g Tris base, 55g 
Boric Acid, 7.5g EDTA) with 900 ml of dH20 and heated until the agarose was dissolved. 
The solution was then left to cool and the agarose gel apparatus was prepared by taping 
both sides of the tank and positioning the comb in the slots. Once the agarose TBE 
solution had cooled, 7µl of Ethidium Bromide was added and the solution was mixed to 
dissolve and poured into the casting tray. Additional TBE buffer was added into the tray 
until the gel was immersed. 5µl of Peqlab DNA ladder (Cat no: 25-2000) was loaded into 
one of the wells and 5µl of the plasmid was mixed with 5µl of DNA loading buffer and 
loaded into another well and left to run at 70V for 1 hour. The amount of plasmid DNA 
was estimated at OD260 using the nanodrop. 
2.18 Ion Exchange 
An anion column which is a positively charged solid support, DEAE Sepharose was used 
to further purify negatively charged proteins. 5 ml of DEAE sepharose (GE Healthcare 
Life Sciences, Cat no:17-0709-01) resin was packed in a column and washed with three 
bed volumes of distilled H20. The protein subjected to ion exchange was dialysed 
overnight in 20mM Tris pH7.5 and 100mM NaCl. The column was equilibrated with 
three bed volumes of dialysis buffer. Next, the protein sample was passed through the 
column. If the peak molarity of NaCl required to elute the protein was initially known, 
this was collected in 10ml of 1ml fractions. 30µl was removed to run on a SDS-PAGE gel 
and the fractions were frozen at -20.  If the elution peak was not known, only 2ml of 
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protein sample was initially passed and a NaCl gradient was performed which involved 
using different NaCl concentrations, 100mM, 200mM, 300mM, 400mM, 500mM, 
600mM, 700mM and 800mM. 10ml of each concentration of NaCl was passed through 
the column and collected. 30µl of each NaCl concentration was mixed with 30µl of 
treatment buffer and run on a gel to see at which concentration the protein elutes at. 
Once the concentration was known, ion exchange was repeated using the total protein 
sample and eluted at the relevant concentration in 1ml fractions. Samples were frozen 
at -20. 
2.19 Biotinylation of Proteins 
2.2mg of biotin (Sigma, Cat no: B4501-100MG) was weighed out and dissolved into an 
eppendorf tube containing 400µl of dH20 and dissolved. 3µg of the biotin mixture was 
added per 100µg of the protein and incubated for 1 hour at room temperature. Next, the 
protein was dialysed against 1 litre of PBS. To confirm biotinylation of the protein, 
1µg/well of the protein was coated on microtitre wells and probed with Streptavidin-
HRP. 
2.20 Limulus Amebocyte Lysate (LAL) assay 
The LAL assay is a test that detects the gram negative bacterial endotoxin LPS within 
protein samples. By adding the LAL reagent, the LPS level is identified by the sample 
undergoing a colometric change to yellow. The absorbance is read at a wavelength of 
405nm using a spectophotometre and the endotoxin level determined using the 









Endotoxin Standard Curve graph 
 
Figure 2.5: Endotoxin standard curve:  Standard graph to show levels of endotoxin 
concentration provided in the kit. The endotoxin level in the protein sample can be calculated 
according to the graph.  
The LAL reagent contains lyophilized lysate from Limulus polyphemus. LPS present in 
the protein sample catalyses a pro enzyme in the Limulus Amebocyte Lysate to an active 
enzyme. The activated enzyme then catalyses splitting pNA. Once the substrate is 
released it is measured spectophotometrically against a linear gradient of a standard 
endotoxic graph (figure 2.5). 
Each standard contains approximately 15-40 Endotixin Units (EU) of lyophilized 
endotoxin. Once vial is reconstituted with 1ml of LAL reagent water at room 
temperature (to yield a concentration stated on the manual, eg, 24 EU.ml) and vortexed 
for 15 minutes to detach the endotocin from the glass. The substrate used is 
approximated 7mg of lyopholised substrate which is reconstituted in 6.5ml of LAL 
reagent water to yield a concentration of ~2mM. To prepare a set of standards, the 
reconstituted endotoxin vials were vortexed for 1 minute and then diluted to 1EU/ml. 
0.5ml of this was transferred into another glass vial and diluted with 0.5ml LAL reagent 
water to halve the concentration of EU/ml. 5-10 standards were prepared and vortexed 
for 1 minute before use. The samples were pipetted from tube to tube at the same rate 














2.21 Removal of endotoxin containments from recombinant proteins purified 
from E.coli 
The removal of endotoxins from recombinant proteins is important to prevent 
interference and false positive signals in further studies caused by LPS. LPS is found on 
the outer cell membrance of gram negative bacteria. Thermo Scientific Pierce High 
Capacity endotoxin removal resin in spin columns were used for the removal of LPS. 
The resin contained cellulose beads with covalently attached poly-L-lysine which has a 
high affinity for endotoxins. The binding capacity is 2 million EU per ml, reducing 
endotoxin levels by 99% and should typically result with a final endotoxin 
concentration below 5 EU/ml which is of an acceptable range. 
The use of the columns was followed as instructed by the manual provided. The column 
was briefly regenerated incubating the spin column in 5 bed volumes of 0.2M NaOH in 
95% ethanol for 1-2 hours at room temperature. The column was then washed with 5 
bed volumes of 2M NaCl followed by 5 bed volumes of endotoxin free, ultra-pure water. 
The column was equiliberated with 5 bed volumes of sodium phosphate buffer 
(Na2HP04 -1.42g in 10ml LPS free and autoclave, for NaH2PO4 add 1.2g in 10ml LPS free 
water and autoclave. The sample was added to the column and incubated overnight at 
room temperature and eluted the next day. The flow through was collected and samples 
were eluted in 1ml eppendorfs 
2.22 Preparation of PBMCs 
Dr. Ansar Pathan, Brunel Biosciences bled candidates willing to donate blood. This 
procedure was approved by the school’s ethical committee. The blood was collected in a 
50ml falcon tube containing 100µl of heparin to prevent clotting. Next, the blood was 
mixed with an equal amount of RPMI. Five 15ml falcon tubes were filled with 4ml of 
Ficoll and the blood was carefully transferred into each tube up to the top ensuring that 
the blood does not sink past the Ficoll layer. The falcon tubes were then spun at 2000 
rpm for 15 minutes with the brake on the centrifuge off. Once the Ficoll had separated 
the blood components, the plasma, which was the top layer, was collected using a sterile 
Pasteur pipette into another falcon tube. The PBMCs, which appear as a white 
precipitate, were carefully sucked out using a Pasteur pipette and transferred into 
another 50 ml falcon tube. The next step involved filling the PBMCs to the top with RPMI 
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and spinning at 1500 for 10minutes. The RPMI was discarded (which contained Ficoll) 
and cells were re-suspended in 50ml of fresh RPMI. The cells were then mixed by 
inverting the falcon tube and counted. The PBMCs were spun once again in the same 
conditions and re-suspended in 2ml of FCS. 2ml of 20% DMSO in RPMI was also added 
to the cells and the cells were aliquoted into 1ml cryogenic vials and frozen at -80 
before transferring to liquid nitrogen. 
2.23 Counting Cells (PBMCs) 
10µl of cells were pipetted onto a section of a hemocytometre and a clear plastic slide 
placed on top which would allow the cells to flow by lamina flow. The haemocytometer 
was placed under the microscope and cells visible within 12 squares were counted with 
a cell counter. The total amount was multiplied by 104 and spun at 1500 for 10 minutes, 
and resuspended in the equivalent amount of RPMI. 
2.24 Preparation of Serum 
AB Human Serum was used for the cellular assay. 50ml of the serum in a falcon tube 
was thawed at 37°C and heated in a water bath at 56°C for 30 minutes to inactivate 
complement components. Next, the serum was spun at 3000rpm for 30 minutes to spin 
down any debris. The serum was then filtered using a vacuum filter and aliquoted into 

















CHAPTER 3:  
Examining the interaction between 
individual globular head modules of 












The gC1q domain of C1q holds a heterotrimeric configuration made up of three 
individual chains, ghA, ghB and ghC. The main receptor for this globular head region of 
C1q has been identified as gC1qR. There is very little known about the nature of 
interaction between the gC1q domain of C1q and gC1qR receptor. Here, we examined 
whether ghA, ghB, and ghC can interact independently with gC1qR. Although the 
binding site for C1q has been identified on gC1qR, we further sought to recognise the 
sites on the globular head modules that are complementary in this interaction via the 
expression and purification of single residue substitution mutants of each module. We 
have shown that ghA, ghB and ghC all bind independently to gC1qR. Consistent with 
previous data our results confirm that Arg162 of the ghA chain is central in facilitating 
the binding between gC1qR and C1q. In addition to this we have discovered that a single 
amino acid substitution of Arginine to Glutamate in residue 114 of the ghB module 
enhances the interaction and binds better than the wild-type ghB module. Mutational 
analysis revealed that the interaction is ionic and reliant on multiple contacts. In order 
to investigate a correlation between induced expression of C1q and gC1qR in adherent 
monocytes, we observed a concomitant rise in the levels of C1q and gC1qR within 48 
hours of adherence. This was altered in a biphasic manner by exposure of monocytes to 
a PAMP i.e. LPS. We also examined if C1q mediated inhibition of PHA-stimulated PBMC 
proliferation is modulated by soluble gC1qR as well as recombinant globular modules. 
Our results suggest that interaction between the globular region and gC1qR is likely to 









3.2 Introduction  
C1q is the first sub component of the classical complement pathway that links innate 
and adaptive immunity by virtue of recognising IgG and IgM on immune complexes 
(Reid et al, 1976). Structurally C1q is made up of 6A, 6B and 6C polypeptide chains. Each 
chain is followed by an N-terminal collagen region (CLR) and a C-terminal globular head 
domain (C terminal) of ghA, ghB or ghC (Kishore and Reid, 2000). The globular head 
modules come together to give rise to a heterotrimeric gC1q domain. C1q is able to bind 
to an array of self, non-self and altered self ligands (Reid, 1989; Reid et al, 2002; (Sim et 
al., 2007); Nayak et al, 2010; Kishore et al 2004) and perform multiple functions. (Nayak 
et al., 2010). The versatility of C1q is offered by the modular organisation of the 
individual globular heads A, B and C (Kishore et al., 2004); (Kojouharova et al., 2003); 
(Kishore et al., 2002); Kishore et al., 1998).  
 
A number of cell surface receptors for C1q have been reported. C1qRp, also identified as 
CD93 (Steinberger et al., 2002) is a receptor for the CLR of C1q through its role in 
eliminating pathogens and immune complexes by enhancing C1q mediated 
phagocytosis by monocytes (Guan et al., 1994). CR1 is another CLR specific receptor for 
C1q which recognises IC opsonised by C3b and C4b (Medof et al., 1982). Although C1q 
also opsonises IC, research has shown that CR1 failed to remove IC in patients deficient 
for C3b and C4b which highlights that the interaction between C1q and this receptor is 
not essential for the clearance of IC. β1 integrin is an additional collegenous binding 
complement receptor (Edelson et al., 2006)  expressed on fibroblasts and endothelial 
cells (Zutter and Edelson, 2007). C1q has been demonstrated as a 1 integrin adhesive 
ligand through its ability to bind this receptor on peripheral mononuclear cells allowing 
adhesion of these cells to complement containing immune complexes in a C1q and 1 
integrin manner (Zutter and Edelson 2007). Consequently this interaction is shown to 
stimulate cytokine secretion which suggests a role for this receptor in the innate 
immune response. CRT is an intracellularly expressed CLR binding receptor  (Peerschke 
et al., 1994; Malhotra et al., 1994). Its involvement with C1q has been shown to play a 
role in the clearance of apoptotic and necrotic cells (Gregory and Devitt, 2004; Ogden et 
al., 2001).  Here, C1q binds to PS on apoptotic cells via its gC1q domain and its CLR 
region is able to bind to CRT linked to CD91 on the monocytic cell surface (Basu et al., 
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2001), leading to apoptotic cell phagocytosis. In addition to this, it has recently emerged 
that apoptotic cell clearance is also regulated by CRT being able to bind the globular 
region of C1q, with this interaction mediated by the CRT globular domain, (Kishore et al 
1997a, 1997b; Paidassi et al., 2011). 
 
A C1q receptor exclusive to the gC1q domain called gC1qR (33kDa) has been described. 
gC1qR is an highly acidic protein which is known to bind to the globular heads of C1q 
(Ghebrehiwet et al., 1994; Ghebrehiwet and Peerschke, 1998).   Subsequently, gC1qR 
has emerged as a multi ligand binding and multi-functional protein, alongside binding to 
proteins involved in blood clotting such as thrombin and vitronectin (Lim et al., 1996). 
gC1qR activates the coagulation cascade through binding to HK on endothelial cells 
(Joseph et al 1996)  which activates the vasoactive peptide BK, making the vessel wall 
more permeable, leading to an influx of tissue fluid (Herwald et al., 1996). This 
highlights a role for gC1qR in the control of inflammation. (See table 1.4 from chapter 1) 
Although the gC1q-gC1qR interaction was discovered a long time ago (Ghebrehiwet et al 
1994), the complementary binding sites and the nature of interaction has not been 
established. The gC1q binding site on gC1qR is implicated to be located on residues 76-
93 (Ghebrehiwet et al., 2002), The availability of the individual globular head fragments 
ghA, ghB and ghC as recombinant gC1q modules expressed in E. coli (Kishore et al., 
2003) has given us the opportunity to reassess gC1q-gC1qR interaction and map the 
specific globular head gC1qR binds too. The structure function relationship within the 
gC1q domain is now better understood (Kishore et al 2003; Ghai et al 2007; Kishore et 
al 2005). It is now known that ghA, ghB and ghC are functionally independent modules. 
Together, as a heterotrimeric structure, this impact upon versatility and stabilisation for 
the range of ligands C1q can bind too. This is evident in the case of the HIV gp41 peptide 
601-613 which preferentially binds to ghA (Kishore et al 2003) and the beta amyloid 
peptide specifically interacting with ghB, (Kishore et al 2003). With the modularity of 
gC1q explained, it is now to our understanding that each globular region functions 
differently in terms of ligand binding (Kishore et al 2003,  
 
The crystal structure of gC1qR has been revealed as three monomers held together to 
form a trimer per gC1qR molecule (Jiang et al., 1999). Each monomer consists of seven 
anti-parallel β strands filled by an N-terminal and two C-terminal α helices. gC1qR has 
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different charge distribution, with one side of its ‘donut’ shaped structure exposed to be 
very negatively charged, the ‘solution face’ and the reverse being basic, the ‘membrane 
face’ (Ghebrehiwet et al 2002). The C1q binding site 76-94 is only exposed on the highly 
charged solution face, (Ghebrehiwet et al 2002). Given that the C1q binding site on 
gC1qR has been identified, we sought to identify the complementary residues on the 
gC1q domain that are involved in this interaction. Previous studies have highlighted 
ArgB114 and ArgB129 of the B chain to be central in the C1q-IgG interaction, (Kojouharova 
et al 2004) which is the first step in the activation of the classical pathway (Kishore and 
Reid, 2000). It has previously been shown that C1q binding to gC1qR on platelets and 
endothelial cells induces complement activation independent of IgG (Peerschke et al., 
2006). Like C1q, gC1qR also has an anti-proliferative effect on B and T lymphocytes 
(Ghebrehiwet et al., 1990).  In this chapter, the questions we have addressed are as 
follows: 
 
1. What is the nature of complementary binding sites involved in the gC1q-gC1qR 
interaction? 
2. Is there a concomitant relationship between expression of C1q and gC1qR in 
monocytes/macrophages under inflammatory conditions? 
3. Do recombinant globular modules of C1q interfere with gC1q or C1q mediated 








3.3 Materials and Methods  
3.3.1 Proteins  
C1q, Wild-Type ghA, ghB, ghC and their substitution mutants, gC1qR and its deletion 
mutants were produced as described in Materials and Methods 
3.3.2 ELISA to examine interaction of ghA, ghB and ghC with gC1qR  
ELISA was performed to examine the interaction between the C1q globular head 
modules and gC1qR. 1µg of gC1qR in carbonate - bicarbonate buffer was coated on 
microtitre wells overnight at 4°C. The microtitre wells were blocked with 2% BSA for 2 
hours at 37°C.  Next, the plate was washed with PBS + 0.05% Tween 20 three times. 
Different concentrations (2.5, 1.25, 0.625 and 0.312µg/well) of ghA, ghB or ghC  (MBP 
as a control) were diluted in calcium buffer (Tris pH 8.8, CaCl2 and 100mM NaCl) and 
added to wells. The plate was kept at 37°C for 1 hour and 4°C for 1 hour. Following 
further washes, bound protein was detected by anti-MBP mAb for 1 hour. After the 
addition of the secondary antibody rabbit anti-mouse IgG-HRP diluted in PBS (1:5000) 
and incubated for a hour at 37°C.  The colour was developed using OPD and the plate 
was read at 450nm.  
3.3.3 ELISA to examine binding of C1q to gC1qR 
Microtitre wells were coated in duplicates with different concentrations of C1q (5, 2.5, 
1.25 and 0.625µg/well) in carbonate- bicarbonate buffer, pH 9.6 overnight at 4°C. The 
microtitre wells were blocked with 2% v/w BSA in PBS for 1 hour at 37ºC. Wells were 
then washed with PBS + 0.05% v/w Tween. 2.5µg of gC1qR was added to each well and 
incubated for an hour at 37ºC. Following repeated washes, bound gC1qR was detected 
by anti-gC1qR pAb (1:1000). Protein A-HRP 1:1000 in PBS and incubated for a hour at 
37°C. Colour was developed using OPD tablets   
3.3.4 ELISA to examine binding of ghA module to gC1qR deletion mutants 
Microtitre wells were coated overnight at 4°C in duplicates in carbonate-bicarbonate 
buffer with different concentrations (1, 0.5, 0.25µg/well) of each gC1qR deletion mutant 
(∆144-148, ∆144-162, ∆174-180, ∆154-162∆, 190-192, ∆196-202, ∆204-218, ∆w233g, 
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∆74-96.) The wells were blocked with 2% BSA in PBS for 2 hours at 37°C. Next, the 
wells were washed three times with PBS+0.05% Tween and 2.5µg/well of ghA in 
calcium buffer was added to each well and incubated for 1.5 hours at 37°C and 1.5 hours 
at 4°C. The wells were washed three more times with PBS + 0.05% Tween and 
incubated in 100µl of anti-MBP mAb (1:5000). The colour was developed after the use 
of rabbit-anti mouse IgG-HRP and OPD as described earlier. 
3.3.5 Preparing Sheep Red Blood Cells (SRBCs) 
5ml of sheep blood (Fisher Catalog No.: 50-177-000) was divided between two 50ml 
falcon tubes. Each tube was filled with 20ml of Dulbecco’s PBS comprising of 0.9mM 
CaCl2, 2.7mM KCL, 0.5mM MgCl2H20, 138mM NaCl and 8.1mM Na2HP04 and spun at 
3000rpm for 10 minutes. The supernatant was carefully discarded without disrupting 
the pellet and the cells were washed three more times by re-suspending in Dulbecco’s 
PBS (DPBS) using the same procedure. After the last wash, the cells in each tube were 
resuspended in 10ml of DPBS and the cell concentration was adjusted to 109 per ml. 
This was carried out by taking 100µl of cells into a quartz cuvette and mixing with 1.4ml 
of dH20 to cause complete haemolysis. The absorbance was read at an wavelength of 
OD541 to 0.7 which represented 109. If the OD was too high then the sample was further 
diluted with DPBS. One falcon tube of the 109 cells were sensitised with 100µl of as 
Haemolysin (IgG and IgM) to yield the sensitised erythrocytes (EA). The falcon tubes 
were mixed through gentle inversions and incubated for 15 minutes each at 37°C ice. 
The cells were then spun at 3000rpm for 10 minutes and the supernatant was 
discarded. The pellet was re-suspended in DPBS and washed two more times and re-
suspended in 50ml Dextrose Gelatin Veronal Buffer DGVB++ comprising of 0.15mM 
CaCl2, 141mM NaCl, 0.5Mm MgCl2, 1.8mM Sodium Barbitol, 3.1mM Barbitone and 0.1% 
v/w gelatine. Next, the falcon tubes were centrifuged three times for 5 minutes and re-
suspended in DGVB++, with the first speed at 2000rpm, the second spin at 1000rpm, and 
500rpm for the third wash. Cells were finally re-suspended in 10ml of DGVB++.  Both the 
EA and E cells (non-sensitised SRBCs) were stored at 4°C. 
3.3.6 Testing EA and E cells for CH50 value 
To test the cells, 10 eppendorf tubes were labelled 1-10 and Normal Human Serum 
(NHS) was diluted to 1/10 in DGVB to give a final concentration of 200µl. 100µl of 
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DGVB++ was added in tubes 2-10 and serial dilutions of the serum were performed by 
taking 100µl from tube 1 and mixing into each tube up to tube 10 with the final 100µl 
discarded. Another 10 eppendorf tubes were labelled 11-20 and the exact same 
procedure was carried. The samples were incubated at 37°C for 1 hour. Next, the EA 
cells and E cells were diluted to 108/ml in DGVB++ by adding 1ml of the cells to 9ml of 
dH20 in a 50ml falcon tube. 100µl of E cells were added to 100µl of each serum dilution 
in tubes 1-10 and 100µl of EA cells to tubes 11-20. 100µl of EA cells with a 100µl of 
dH20 was used as a positive control. The samples were incubated for a further 1 hour at 
37°C. Next, the samples were spun at 5000rpm for 5 minutes and 180µl of the 
supernatant was transferred onto a microtitre plate and read at an 0D of 405mm.  
3.3.7 Western Blotting 
To verify the immunoreactivity of the recombinant gC1qR expressed and purified, western  
blotting was performed.10µg of recombinant gC1qR was run on an 12% v/w SDS-PAGE 
gel and transferred for 1 hour onto PDVF membrane. The membrane was blocked for 1 
hour at room temperature with 5% non-fat milk in PBS, followed by  pAb anti-gC1qR 
(1:1000) incubated at room temperature overnight. Following this the membrane was 
washed 3 times in PBS-Tween 0.02% and probed with PA-HRP in PBS,  for  1 hour at room 
temperature (1:1000). Colour was developed using DAB.  
 3.3.8 Far Western Blot to show gC1qR binding to ghA, ghB and ghC. 
10µg of ghA, ghB, ghC and MBP was run on a gel and transferred onto a PDVF 
membrane for 1 hour at 320m. The membrane was then blocked for 2 hours with 5% 
non-milk fat powder in PBS at room temperature. 15µg of gC1qR in PBS was added to 
the membrane and incubated overnight at room temperature. The next morning, the 
membrane was washed 3 times for 20 minutes each with 0.02% PBS-Tween 20. Anti-
gC1qR pAb (1:1000) was added in 2% non-fat milk in PBS and the membrane was 
incubated for 2 hours at 37°C. Next, the membrane was washed as mentioned above and 
Protein A-HRP (1:1000) was diluted in 2% non-fat milk PBS and flooded on the 
membrane for 1 hour at room temperature. Once again the membrane was washed and 





 3.3.9 Far Western Blot to show ghA, ghB and ghC binding to gC1qR 
 15µg of gC1qR was loaded on a 12% SDS-PAGE gel in three wells and run at 120v. The 
gel was cut into three sections and transferred onto PDV membrane for 1 hour at 
320ma. The membrane was also cut into three strips and blocked with 5% non-fat milk 
in PBS for 2 hours at room temperature. 10µg of ghA, ghB and ghC in Calcium buffer 
were added to each strip and incubated overnight at room temperature. The 
membranes were then washed 3 times in PBS-Tween for 20 minutes each and 10µl of 
anti-MBP mAb in 2% non-fat milk was added to each membrane and incubated for 2 
hours at 37°C. Following washing 3 times in PBS-Tween for 20 minutes each, 10µl of 
rabbit anti-mouse IgG-HRP in 2% non-fat milk was added and incubated for 1 hour at 
room temperature. The bands were developed using DAB tablets dissolved in water.  
3.3.10 Assay for the solid and solution phase complement activation by 
recombinant gC1qR 
To see whether recombinant gC1qR produced using a new expression system was able 
to activate complement in solution as well as solid phase, haemolytic assays were 
performed. Different concentrations of gC1qR (10, 5, 2.5, 1.25., 0.625µg) were incubated 
at 37⁰C for 1 hour with NHS in DGVB++  (at a dilution of  1:40 ) to give a total volume of 
100µl. Then, 100µl of EA cells (1 x 108) were then added to each sample and incubated 
for 1 hour. Samples were spun down for 5 minutes at 5000rpm and 100µl of the 
supernatant was collected and read at 520nm. dH20 and EA cells were used for 100% 
lysis. For solid phase studies, gC1qR was bound to microtitre wells at the same 
concentrations overnight at 4°C.  NHS in DGVB++ was added using the same procedure 
mentioned above and the assay was developed in the same manner 
3.3.11 Complement assays using gC1qR deletion mutants 
Microtitre wells were coated with 4µg/ml of each gC1qR deletion mutant, ∆144-148, 
∆144-162, ∆174-180, ∆154-162∆, 190-192, ∆196-202, ∆204-218, ∆w233g, ∆74-96, WT 
gC1qR and heat-aggregated IgG in carbonate-bicarbonate buffer, p.H 9.8 and incubated 
at 37°C for 2 hours. Contents were discarded and the wells were blocked for 1 hour with 
2% BSA. Next, wells were washed 3 times with DGVB++ and 100µl of 1/10 dilution of 
NHS in DGVB++  was added to each well and incubated for 1 hour at 37°C. The wells were 
repeatedly washed three times in DGVB++ and biotinylated anti-C4d (1:2000) diluted in 
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DGVB++ was added to the wells and incubated for a hour at 37°. The secondary antibody 
used was Neutravidin conjugated to Alkaline Phosphotase (AP) diluted in DGVB++, was 
incubated for an hour at 37°C. Following repeated washing with DGVB++, bound C4d 
was detected using Para-nitrophenylphosphate (PNPP) substrate. 
3.3.12 Expression analysis of C1q and gC1qR following monocyte adherence and 
LPS challenge 
3.3.12.1 Preparation of PBMCs 
Whole blood (50ml) was taken from healthy consenting human subjects and 2 units/ml 
of heparin (Wockhardt) added to prevent clotting. Blood was then diluted with an equal 
volume of RPMI 1640 (Sigma-Aldrich). To isolate monocytes, blood/RPMI was 
separated on a Ficol column (Ficol-Plaque Plus, GE healthcare) by centrifugation at 
2000 rpm for 16 minutes at room temperature. Following the removal of the top serum 
layer, subsequent peripheral blood mononuclear cell (PBMC) interphase layer was 
carefully removed. An equal volume of RPMI 1640 was then added and the cells pelleted 
by centrifugation at 1500 rpm for 10mins at room temperature. Cells were then 
resuspended in 50mls of RPMI and the cell concentration determined using a 
hemocytometer. Approximately 7x107 cells were obtained in total.  
3.3.12.2 RNA extraction and qPCR,  
Approximately 5x106 cells were added to each culture plate in 5 ml of RPMI 1640, 
containing 10% Fetal Calf Serum (FCS), 100μg/ml penicillin-streptomycin and 2mM L-
glutamine. Cells were then incubated at 37°C with 5% CO2 atmosphere and left to 
adhere. Cells were then harvested at the following time points of incubation for 
adherence: 2 hrs, 24hrs, 48hrs, 72hrs, 5 days and 7 days. Identical cultures at the above 
time-points were also setup with the addition of 20ng/μl of LPS (Salmonella 
typhimurium, Sigma-Aldrich). Adherent cells with or without LPS from each timepoint 
were harvested by removing the media from the plate and incubating cells in RPMI 
1640, containing 0.025% trypsin/ 0.01% EDTA for 5 mins at 37°C. Cells were removed 
using a cell scraper and an equal volume of RPMI 1640, containing 10% FCS added to 
the harvested cells. Cells counts were then determined on a haemocytometer. Cells were 
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pelleted by centrifugation at 1500 rpm for 10 mins at room temperature and the 
supernatant removed, and cell pellets stored at -80°C until RNA extraction procedure  
Total RNA was extracted from frozen cell pellets using the GenElute Mammalian Total 
RNA Purification Kit (Sigma-Aldrich). Samples were then treated with DNase I (Sigma-
Aldrich) to remove any contaminating DNA. Samples were then heated at 70⁰C for 10 
min to inactivate both the DNase I and the RNase, and subsequently chilled on ice. The 
amount of total RNA was measured by determining the absorbance at 260nm using the 
NanoDrop 2000/2000c (Thermo-Fisher Scientific) and the purity of the RNA 
determined using the ratio of absorbance at 260nm and 280 nm. Complementary DNA 
(cDNA) was synthesized using High Capacity RNA to cDNA Kit (Applied Biosystems) 
from a quantity of 2μg of total RNA extract. 
Primer sequences were designed and analyzed for specificity using the nucleotide Basic 
Local Alignment Search Tool and Primer-BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The following primers were used: For 18S 
rRNA gene (endogenous control): 18S forward (5’-ATGGCCGTTCTTAGTTGGTG-3’), 18S 
reverse (5’CGCTGAGCCAGTCAGTGTAG-3’), for C1q gene: qC1qC forward 
(5’CAAAGGGCAGAAGGGAGAAC-3’), qC1q reverse (5’ATCTGATCAGGCTGTTGGGT-3’) and 
for gC1qR gene: gC1qR forward (5’AACAACAGCATCCCACCAAC-3’), gC1qR reverse 
(5’AGATGTCACTCTCAGCCTCG-3’). 
PCR was performed on all cDNA samples to assess the quality of the cDNA. The qPCR 
assays were performed for the expression C1qR and gC1qR. The qPCR reaction 
consisted of 5 μl Power SYBR Green MasterMix (Applied Biosystems), 75 nM of forward 
and reverse primer, 500 ng template cDNA in a 10 μl final reaction volume. PCR was 
performed in a 7900HT Fast Real-Time PCR System (Applied Biosystems). The initial 
steps were 2 minutes incubation at 50°C followed by 10 minutes incubation at 95°C, the 
template was then amplified for 40 cycles under these conditions: 15 seconds 
incubation at 95°C and 1 minute incubation at 60°C. Samples were normalized using the 
expression of human 18S rRNA. Data was analyzed using the RQ Manager Version 1.2.1 
(Applied Biosystems). Ct (cycle threshold) values for each  target gene were calculated 
and the relative expression of each cytokine target gene was calculated using the 
Relative Quantification (RQ) value, using the formula: RQ = 2 –ΔΔCt for each cytokine 
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target gene, and comparing relative expression with that of the 18S rRNA constitutive 
gene product. Assays were carried out twice in triplicate. 
Statistical analysis was performed using GraphPad Prism version 6.0 (GraphPad 
Software). An unpaired 2-side t-test was used to compare the means of the expressed 
targets of the timepoints analyzed, using the 2h timepoint as calibrator. P values were 
computed, graphs compiled and analysed. 
3.3.13 Cell Proliferation Assay 
3.3.13.1 Titrating PHA (Phytohaemagglutinin) 
To work out the optimum concentration of PHA required to stimulate PBMCs, pha was 
titrated with cells. Three peoples PBMCs vials were removed from liquid nitrogen and 
thawed at 37°C. Three falcon tubes were filled to 10ml with RPMI containing Fetal Calf 
Serum and each vial of cells were added to a tube and spun at 1500 for 10 minutes. The 
cells were then resuspended in 5ml RPMI and counted.  Next the cells were spun at 
1500 for 10mins and resuspended in the correct volume of prepared medium, 
consisting of RPMI, L-glutamine, Pen strap, sodium pyruvate and AV serum to give a 
concentration of 0.5 million cells per ml. 100,000 cells of each persons PBMCs were 
added per well into sterile U bottom microtitre culture plates. Following this, various 
concentrations of PHA, (1, 0.5 and 10µg/ml) were added to the cells and placed in a CO2 
incubator to allow proliferation to take place. Three days later the plate was pulsed, 
harvested and counted as described. 
3.3.13.2 Cell proliferation assay 
The PBMCs of three different subjects were used to carry out the proliferation assay. 
PBMCs frozen in liquid nitrogen were thawed at 37°C until a slight bit of ice remained. 
The cells were transferred into 3 falcon tubes containing 10ml of RPMI with FCS. The 
samples were spun at 1500rpm for 10 minutes and the cells were resuspended in 10ml 
of RPMI. The cells were counted using the procedure mentioned in the materials and 
methods section and spun at 1500rpm for 10 minutes. The cell volumes were 
resuspended accordingly with RPMI medium (stock solution: 87ml RPMI, 1ml L-
Glutamine, 1ml Pennicilin-Streptomycin, 1ml Sodium Pyruvate and 10ml filtered AB 
serum). Half of the cells were treated with 1µg/ml of PHA and 700µl of this solution was 
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added to each eppendorf tube. 10µg of the antigens ghA, ghB, ghC, gC1qR, MBP or C1q 
were also added to each sample of cells and mixed by vortexing. The same procedure 
mentioned above was carried out with the PBMCs unstimulated with PHA to be used as 
negative controls. The experiment was carried out in triplicates; therefore 200µl of each 
sample was pipetted three times into a sterile, round ‘U’ bottom microtitre well plate. 
The plate was then placed in a 37°C CO2 incubator and pulsed with thymidine on day 3. 





























Expression and purification of C1q globular head substitution mutants 
 

























ghA, ghB and ghC single residue substitution mutants were expressed and purified to determine 















































Figure: 3.1: 7.5 % w/v SDS-PAGE of purified human C1q under reducing conditions. The 
three chains of C1q can easily be seen. The higher bands represent dimers and multimers of the 






















                                                        
Figure 3.2: (12% under reducing conditions). SDS-PAGE showing expression of the MBP-
linked globular head mutant fusion proteins ghA-R162A, ghA-R162E, ghB-R163E, ghB-
R163A, ghB-R114A, ghB-R114Q, ghB-R114Q, ghB-R129A, ghB-R129E, ghB-T175L, ghB-
L136G, ghB-H117D. E. coli BL21 strain individually transformed with plasmids containing 
mutant forms of C1q globular head modules was induced with IPTG for 3 hours and a cell pellet 
of 100µl of bacterial culture was boiled under reduced conditions and loaded in each lane. 
Bacterial cells, grown in parallel but not induced with IPTG were used as an uninduced control. 
A) Lane 1: induced sample of ghA-R162A, Lane 2: Uninduced sample of ghA-R162A. Lane 3: 
Induced sample of ghA-R162E. Lane 4: uninduced sample of ghA-R162E, Lane 5: Molecular 
marker. B)  Lane 1:Induced sample of ghB-R163E,  Lane 2: Induced sample of ghB-R163A,  Lane 
3: Uninduced ghB-R163A, Lane 4: Uninduced ghB-R163E, Lane 5: Induced ghB-R129A, Lane 6: 
Uninduced ghB-R129A, Lane 7: Induced ghB-R129E, Lane 8: Uninduced ghB-R129E, Lane 9: C) 
Lane 1:Molecular marker, Lane 2:  Uninduced ghB-R114Q, Lane 3: Induced ghB-R114Q, Lane 4: 
Uninduced ghB-R114A, Lane 5: Induced ghB-R114A,  Lane 6: Uinduced ghB-H117D, Lane 7: 
Induced ghB-H117D, Lane 8: Uninduced ghB-T175L, Lane 9: Induced ghB-T175L. D) Lane 1:  
Molecular marker, Lane 2: Uninduced ghB-L136G, Lane 3: Induced ghB-L136G, Lane 4: 



















Uninduced ghC-R156Q, Lane 5: Induced ghC-R156E, Lane 6: Uninduced ghC-R156E, Lane 7: 
Induced ghC-R156E, Lane 8: Uinduced ghC-H101A, Lane 9: Induced ghC-H101A, E) Lane 1: 
Induced ghC-L170E, Lane 2: Uninduced ghC-L170E, Lane 3: Molecular marker.  Expression for 
all samples shown under the 66kda marker  
3.4.1 Amylose Resin Purification 
Following lysis and sonication, the supernatant of each protein was subjected to 
purification on an amylose resin column. Since the globular heads were expressed as 
fusion proteins to MBP, an amylose resin column was used, which would enable MBP to 
bind to the column and all other E.coli proteins would flow through. The bound MBP 
fused proteins were eluted by 10mM Maltose.  The elutions were run on a 10% SDS-
PAGE to assess for purity. As shown in figure 3.3, the fusion proteins had significant 
E.coli protein contamination with the exception of ghA-R162A, ghA R162E and ghB-
R162A, which appeared relatively clean. Therefore the fusion proteins were subjected 
to ion exchange for further purity (Figure 3.5). 
3.4.2 Ion Exchange of globular head substitution mutants 
Ion exchange uses a positively charged solid support to attract the charge of a 
negatively charged protein. In this case we used an anion column made up of DEAE 
Sepharose. Once the protein is bound to the column, Sodium Chloride is used to elute 
the protein. In ion exchange, chloride is the counter ion as chloride is exchanged for the 
protein on the matrix which allows the protein to be displaced and elute. A gradient was 
performed where different NaCl concentrations ranging from 0.1-0.6M was passed 
through the column and eluted protein was run on a SDS-PAGE gel. Following dialysis 
against 100mM NaCl the mutants ghB-R163E, ghB-R114A, ghB-R114Q, ghB- R129A, 
ghB-R129E, ghB- H117D, ghB- L136G, ghB-T175L, ghC-R156E, ghC-H101A and ghC-
L170E were passed through DEAE sepharose and eluted at a known concentration of 
0.4M (Kishore et al 2004). Samples were collected in 1ml fractions and run on a 10% 









Figure 3.3: Purified membrane fraction of MBP-fused ghA-R162A, MBP-fused ghA-R162E,  
MBP-fused ghB-R163A, MBP-fused ghB-R163E , MBP-fused ghB-R114A, MBP-fused ghB-
R114Q, MBP fused ghB-R129A, MBP fused ghB-R129E, after flowing through Amylose 
resin column.  Following sonication, samples were run through an Amylose Resin column and 
eluted with 10mM Maltose. 2ml membrane fractions were collected and run on a 10% gel. a) 
Lane 1 – 7: Purified ghA-R162A,: Lane 8: Molecular marker, b) Lane 1: Molecular marker, Lane 2-
5: Purified ghA-R162E, lane 6-10: Purified ghB R163A. c) Lane 1: Molecular marker, Lane 2-5: 
Purified ghB- R163E, d) Lane 1: Molecular marker, Lane 2-6: Purified ghB-R114A, Lane 7-9: 
Purified ghB-R114Q. e) Lane 1: Molecular marker, Lane 2-5: Purified ghB-R129A. f) Lane1-7: 
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Figure 3.4: Purified membrane fraction of MBP-fused ghB-H117D, MBP-fused ghB-L136G,  
MBP-fused ghB-T175L, MBP-fused ghC-R156E , MBP-fused ghC-H101A, MBP-fused ghC-
L170E, after flowing through Amylose resin column.  Following sonication, samples were 
run through an Amylose Resin column and eluted with 10mM Maltose. 2ml membrane fractions 
were collected and run on a 10% gel. a) Lane 1 – 6: Purified ghB-H117D, b) Lane 1: Molecular 
marker, Lane 2-7: Purified ghB-L136G, lane 8-10: Purified ghB-T175L. c) Lane 1: Molecular 
marker, Lane 2-6: Purified ghC- R156E, lane 8-10: Purified ghC-H101A d) Lane 1-9: Purified ghC-





















Figure 3.5: Purified membrane fraction of globular head mutants after ion exchange. 
Following purfication on amylose resin column, samples were dialysed against 20mM Tris and 
100mM NaCl and loaded on a DEAE sepharose column. Fractions were eluted at 0.6M NaCl and 
run on a 10% v/w SDS gel. A) Lane 1: Purified ghB-R163E, Lane 2: Purified ghB-R114A, Lane 3: 
Purified ghB-R114Q, Lane 4: Purified ghB-R129A, Lane 5: Purified ghB-R129E, Lane 6: Purified 
ghB-H117D, Lane 7: Molecular marker. B) Lane 1: Molecular marker, Lane 2: Purified ghB-
L136G, Lane 3: Purified ghB-T175L, Lane 4: Purified ghC-R156E, lane 5: Purified ghC-H101A, 








Figure 3.6: Expression and purification of MBP-fused globular head domains ghA-R162A, 
ghA-R162E, ghB-R114A, ghB-R114Q, a) Lane 1: Molecular marker, Lane 2: Uninduced ghA-
R162A, Lane 3: Induced R162A, Lane 4: Supernatant of R162A following lysis and sonication, 
Lane 5: Purified R162A following Amylose resin chromatography, b) Lane 1: Uninduced ghA-
R162E, Lane 2: Induced R162E, Lane 3: Supernatant of R162E following lysis and sonication, 
Lane 4: Purified R162E fraction following Amylose resin chromatography, c) Lane 1: Molecular 
marker, Lane 2:Uninduced ghB-R114A , Lane 3: Induced R114A, following amylose exchange 
chromatography, d) Lane 1: Uninduced ghB-R114Q, Lane 2: Induced R114Q, Lane 3: 
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Figure 3.7: Expression and purification of MBP-fused globular head domains ghB-R163A, 
ghB-R163E, ghB-R129A, ghB-R129E, a) Lane 1: Molecular marker, Lane 2: Uninduced ghB-
R163A, Lane 3: Induced R163A, Lane 4: Supernatant of R163A following lysis and sonication, 
Lane 5: Purified R163A following Amylose resin chromatography, b) Lane 1: Molecular marker, , 
Lane 2: Uninduced ghB-R163E, Lane 3: Induced R163E, Lane 4: Supernatant of R163E following 
lysis and sonication,  Lane 5: Purified R163E fraction following Amylose resin chromatography, 
c) Lane 1: Molecular marker, Lane 2:Uninduced ghB-R129A , Lane 3: Induced R129A, Lane 4: 
Supernatant of R129A following lysis and sonication, Lane 5: Purified R129A following amylose 
exchange chromatography, d) Lane 1:Molecular marker, Lane 2: Uninduced ghB-R129E, Lane 3: 
Induced R129E, Lane 4: Supernatant of R129E after lysis and sonication Lane 5: Purified R129E  





Figure 3.8: Expression and purification of MBP-fused globular head domains ghB-H117D, 
ghB-T175L, ghB-L136G, ghC-R156Q, a) Lane 1: : Uninduced ghB-H117D Lane 2 : Induced 
H117D, Lane 3: Supernatant of H117D following lysis and sonication Lane 4:, Purified H117D 
following Amylose resin chromatography b) Lane 1: Molecular marker, , Lane 2: Uninduced ghB-
T175L,  Lane 3: Induced T175L, Lane 4: Supernatant of T175L following lysis and sonication,  
Lane 5: Purified T175L fraction following Amylose resin chromatography, c) Lane 1: :Uninduced 
ghB-L136G, Lane 2: Induced L136G Lane 3: Supernatant of L136G following lysis and sonication, 
Lane 4:  Purified L136G following amylose exchange chromatography, d) Lane 1:Molecular 
marker, Lane 2: Uninduced ghC-R156Q, Lane 3: Induced R156Q, Lane 4: Supernatant of R156Q 





Figure 3.9: Expression and purification of MBP-fused globular head domains ghC-R156E, 
ghC-L170E,  ghC-H101A,  a) Lane 1:Molecular marker, Lane 2:  Uninduced ghC-R156E,  Lane 3 : 
Induced R156E, Lane 4: Supernatant of R156E  following lysis and sonication Lane 5:, Purified 
R156E following Amylose resin chromatography b) Lane 1: Molecular marker,  Lane 2: 
Uninduced ghC-L170E,  Lane 3: Induced L170E, Lane 4: Supernatant of L170E  following lysis 
and sonication,  Lane 5: Purified L170E  fraction following Amylose resin chromatography, c) 
Lane 1: Molecular marker, Lane 2: Uninduced ghC-H101A, Lane 3: Induced H101A,  Lane 4: 
Supernatant of H101A following lysis and sonication, Lane 5:  Purified H101A  following 





Figure 3.10: Purified MBP fused ghA, ghB and ghC following Amylose Resin 















Figure 3.11: Purified MBP fused ghA-R162A and R162E following Amylose Resin 
chromatography Lane 1: Molecular marker, Lane 2:ghA-R162A, Lane 3: ghA-R162E, 
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Figure 3.12: Purified MBP fused ghB mutants following Amylose resin and ion exchange 
chromatography: Lane 1: ghB-R114A, Lane 2: ghB-R114Q, Lane 3: ghB- R163A, Lane 4:ghB- 

















Figure 3.13: Purified MBP fused ghC mutants following Amylose resin chromatography: 
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Figure 3.14: Expression of recombinant gC1qR following induction: gC1qR was 
transformed in E. coli BL21 and was induced with IPTG for 3 hours. A cell pellet of 100µl of 
bacterial culture was boiled under reduced conditions and loaded in each lane. Bacterial cells, 
grown in parallel but not induced with IPTG were used as a uninduced control.  Lane 1: 
Molecular marker, Lane 2, 4, 5 and 7: Induced sample of gC1qR. Lane 3, 7 and 8: Uninduced 





Figure 3.15:  Supernatant of gC1qR after sonication. After observed expression following 
IPTG induction, lysis buffer was added to the protein pellet and samples were sonicated for 8 
cycles for 30 seconds. Samples were spun down and supernatant was collected and run on a gel. 
a) Lane 1: Molecular marker. Lane 2 and 3: Supernatant of gC1qR. b) Lane 3: Molecular Marker 
Lane 2 and 3: Supernatant of gC1qR.  Expression is shown under the 35kDa marker.  
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Figure 3.16: Purification of gC1qR: The gC1qR lysate was dialysed against 20mM Tris and 100mM 
NaCl at 4°C overnight. The supernatant was then spun at 4500 for 15 minutes and passed through a 
5ml DEAE Sepharose column which was pre-equilibrated with 5 bed volumes of dialysis buffer. 
Purified gC1qR was eluted at a concentration of 450mM NaCl. Elutions were collected in 1ml 
fractions and each sample was run on a 12% SDS PAGE gel.  a) Lane 1: Molecular Marker, Lane 2-9: 


















Figure 3.17: Expression and purification of 33kDa gC1qR. E. coli BL21 strain individually 
transformed with plasmid containing gC1qR was induced with IPTG for 3 hours and a cell pellet 
of 100µl of bacterial culture was boiled under reduced conditions (lane 2). Bacterial cells, grown 
in parallel but not induced with IPTG were used as an uninduced control (lane 1). After 
observed expression following IPTG induction, lysis buffer was added to the protein pellet and 
samples were sonicated for 8 cycles for 30 seconds. Samples were spun down and supernatant 
was collected and run on a gel (Lane 3.) The supernatant was then dialysed against 20mM Tris 
overnight and purified on a DEAE sepharose column, protein samples were eluted using 0.45M 
NaCl (lane 4). Expression was shown under the 35kDa marker Lane 1: Standard protein 
molecular marker. Lane 2: Uninduced expression of gC1qR, Lane 3: Induced expression of 




















Figure 3.18:  Biotinylated gC1qR: 2.2mg of biotin was dissolved in 400µl of H20. 3µl of this 
mixture was added per 100µg of protein and incubated at room temperature for 1 hour and 
dialysed against PBS to get rid of any excess biotin. The sample was then run on a gel to confirm. 
Lane 1: molecular marker, Lane 2: Biotinylated gC1qR. Expression is observed in lane 1 at 











Figure 3.19 : Western Blotting to show purification of recombinant gC1qR: Expression and 
purification of recombinant gC1qR was verified by Western Blotting. 10µg of recombinant 
gC1qR protein was run on a 12% v/w gel and transferred for 1 hour at 320mA onto 
nitrocellulose membrane. Following blocking for 1 hour at room temperature with 5% non-fat 
milk in PBS, the membrane was probed with polyclonal antibody anti-gC1qR (1:5000). After this 
the membrane was washed 3 times in PBS-Tween 0.02%. PA-HRP was added (1:500) and colour 





Figure 3.20: Hemolytic assay: 10
9
 /ml sheep erythrocytes in DGVB
++ 
were washed 3 x in DPBS 
and sensitised (37° for 30 minutes) with a dilution of IgG anti sheep red blood cell stroma. After 
incubation the sensitised EA’s were pelleted, washed 1x in DPBS and 3x in DGVB and re-
suspended in the same buffer. E cells were prepared in parallel without the addition of 
haemolysin to use as a control. The EA’s were then tested by incubating, (37° for 1 hour) 100µl 
of EA’s with 100µl of a 1:10 dilution (double diluted down) of NHS in DGVB. The percentage 
lysis of the EA and E cells was calculated and plotted, and the ch50 value was obtained at 
observing the dilution of serum that gave 50% lysis. 
3.4.3 Determination of CH50 value of the NHS 
The dilution of serum to use for complement assays was determined by a CH50 value 
test. This test would determine the dilution of serum needed by testing the functional 
capabilities of the serum complement components to cause 50% lysis of the SRBCs, pre 
sensitised with haemolysin. Upon lysis, the haemoglobin released is measured in this 
assay. When sensitised SRBCs were incubated with serum, the classical pathway was 
activated leading to the lysis of the SRBCs. By looking at the graph we were able to see 
that a serum dilution of 1/30 was sufficient to create 50%. E cells were used as a 

























Recombinant gC1qR activates complement in solution and solid phase  
 
 
Figure 3.21: Recombinant gC1qR activates complement in solid phase: gC1qR was coated 
on microtitre wells in carbonate buffer (100µl) at different concentrations, (10, 5, 2.5, 1.25 and 
0.625µg/well) and the plate was incubated overnight at +4 C. Contents were discarded and 1:40 
dilution of NHS in DGVB++ (total volume of 100µl) was added to each well and the plate was 
incubated at 37⁰C. Following this, the wells were washed three times with DGVB++ and 100µl of 
EA cells (1 x 108) were added to each well. This was then incubated for a further hour. After this, 
180µl of each sample was collected in an eppendorf tube and spun down for 5 minutes at 
5000rpm. 100µl of the supernatant was read under 520nm wavelength.  H20 and EA cells were 


























Figure 3.22: Recombinant gC1qR activates complement in solution phase: gC1qR was 
incubated for 1 hour at 37°C at different concentrations, (10, 5, 2.5, 1.25., 0.625µg) with NHS in 
DGVB++ (at a dilution of 1:40) to give a total volume of 100µl.  Following this, 100µl of EA cells (1 
x 108) were added to each sample. This was then incubated for a further hour. After this, 
samples were spun down for 5 minutes at 5000rpm. 100µl of the supernatant was read under 
520nm wavelength. H20 and EA cells were used for 100% lysis. 
3.4.4 Recombinant gC1qR and deletion mutants activate complement 
Previously, gC1qR has been reported to activate complement. Thus, studies were 
performed to evaluate whether gC1qR generated using T7 construct was able to 
activate the classical pathway. Figure 3.21 demonstrates gC1qR incubated in solid phase 
on microtitre wells at different concentrations (10-0.625µg/well) of NHS activated 
complement in a dose dependent manner as the concentration of gC1qR decreased. 
Similar to this, Figure 3.22 shows an identical assay carried out with the exception of 
gC1qR (at the same concentrations) incubated in solution with NHS. Again, consistent 
with the previous complement assay, gC1qR in solution was also able to activate 
complement in a similar dose dependant way. Both figures show that 10µg of gC1qR 
bought C1q mediated haemolysis down by 75%. The availability of gC1qR deletion 
mutants allowed us to determine whether gC1qR with various deleted residues are able 
to activate complement in solid phase. Complement activity was detected using anti C4d 
and IgG was used as a positive control. Our assay showed that all the gC1qR deletion 
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Figure 3.23: ELISA to examine if gC1qR deletion mutants activate complement: a) 
Compared with IgG as a positive control, b) Data shown without IgG. Wells were coated with 
4µg/ml of each gC1qR deletion mutant in coating buffer and incubated at 37°C for two hours. 
Contents were discarded and wells were blocked for 1 hour for 2% BSA. Wells were washed 3 
times with DGVB++ and 100µl of 1/10 dilution of NHS in DGVB++  was added to each well and 
incubated for 1 hour at 37°C. The wells were repeatedly washed in DGVB++ and anti-C4d 
(1:2000) was added in DGVB++ and incubated for a hour at 37°C. Bound C4d was detected with 









































ELISA to examine if gC1qR mutants can activate complement in a 
C3 activation deposition 







Figure 3.24: ELISA to show binding of gC1qR to C1q: Microtitre wells were coated in 
duplicates with different concentrations of C1q, (5, 2.5, 1.25 and 0.625µg/well) and incubated 
overnight at 4°C. Following morning contents were discarded and wells were blocked with 
2%BSA in PBS for 1 hour at 37ºC. Wells were then washed with PBS + 0.05% Tween three times 
and 2.5µg of biotinylated gC1qR was added per well in Calcium buffer and incubated for a 
furthur 1 hour at 37ºC. Following repeated washes, bound gC1qR was detected by streptavidin 
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Figure 3.25: ELISA to assess binding between the globular head receptor gC1qR and ghA, 
ghB, ghC and MBP. gC1qR was coated in coating buffer, Ph 9.6 at a concentration of 1ug/well. 
100µl of this was coated onto microtitre wells and left overnight at 4 degrees. The next morning 
wells were discarded and blocked with PBS containing 2% BSA for 3 hours. After 2 washes in 
PBS-T, the wells were incubated with wild-type forms of ghA, ghB, ghC and MBP as a negative 
control in a calcium buffer (1M Tris pH 7.5, 0.1M CaCl2 and 5M NaCl) at different concentrations 
(2.5, 1.2, 0.62, 0.3, 0.1µg/well) for 1.5 hours at 37 degrees and 1.5 hours at 4 degrees. Following 
washing, bound gh protein was detected using mAb anti-MBP as a primary antibody and goat-
anti mouse HRP conjugate as the secondary antibody 
 
3.4.5 gC1qR binds differentially to three globular head modules of human C1q 
To confirm that gC1qR is the globular head receptor for C1q, binding was measured by 
performing a direct binding ELISA. When biotinylated gC1qR was added to C1q coated 
on microtitre wells, there was a concentration dependent increase clearly indicating 
that gC1qR bound to C1q. (Figure 3.24) 
Different concentrations of the recombinant ghA, ghB and ghC were allowed to bind a 
constant concentration of gC1qR, following probing with the goat anti mouse 





























ghB and ghC modules all bound to gC1qR independently, in a dose dependent manner. 
Figure 3.25 shows that ghA showed stronger binding at a concentration of 2.5µg when 
compared with the other two modules. However the change in concentration from 1.2µg 
showed ghC to increase its binding capacity to gC1qR when compared with ghA and 
ghB. The fact that ghA has shown to bind to gC1qR at a higher affinity at a higher 
concentration is consistant with previous reports by Ghebrehiwet et al, 1996 that has 
implicated ghA to be the most important globular head in the C1q-gC1qR interaction. To 
confirm that each globular head bound independently to gC1qR, far western blots were 
performed using the expressed and purified gC1qR, ghA, ghB and ghC.  By transferring 
ghA, ghB and ghC onto PDVF membrane and probing with gC1qR, we were able to see 
three bands as shown in figure 3.27.  Figure 3.26 shows gC1qR transferred onto PDVF 
membrane and individually adding ghA, ghB and ghC to each blot. The appearance of 
three strong bands validated our previous findings that each globular head binds 




















Figure 3.26: Far Western Blot to show ghA, ghB and ghC bind independantly to gC1qR: 
15µg of gC1qR was loaded on a gel in three wells and run. The gel was cut into three sections 
and transferred onto PDV membrane for 1 hour. The membrane was also cut into three sections 
and blocked with 5% non-fat milk in PBS for 2 hours. 10µg of ghA, ghB and ghC in PBS were 
added to each respective memnbrane strip and incubated overnight at room temperature. The 
membranes were then washed 3 times in PBS-Tween for 20 minutes each and 10µl of mAb anti-
MBP in 2% non fat milk was added to each membrane and incubated for 2 hours at 37 degrees. 
Following washing 3 times in PBS-Tween for 20 minutes each, 10µl of IgG-HRP in 2% non fat 
milk was added and incubated for 1 hour at room temperature. The bands were developed 
using DAB tablets dissolved in water. Lane 1: gC1qR-ghA interaction, Lane 2: gC1qR-ghB 
interaction. Lane 3: gC1qR-ghC  
 
Figure 3.27: Far Western Blot to show gC1qR binding to ghA, ghB and ghC modules: 10µg 
of ghA, ghB, ghC and MBP was run on a gel and transferred onto a PDVF membrane for 1 hour at 
320mA. Following this, the membrane was blocked for 1 hours with 5% non-milk fat powder in 
PBS. 15µg of gC1qR in PBS was added to the membrane and incubated overnight. The next 
morning the membrane was washed 3 times for 20 minutes each with 0.02% PBS-T. Anti-gC1qR 
(1:1000) was added in 2% non-fat milk in PBS and the membrane was incubated for 2 hours at 
37°C. The bands were detected using Protein A-HRP conjugate (1:1000) in PBS and bands were 
developed using DAB tablets. Lane 1: Molecular marker Lane 2: ghA bound to gC1qR, Lane 3: 
ghB bound to gC1qR, Lane 4: ghC bound to gC1qR, Lane 5: MBP (negative control) 
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3.4.6 gC1qR binds to ghA, ghB and ghC independently on far western blot 
A far western blot was performed to examine the interaction between ghA, ghB ghC and 
gC1qR. We examined the binding of the individual globular heads to gC1qR (figure 3.26) 
and the binding of gC1qR to the globular heads (figure 3.27). Both blots revealed that 
ghA, ghB and ghC were able to independently bind to gC1qR on PVDF membrane and 
gC1qR was able to interact with all three globular head modules transferred onto the 
membrane which further validated the gC1qR-C1q interaction.    
3.4.7 ghA R162 is crucial for C1q-gC1qR interaction 
Using ELISA, we examined the gC1qR binding ability of recombinant ghA and its single 
residue mutants ghA-R162A and R162E. Different amounts of gC1qR were coated on 
microtitre wells, incubated with wild-type ghA, R162A and R162E, washed and probed 
with goat anti mouse HRP conjugate. As shown in figure 3.28, substitution of Arg 162 to 
Alanine (R162A) resulted in ~ 80% reduction in gC1qR binding. Similarly substitution 
of Arginine 162 with glutamate (R162E) resulted in similar abrogation of binding when 
compared to wild type ghA. To further confirm these observations, we carried out a far 
western blot, (Figure 3.29) to verify whether the Arg162 residue is specific in the C1q-
gC1qR interaction. Figure 3.29 shows a clear band for wild type ghA. However, probing 
with the mutants yields results consistent with ELISA data. A very faint band was 

















Figure 3.28: Perecentage binding to show inhibition of ghA mutants to gC1qR. B) ELISA to 
show interaction of ghA mutants with gC1qR: Microtitre wells were coated in duplicates with 
different concentrations (1, 0.5, 0.25µg/well) of gC1qR in carbonate buffer and incubated at +4 
overnight. Contents were discarded and wells were blocked for 2 hours with 2% BSA at 37°. 
Following washing with PBS + 0.05% Tween, 2.5ug/well of ghA wild type, R162A, R162E and 
MBP was added and the plate was incubated for 1.5 hours at 37° and 1.5 hours at +4. Wells were 
washed bound protein was detected using anti-MBP (1/5000) and IgG-HRP (1:5000) in PBS. 
Colour was developed using OPD buffer. The plate was read at a wavelength of 450nm. A) The 
percentage inhibition binding of the ghA mutants to gC1qR was worked out by using wild type 
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Figure 3.29: Far Western Blot to show lack of binding of ghA mutants R162A and R162E 
to gC1qR:  10µg of gC1qR was run in three lanes on a 15% SDS gel and transferred for 1 hour at 
320mA onto PDVF membrane. The membrane was blocked for 1 hour in 5% non-fat milk 
powder in PBS at room temperature. Next, the blot was cut into three pieces to separate the 
transferred gC1qR protein. Each strip was then probed with 50µg in 10ml of either WT ghA, 
R162E or R162A in Calcium buffer. This was incubated overnight at room temperature. The 
blots were washed three times in PBS + 0.02% Tween for 10 minutes each on a shaker. Next, the 
primary antibody mAb anti-MBP was added in PBS (1:1000) and left to incubate for 2 hours at 
37°C. The membranes were repeatedly washed and the secondary antibody IgG-HRP was 
diluted in PBS (1:1000) and incubated for 1 hour at room temperature. Following repeated 
bands were developed using DAB tablets Lane 1: Molecular marker, Lane 1: gC1qR probed with 
R162A. Lane 2:  gC1qR probed with WT ghA. Lane 3: gC1qR probed with R162E. 
3.4.8 R114Q appears important for stabilising C1q-gC1qR interaction 
Using ELISA the ability of ghB and its single residue mutants R114Q, R114A, R163A, 
R163E, T175L, R129A, R129E and H117D to bind gC1qR was examined.  gC1qR was 
coated on microtitre wells and probed with recombinant mutational forms of MBP-ghB. 
Results showed that substituting Arg114 to Glutamine (R114Q) bound with a greater 
affinity to gC1qR than the wild type ghB (Figure 3.30). Figure 3.30a shows that this 
substitution increased ghB binding to nearly 30% greater than the wild type ghB when 
the concentration of gC1qR increased from 0.5µg to 1µg, suggesting that the insertion of 
a polar amino acid such as glutamate is able to enhance binding between the two 
proteins. Substituting Arg114 with Alanaine, however, was not comparable with R114Q 
as figure 3.30a shows a minimum of 40% difference in binding between the two 
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mutants to gC1qR.  Out of all the ghB  mutants, R163E showed the most dramatic drop 
in gC1qR binding  than the wild type ghB, with R163E inhibiting binding up to 65%  at 
the highest concentration of gC1qR (1µg). R129A and R1219E showed similar binding 
abilities as figure 3.30a again shows a drop of over 70% compared to wild type ghB 
pointing out that Arginine residues play a role in this interaction. Binding of H117D was 
comparable to this   Calculating from the graph, T175L was shown to inhibit binding up 
to 35% and H117D dropped to 65%. This shows that substituting Arginine with 
glutamate has an adverse effect on the binding of gC1qR as binding was shown to be 
nearly abolished. Substituting His to Asp reduced ghB affinity for gC1qR by nearly 70%, 
when compared to the wild type ghB, which suggests that His117 is important in gC1qR 
binding. Comparing the ghB deletion mutants, the most significant effect observed on 
gC1qR binding was the role of mutants R136E, T175L and H117D suggesting that Arg, 
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Figure 3.30: a) Perecentage binding to show inhibition of ghB mutants to gC1qR. b) ELISA 
to show interaction of ghB mutants with gC1qR:. a) The percentage inhibition binding of the 
ghB mutants to gC1qR was worked out by using wild type ghB binding as 100% positive control. 
b) Microtitre wells were coated in duplicates with different concentrations (1, 0.5, 0.25µg/well)  
of gC1qR in carbonate buffer and incubated at +4 overnight. Contents were discarded and wells 
were blocked for 2 hours with 2% BSA at 37°. Following washing with PBS + 0.05% Tween, 
2.5ug/well of ghB wild type, R114Q, R114A, 129A, R129E, R163E, T175L, H117D  and MBP was 
added and the plate was incubated for 1.5 hours at 37° and 1.5 hours at +4. Wells were washed 
bound protein was detected using anti-MBP (1/5000) and IgG-HRP (1:5000) in PBS. Colour was 
developed using OPD buffer. The plate was read at a wavelength of 450nm 
3.4.9 Contributions of ghC substitutions in gC1qR binding 
Using ghC substitution mutants we were able to examine the ability of R156E, H101A 
and L170E to interact with gC1qR. Our ELISA result revealed that all three substitution 
mutants were able to bind to gC1qR in a dose-dependent manner (figure 3.31b). The 
substitution of Arg156 to Gln revealed that this had no effect in gC1qR binding. R156E 
was able to interact with gC1qR in a similar manner as the WT ghC. The ghC mutant, 
L170E, revealed that by substituting Leu170 with Gln slightly reduced its affinity to 
gC1qR by 13%. A greater reduction of binding (35%) (figure 3.31a) was observed when 
His101 was replaced with Ala, suggesting that this residue of the ghC chain is involved in 
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Figure 3.31: a) Percentage binding to show inhibition of ghC mutants to gC1qR. b) ELISA 
to show interaction of ghC mutants with gC1qR: a) The percentage inhibition binding of the 
ghC mutants to gC1qR was worked out by using wild type ghC binding as 100% positive control 
b) Microtitre wells were coated in duplicates with different concentrations (1, 0.5, 0.25µg/well)  
of gC1qR in carbonate buffer and incubated at +4 overnight. Contents were discarded and wells 
were blocked for 2 hours with 2% BSA at 37°. Following washing with PBS + 0.05% Tween, 
2.5ug/well of ghC wild type, R156E, H101A, L170E and MBP was added and the plate was 
incubated for 1.5 hours at 37° and 1.5 hours at +4. Wells were washed bound protein was 
detected using anti-MBP (1/5000) and IgG-HRP (1:5000) in PBS. Colour was developed using 
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3.4.10 Identification of additional C1q binding sites on gC1qR 
Interestingly, deletion of the previously identified C1q binding site 74-96 appeared to 
support C1q binding as well as WT gC1qR (Figure 3.32) suggesting that there are other 
residues on gC1qR that are key players in the interaction with C1q. However, additional 
domains were identified that drastically reduced C1q binding when deleted. These 
include residues 190-192, 196-202 and 202-218. The fact that residues 190-192 and 
196-202 are essential for trimer formation of gC1qR, indicates that monomeric gC1qR 
does not bind efficiently to C1q. HK has been found to bind to gC1qR at residues 204-
218 and activate the KKS system, and our data suggests that this stretch of 14 residues 
also provides an additional site for C1q, pointing out that these plasma proteins could 
potentially share overlapping sites on gC1qR.  Deleting the single amino acid W233G 
seemed to have no effect in reducing C1q binding suggesting that this petruding residue 





Figure 3.32: ELISA to identify additional binding sites for C1q on gC1qR. Duplicate wells of 
microtiter plates were first coated with 100 μl of wild type or gC1qR mutants (ΔgC1qR) in 
carbonate buffer at different concentrations, (1, 0.5, 0.25µg/well) and incubated overnight at 
















37°C. The wells were then washed three times in PBS +0.05% Tween and wild type ghA  
(2.5µg/well) was added in Calcium buffer. The plate was incubated for 1.5 hours at 37°C and 1.5 
hours at 4°C. Following repeated washes the bound wild type globular head was detected by 
1:5000 dilution of mAb anti-MBP in PBS, followed by IgG-HRP conjucate (1:5000) in PBS. Wells 
were developed using OPD tablets  
 
3.4.11 Concomitant increase of gC1qR and C1q expression in adhesive monocytes 
In order to investigate the pattern of expression of C1q and gC1qR, an assay was 
devised using monocytes. The monocytes were derived from fresh blood and 
maintained in culture in order to become adherent. The adherence phenotype was 
observed using microscopy during the time points analyzed (results not shown) 
outlined in Figures 3.33 and 3.34. The adherence phenotype in vitro simulates the 
adherence of monocytes to endothelial surfaces in vivo during inflammation and is 
therefore relevant to examine the production of C1q by these cells and how this 
expression relates to the levels of expression of the receptor to C1q, namely gC1qR.  
The monocyte adherence assay was conducted in the presence and absence of LPS, 
since it was curious to see if the expression of C1q and gC1qR would be affected by 
stimulation of the monocytes by LPS. C1q expression increased markedly in adherent 
monocytes during adherence, peaking at 72 hrs with a log10 3.5 fold differences in 
expression compared to 2hrs adherence (Figure 3.33). Incubation with LPS had a 
increased C1q expression. There was also an increase in gC1qR expression during 
adherence, with peaks observed at 48 and 72 hrs. In contrast to C1q, the presence of 
LPS downregulated the expression of gC1qR in comparisom to without LPS. This was 
not surprising since gC1qR is not a ligand for LPS.  These results confirm our previous 
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Figure 3.33. Expression of C1q by adherent human monocytes in vitro.  The expression of 
C1q was measured using real time qPCR and the data normalised 18S rRNA gene expression as 
a control. Relative expression (RQ) calculated by using the 2hr timepoint as the calibrator. The 
RQ value was calculated using the formula: RQ = 2–ΔΔCt.  Assays were conducted twice in 
triplicate. Error bars represent ± standard error of the mean. A two-side t-test was performed 
on the data, All samples showed significant expression compared to the calibrator (p≤0.01), 
except where noted: *: 0.01 < p < 0.05; ns: not significant (p≥0.05). LPS , added to cultures at 




































2  h rs 4 8  h rs2 4  h rs 7 2  h rs 5  d a y s 7  d a y s




Figure 3.34. Expression of gC1qR by adherent human monocytes in vitro.  The expression 
of gC1qR was measured using real time qPCR and the data normalised 18S rRNA gene 
expression as a control. Relative expression (RQ) calculated by using the 2hr timepoint as the 
calibrator. The RQ value was calculated using the formula: RQ = 2–ΔΔCt.  Assays were conducted 
twice in triplicate. Error bars represent ± standard error of the mean. A two-side t-test was 
performed on the data. 
3.5 Discussion 
The heterotrimeric gC1q domain belonging to the C-terminal region of C1q contributes 
to the ligand binding property of C1q. C1q being a charge pattern recognition protein is 
able to bind to a range of ligands through its gC1q domain in the presence of calcium 
(Assimeh and Painter, 1975;  Roumenia et al 2006). Intriguingly the configuration of the 
heterotrimeric gC1q module is also found in a range of non complement proteins (Ghai 
et al 2007; Carland and Gerwick, 2010, Tang et al., 2005) such as collagen VIII (Kishore 
et al 1999; 2000; 2004; Csako et al., 1981) precerebellin (Gerwick et al., 2000) and 
multimerin (Mei et al., 2008). Crystal structure analysis of the gC1q domain shows a 
sphere-shaped, heterotrimeric arrangement with the N and C terminal ends of each 
domain residing at the base of the trimer. Alongside this, the crystal structure has also 
identified an exposed Ca2+ ion located at the apex; this ion has been implicated to be 
important in the binding of gC1q to its ligand.  
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The main receptor on the cell surface identified for the gC1q domain is gC1qR. However 
the function and contributions of ghA, ghB and ghC in binding to gC1qR has not been 
specified. Therefore, recombinant forms of ghA, ghB, ghC and were expressed and 
purified in order to understand whether these C-terminal globular regions function 
individually or whether C1q’s ability to bind its receptor is dependant on these globular 
head modules in a combined structure. In addition to the recombinant forms of ghA, ghB 
and ghC, single residue substitution mutants of each domain were also expressed and 
purified in an attempt to define the residues important in this interaction. Previous 
studies have shown that gC1qR inhibits complement activation by binding to the gC1q 
domain of C1q, thereby preventing IgG from binding to the globular heads. Therefore it 
was hypothesised that the binding sites for gC1qR and IgG may overlap, with literature 
showing that one of the IgG binding sites resides on Arg162 of the A chain. This has been 
made evident in the mutational studies where mutant R162E reduced the ability of C1q 
to bind to IgG by 35% (Kojouharova et al 2004). The role of arginine residues in the C1q 
globular domain has previously been considered important which is interesting as 
figure 3.26 suggests that the A chain is also preferential in the binding between C1q and 
gC1qR. Alongside this, previous experiments were carried out by Ghebrehiwet et al, 
1997 that showed that the Arg residue Arg162 in C1q is significant in gC1qR binding.  A 
peptide corresponding to the A-chain with the Arg residues at position 162 substituted 
to Glu showed no binding whereas the A-chain peptide with the Arg residues intact 
bound strongly to gC1qR. It has also been noted that residues 154-165 of the A chain is 
implicated in IgG binding (Marques et al., 1993) and inhibition studies have 
demonstrated that the complex of C1q and gC1qR prevented SRBCs to bind to C1q and 
diminished complement activation. This data supports the findings of our experiments 
as figure 3.28 clearly indicates that substitution of the Arginine residue in ghA abolishes 
its binding ability to gC1qR.  , illustrating that within the A-chain, Arg 162 could be the 






Figure 3.34: Structural analysis of gC1q showing mutated residues: a) Structure of gC1q 
globular head region, green, blue and magenta region represents ghA, ghB and ghC. Location of 
ghB mutant R114 is represented as a red stick situated at the side chain. ghA mutant R162 





We further examined the contributions of Arg114, Arg163 and His117 (of ghB) and Arg156 
(of ghC) to the C1q-gC1qR interaction by substituting them with either neutral or 
negatively charged residues. Our experiments showed that the substitution of Arg to the 
negatively charged residue glutamine in amino acid 114 of the B chain increased 
binding to gC1qR even greater than the wild type ghB. 
The observation that a substitution mutant is interacting better than the wild-type is of 
great interest. In addition, experiments involving chemical modification of certain 
amino acid residues have associated Arg114 of the B chain to be an important residue in 
IgG binding. This suggests that although the B chain requires ionic amino acids at this 
specific position for IgG binding, such strong ionic interactions situated in ghB are not as 
favourable for gC1qR binding, as glutamate at position 114 bound gC1qR with greater 





Figure 3.36: Crystal structure analysis of globular head region. A) Individual ghA, ghB and 
ghC heads showing situation of the Ca+ ion at the apex. B) gC1q domain. C) Globular head 
domain showing location of important residues implicated in ligand binding found on ghA, ghB 
and ghC. D) gC1q domain illustrating vital residues of ghA, ghB and ghC. 
 
The availability of a crystal structure of gC1qR (Jiang et al 1999) has enabled 
Ghebrehiwet et al to generate gC1qR deletion mutants to confirm previous binding sites 
as well as identify new ones. The domains were deleted on the basis of holding a 
functional role. By analysing the interaction between the gC1qR deletion mutants and 
ghA, the preferential binder from C1q we can conclude that gC1qR holds additional 
binding sites for C1q. Residues 74-96 which have been noted as the C1q binding site on 
129 
 
gC1qR appeared to bind as strongly as WT gC1qR, whereas the HK binding site 
comprising of residues 204-218 and encoded by exon V demonstrated a drastic 
decrease in interacting with ghA. Deletion of residues 192-196 and 196-202 also 
displayed a reduction of binding to ghA implying that these residues are important for 
C1q binding. Remarkably, Ghebrehiwet et al 2011has revealed that residues 192-196 
and 196-202 are also important for HK binding as deletion of these residues abrogated 
the binding of gC1qR to HK. This therefore draws the conclusion that three binding sites 
have been revealed that appear to be important in interacting with both plasma 
proteins C1q and HK. HK has been associated with vascular permeability promoting 
angiogenesis (Guo and Coleman 2005). Therefore, the idea of C1q sharing an 
overlapping site with HK on gC1qR suggests that C1q could be used as a therapeutic 
molecule to intervene between gC1qR and HK binding to prevent vascular leakage and 
consequent inflammation. 
 
The expression of C1q and gC1qR in adherent monocytes, using qPCR, appeared to 
suggest that the receptor and the effector protein i.e. C1q are up-regulated with 
adherence that mimics pro-inflammatory context. The concomitant expression was 
biphasic suggesting expression, first via preformed transcripts followed by new wave of 
transcription. These results appear to suggest that the two proteins are co-expressed 
under pro-inflammatory conditions and can regulate each other’s functions. When LPS 
was used, the expression of C1q was upregulated, but gC1qR levels were reduced, 
suggesting that gC1qR is not directly involved in C1q-mediated effector functions 














Tripartite molecular interaction 
between C1q, gC1qR and DC-SIGN: 











Dendritic Cells (DCs) are identified as the most potent antigen presenting cells within 
the immune system. Their ability to be the only APCs to prime naïve T-cells has become 
a hot topic of study due to the role of its receptor DC-SIGN, which in the last decade has 
been shown to regulate a wide range of immune functions. Recently this C-type lectin 
has emerged as a C1q binder, forming a trimeric complex involving gC1qR on the 
surface of immature DCs. We expressed and purified recombinant DC-SIGN and SIGN-R 
domains, the tetrameric form comprising of the entire extra cellular domain including 
the α helical neck, and the carbohydrate recognition domain in its monomeric form. 
Direct binding studies revealed that both variants were able to bind independently to 
the individual globular head modules ghA, ghB and ghC, with ghB being the preferential 
binder. Mutational analysis using single amino acid substitutions of the globular heads 
showed that TyrB175 and LysB136 appear critical in facilitating the C1q-DC-SIGN/SIGN-R 
interaction. Competitive studies also demonstrated that gC1qR and ghB share 
overlapping sites on DC-SIGN implying that HIV pathogenesis could be modulated due 
to the interplay of gC1qR-C1q with DC-SIGN.  
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4.2 Introduction  
Dendritic Cells (DCs)  are the most powerful antigen presenting cells (APCs) within the 
immune system (Dorfel et al., 2005) (Ni and ONeill, 1997). They are capable of 
capturing and degrading pathogens by recognizing molecular patterns expressed by 
pathogens, through a series of pattern recognition receptors (PRR) known as C-type 
lectins  (Weis et al., 1998) Essentially C-type lectins are recognized through their ability 
to bind carbohydrates in a calcium-dependent manner (Weis et al., 1992). The role of 
DCs within the immue system is vital in initating immune responses due  to being the 
only cell type able to activate naïve T-Cells (Austyn et al., 1983). This contact between 
DCs and T cells is vital in producing primary immune responses. Dendritic Cell specific 
Intracellular  Adhesion Grabbing Non Integrin (DC-SIGN) is a C-type lectin  expressed on 
DCs which, functions  to mediate interactions between DCs and T cells through 
interacting with Intracellular Adhesion Molecule-3 (ICAM-3) (Geijtenbeek et al., 2000c). 
The importance of DC-SIGN as a mediator in this interaction has been supported by the 
inhibition of this binding preventing DC induced proliferation of resting T cells 
(Geijtenbeek et al., 2000c).  
DC-SIGN has been shown to play a role in cell migration (Liu et al., 2002).  DCs adhere to 
endothelial cells expressing high levels of ICAM-2 which bind DC-SIGN. Furthur 
interactions between Lymphocyte Function-Associated Antigen-1 (LFA-1) and ICAM-1 
with ICAM-2 – DC-SIGN promote transendothelial  migration of DCs, allowing them to 
travel from the blood to the lymphatic system where they can induce T cell responses. 
The role of DC-SIGN in boosting  immunity has been further explored by Martinez et al 
who has shown that DC-SIGN stimulates CD3-activated T-cells to produce IL-2 which in 
turn enhances T- cell differentiation (Martinez et al., 2005).  As well as participating in a 
range of functions to promote immunity, this receptor also engages in activities that 
bring upon immune suppression (Tong et al 2006) . This is evident through the ability 
of DC-SIGN to bind to a range of viral proteins and pathogens, including the glycolipid  
ManLAM of Mycobacterium tuberculosis (M.tb) (Turville et al., 2001). The binding of DC-
SIGN to this cell wall component inhibits DC maturation through the suppression of Toll 
like Receptor (TLR-4) (Maeda et al., 2003). Such a cross-talk between TLRs and DC-SIGN 
that generates anti-inflammatory effects points out the two dimensional role of DC-SIGN 
in immunoregulation.  DC-SIGN’s immunosuppressive role is furthur highlighted 
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through its ability to bind to the HIV-1 envelope protein gp120 (Curtis et al., 1992), 
where instead of  permitting entry and infecting DCs, this protein behaves as a reservoir 
by allowing DC to carry HIV-1 to the lymph nodes where it is transmitted to CD4+ T cells 
leading to immunodeficiency (Geijtenbeek et al., 2000b). The Hepatitis C Virus (HCV) 
envelope glycoprotein E2 is another viral protein DC-SIGN engages with (Pohlmann et 
al., 2003) to inhibit immunity. This is achieved through utilizing its high quality 
endocytic capability to internalize the viral antigen leading to the infection of DCs 
(Lozach et al., 2003).  Structurally, DC-SIGN is composed of an extracellular domain 
which exists as a tetramer, stabalised by an α helical neck region, followed by a 
Carbohydrate Recognition Domain (CRD),  (Mitchell et al., 2001). Its affinity for N-linked 
high mannose oligosaccharides is evident through its ligands gp120 and ICAM-3 being 
highly glycosylated, indicating that this binding is mediated through the CRD region 
(Curtis et al., 1992).  
The importance of DC-SIGN as an immune molecule has been a central topic of study in 
the past decade. Possible therapeutic roles for DC-SIGN has been suggested owing to its 
ability to induce T cell proliferation when targeted with DC-SIGN antibodies conjugated 
with antigens (Singh et al., 2009). Sarkar et al 2013 have shown that the interaction 
between gp120 and DC-SIGN triggers a drop in IL-6 production by iDCs.  In addition to 
this, gp120 binding to DC-SIGN has also been shown to suppress the anti-apoptotic 
activity of Nef and induce apoptosis in iDCs (Sarkar et al., 2013). Thus, HIV pathogensis 
heavily relies on the interplay of molecular mechanisms involving DC-SIGN (Sarkar et 
al., 2013).  
The interesting fact about DC-SIGN expression restricted to DCs points out the 
contradicting functions of this C-type lectin: its role as an immunostimulatory molecule 
facilitating DC interaction with naïve T cells to enhance immunity; and a promoter of 
HIV-1 infection via binding viral ligands. It has, therefore, become of great interest to 
discover possible modulators of HIV-1 infection that can interfere with such 
interactions. The targeting of glycans of glycoroteins using CBAs (carbohydrate binding 
agents) has become increasingly attractive area of research, indicating that such 
molecules could potentially act as inhibitors at preventing viral entry between the viral 
protein and its target cell (Balzarini and Van Damme, 2007). Such therapeutic strategies 
have proved to be effective at preventing DC-SIGN directed HIV-1 transmission to CD4+ 
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T-cells (Balzarini et al., 2007). Very recently, the microbicide lectin drug GRFT 
(Griffithsia) isolated from the red algae, has been shown to not only inhibit DC-SIGN 
mediated capture and transmission of HIV-1 to CD4+ T-cells , but to also dissociate 
gp120 from  the gp120-DC-SIGN complex (Hoorelbeke et al., 2013) 
Recently, it has emerged that DC-SIGN binds to C1q via its globular head region (Hosszu 
et al., 2012), forming a trimeric complex with gC1qR, on the surface of immature DCs. 
Both C1q and gC1qR are known to associate with the viral envelope protein gp41 of 
HIV-1 (Fausther-Bovendo et al., 2010). C1q-gp41 has been shown to activate 
complement (Ebenbichler et al., 1991), whereas gC1qR has been identified with a novel 
role of being the receptor on CD4+ T-cells that binds to gp41 and targets healthy CD4+ T 
cells to Natural Killer (NK) cell-mediated lysis (Fausther-Bovendo et al., 2010). The 
recently discovered trimeric complex on immature DCs has been hypothesized to play a 
role in DC differentiation through signaling via DC-SIGN activating the NFκ B pathway.  
The ghA module has previously been shown to bind differentially to gp41 peptide 
(Kishore et al, 2003). Thus, we further examined the interaction between globular head 
modules and DC-SIGN, with the idea that this interaction may interefere with HIV-1 
infection. Here, we show that ghB preferentially binds to DC-SIGN and SIGN-R. It also 
appears that ghB and IgG binding sites on DC-SIGN are overlapping and shared since 
Lys136 and Tyr175 on ghB, which have been previously shown to be significant for 
binding to IgG  and vital for gC1q assembley (Gadjeva et al., 2010) are important for 
C1q-DC-SIGN binding.  
Previously, structure-function studies have demonstrated that the CRD region of DC-
SIGN is the specific site for ligand binding and only functions in the presence of the neck 
region within the Extra Cellular Domain (ECD) (Lozach et al., 2003). The use of 
recombinant forms of DC-SIGN tetramer and DC-SIGN monomer (CRD) alone has 







4.3 Materials and methods  
4.3.1 Construct expressing DC-SIGN Tetramer, DC-SIGN Monomer, SIGN-R 
Tetramer, SIGN-R Monomer 
The cDNA was inserted in the pT5T expression vector  at the BamHI restriction site and 
the plasmids were used to transform Escherichia coli strain BL21/DE3. 
4.3.2 Expression of DC-SIGN and SIGN-R as monomers and tetramers 
Plasmids containing the full length and truncated cDNA of each protein were kindly 
provided by Dr.Daniel Mitchell from the University of Warwick. The cDNA was inserted 
into the pT5T expression vector at the BamHI restriction site and the plasmids were 
transformed in Escherichia coli strain BL21/DE3 (Mitchell et al, 2002) The purified 
plasmid DNA was transformed into BL21 DE3 cells using the protocol described in 
Material and Methods chapter. Various constructs designed to express DC-SIGN 
tetramer, DC-SIGN monomer, SIGN-R tetramer and SIGN-R monomer containing 
transformed cells were plated onto agar with ampicillin added, whereas SIGN-R 
monomer transformant was plated onto agar with kanamycin added. Both antibiotics 
were added to a concentration of 50µg/ml and incubated at 37°C overnight. 150µl of 
cells were added to each plate and spread using a sterile plastic spreader. Protein 
expression was performed using Luria-Bertani medium with 50mg/ml of ampicillin. A 
single transformed colony of DC-SIGN or SIGN-R was grown overnight at 37°C in 15ml 
LB and diluted in 1 litre of LB that was incubated at 37°C until an A550 of 0.7 was 
reached. The culture was induced with 10mM  isopropyl-b-D-thiogalactoside (IPTG) and  
was incubated for an additional 3 hours at 37°C. Bacteria were centrifuged at 4500rpm 
for 15 minutes at 4°C and the pellet was collected.  
4.3.4 Inclusion body preparation  
The cell pellet was treated with 22ml of lysis buffer (100mM Tris pH 7.5, 0.5M NaCl, 
lysozyme, 2.5mM EDTA and PMSF) and left to shake for 1 hour at 4°C. Cells were 
sonicated on ice for 10 cycles for 30 seconds with 2 minute gaps to ensure complete 
lysis of cells. The lysate was centrifuged at 10,000rpm for 15min at 4°C. The 
supernatant was then discarded and the inclusion body pellet was mixed with 20ml of 
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6M Urea, 100mM Tris pH 7.5 and 20µl β-mercapthethanol. This solution was left 
shaking on a rotor in the cold room for 1 hour  
4.3.5 Refolding protocol  
The mixture was then centrifuged at 13,000rpm for 30mins at 4°C. . The supernatant 
was collected into a beaker and whilst gently placed on a magnetic stirrer 80ml of 
loading buffer (1M NaCl, 25mM Tris pH 8.0, 5mM CaCl2) was added slowly drop by drop 
using a drop wise diluting method to create a gradient. The mixture was then dialysed 
against two litres of loading buffer and changed three times every six hours.  
4.3.6 Purification of recombinant proteins 
Following further centrifugation at 13,000 rpm for 15mins at 4°C, the supernatant was 
loaded onto a mannon agarose column (5ml) pre-equilibrated 5 times with loading 
buffer. The column was washed again with 5 bed volumes of loading buffer and purified 
protein was collected in 1ml fractions of elution buffer (1M NaCl, 25mM Tris-HCL pH 
7.8, and 2.5mM EDTA). The absorbance was read at 280nm and fractions were frozen at 
-20°C. Purity of protein was analysed by SDS-PAGE. 
4.3.7 Direct Binding ELISA 
Microtitre wells were coated in duplicates with different concentrations of protein (DC-
SIGN or SIGN-R) (5, 2.5, 1.25 and 0.625µg/well in bicarbonate buffer pH 9.6) and left 
overnight at 4°C. Wells were blocked with 100µl of 2%v/w BSA in PBS for for 2 hours at 
37°C. Following three washes with PBS + 0.05% Tween, 2.5µg/well of ghA, ghB and ghC 
(100µl)  was added  in calcium buffer (50mM Nacl, 100mM Tris and 5mM CaCl2) MBP 
was used as a negative control. The plate was incubated at 37°C for 1.5hours and a 
further 1.5hours at 4°C. The wells were washed and the bound protein was detected 
with anti-MBP mAb in PBS (1:5000), followed by rabbit anti-mouse IgG-HRP (1:5000). 
Colour was developed using OPD and read at 415mm 
4.3.8 Competitive ELISA 
The optimum concentration for DC-SIGN and SIGN-R binding was chosen based on the 
result of the direct binding ELISA. Proteins were immobilized on microtitre wells by 
overnight incubation at 4°C of 100µl of 5µg/well in carbonate/bicarbonate buffer, pH 
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9.6. Wells were blocked with 2%v/w BSA in PBS for 2 hours at 37°C. Following washing 
with PBS + 0.05% Tween, the plate was incubated with a constant concentration 
(5µg/well) of the first competing protein (gC1qR) and various concentrations (5, 2.5, 
1.25, 0.625µg/well) of the second competing protein (ghB) in calcium buffer to give a 
total of 100µl per well. After incubating for 1.5 hours at 37°C and 1.5 hours at 4° the 
microtitre wells were washed and rabbit anti-gC1qR pAb (1:000) in PBS was added and 
incubated for a further 1 hour at 37°C. Bound protein was detected by Protein A-HRP 
conjucate (1:5000) and developed using OPD. Data was plotted to determine inhibitory 
values of competitive ligand binding. 
4.3.9 Western Blotting 
ghA, ghB and ghC (15µg) were separated by 12% SDS-PAGE gel and transferred onto  
PDVF membrane for 1 hour at 320ma. Membrane was blocked in 5% non fat milk (1 
hour at room temperature) and 20µg of DC-SIGN in loading buffer was added and 
incubated (overnight at room temperature). The blot was washed three times for 10 
minutes in PBS containing 0.05% Tween and incubated in primary antibody pAb anti-
DC-SIGN (1:1000) in 1% non fat milk (2 hours at 37°C). Following subsequent washes, 
the membrane was incubated with Protein A conjucated HRP (1:1000) (1 hour at room 
temperature). The blot was developed using DAB substrate 
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4.4 Results  
4.4.1 Expression and Purification of DC-SIGN and SIGN-R tetramer and monomer  
Both DC-SIGN and SIGN-R comprising of the entire extracellular domain and the CRD 
region alone were expressed in E. coli and purified on Mannose Sepharose.  The CRD 
fragments of DC-SIGN and SIGN-R bound mannose weakly as they eluted in the wash 
fraction. The ECD domains of both DC-SIGN and SIGN-R bound to mannose with much 
greater affinity in the presence of Ca+ and eluted with EDTA   
 





Figure 4.1: Induction of DC-SIGN Tetramer, DC-SIGN Monomer, SIGN-R Tetramer,  
SIGN-R Monomer: a) Lane 1: Molecular Marker, Lane 2: Uninduced DC-SIGN tetramer,  
Lane 3: Induced DC-SIGN tetramer, Lane 4: Uninduced DC-SIGN momomer, Lane 5: Induced  
DC-SIGN monomer, Lane 6: Uninduced SIGN-R Monomer, Lane 7: Induced SIGN-R  
Monomer. b) Lane 1: Molecular marker, Lane 2: Uninduced SIGN-R tetramer, Lane 3:  











Figure 4.2: SDS-polyacrylamide gel electrophoresis of purified soluble a) and b) DC-SIGN 
Tetramer, c) and d) SIGN-R Tetramer  purification by Mannon -Agarose affinity 
chromatography. a) Lane 1: Molecular marker, Lane 2-9: purified DC-SIGN tetramer, Lane 10: 
Flow through. b) Lane 1-6: Purified DC-SIGN tetramer. c) Lane 1-9: Purified SIGN-R tetramer. d) 
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Figure 4.3: SDS-polyacrylamide gel electrophoresis of purified soluble a) DC-SIGN 
Monomer, b) SIGN-R Monomer purification by Mannon -Agarose affinity chromatography. 
Proteins were expressed in 1 litre of bacterial culture and elution fractions were collected in 
1ml fractions on a 5ml column in buffer containing 5mM EDTA. 12% gel was stained with 
Coomassie Blue.  A) Lane 1: Molecular Marker, Lane 2-6: Eluted purified DC-SIGN Monomer . B) 



























Figure 4.4: Expression and purification of DC-SIGN R:  Lane 1: Molecular marker , Lane 2: 
Uninduced  sample, Lane 3: Induced sample, Lane 4: Supernatant after sonication, Lane 5: 




4.4.2 Both DC-SIGN and SIGN-R Tetramer and Monomer bind to C1q 
Previously, Kang et al has shown that SIGN-R interacts with C1q and recently, work by 
Hosszu et al revealed that DC-SIGN bound directly to C1q. In this present study we 
sought to determine whether this binding is mediated solely through the CRD region, or 
whether the alpha helical neck is also a necessity. We examined direct binding of both 
the tetrameric and monomeric variants of DC-SIGN and SIGN-R with purified human 
C1q on microtitre plates. Figures 4.5 and 4.6 shows the results of the ELISA represented 
that both DC-SIGN and SIGN-R in their full length configuration (Tetramers) and the 
CRD alone (monomers) were able to bind to C1q in a dose dependent manner. 
Experiment showed a strong binding of the tetramers to C1q when compared to the 
CRD region alone, with the ability of C1q to bind nearly 50% more when the alpha 
helical neck is intact. Furthermore the results above also demonstrate that C1q has a 









Figure 4.5: ELISA to show binding of C1q to DC-SIGN and SIGN-R:  C1q was coated at 
different concentrations (5. 2.5, 1.25, 0.625µg/well) and left overnight at +4. Contents were 
discarded and wells were blocked with 2% BSA in PBS for 2 hours at 37°C. The wells were 
washed 3 times with PBS + 0.05% Tween and 2µg/well of DC-SIGN Tetramer or SIGN-R 
Tetramer was added in Calcium buffer (5mM CaCl2) and incubated at 1.5 hours at 37 degrees 
and 1.5 hours at 4°C. Bound protein was probed with anti-DC-SIGN pAb (1:1000) or anti SIGN-R 
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Figure 4.6: ELISA to show binding of C1q to DC-SIGN Monomer and SIGN-R Monomer:  DC-
SIGN Monomer and SIGN-R monomer were coated at different concentrations (5. 2.5, 1.25, 
0.625µg/well) and left overnight at 4°C. Contents were discarded and wells were blocked with 
2% BSA in PBS for 2 hours at 37°C. The wells were washed 3 times with PBS + 0.05% Tween 
and 2µg/well of C1q was added in Calcium buffer (5mM CaCl2) and incubated at 1.5 hours at 37 
degrees and 1.5 hours at +4. Bound C1q was probed with anti-C1q pAb (1:1000) following 
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4.4.3 DC-SIGN and SIGN-R neck region is required for binding to C1q individual 
globular chains 
Fragments of DC-SIGN and SIGN-R comprising of the complete extracellular domain and 
the CRD region were expressed in E.coli and purified on mannan-agarose column. 
Ligand binding studies were performed by ELISA where tetrameric and monomeric DC-
SIGN and SIGN-R coated on microtitre wells were probed with  ghA, ghB and ghC to 
examine whether these globular heads are able to bind to the ECD and CRD with similar 
avidity. Our experiments show that ghA, ghB and ghC bound with much greater affinity 
to DC-SIGN and SIGN-R Tetramer in comparison to the monomeric CRD variants, 
indicating that the neck is also preferentially required for the individual globular heads 
to bind efficiently. Figures 4.7 and 4.8 below also reveal that ghA, ghB and ghC bind 
SIGN-R with greater affinity that DC-SIGN. 
4.4.4 DC-SIGN and SIGN-R bind preferentially to ghB  
C1q binds to DC-SIGN via its globular head region, and due to the individual modularity 
within the gC1q region, we sought to map which chain is specific for DC-SIGN binding. 
By using single monomeric fragments of individual globular head chains ghA, ghB and 
ghC, we were able to asses which region of the C1q globular head is specific to DC-SIGN 
and SIGN-R. When DC-SIGN and SIGN-R were coated on microtitre wells and probed 
with ghA, ghB and ghC, all three globular heads bounds DC-SIGN and SIGN-R in a dose 
dependant manner indicating that all three heads are capable of binding to the ligands 
independently. Furthermore, our experiments show that it is the ghB chain of C1q that 
is preferential in this binding to DC-SIGN as the ghB module bound much better to DC-
SIGN when compared to ghA and ghC. In addition, ghB was the better binder to SIGN-R. 
Interestingly ghA was able to bind better with SIGN-R than DC-SIGN (Figure 4.7 and 
4.8). Direct binding ELISA showed that both DC-SIGN and SIGN-R had less affinity for 
ghC when compared with ghA and ghB (figures 4.7 and 4.8). The binding properties of 
of ghA, ghB and ghC for DC-SIGN and SIGN-R Tetramer were similar when the CRD 
region was probed with the individual globular heads. Although the binding of ghA, ghB 
and ghC to the CRD domain was significantly lower, ghB was still the most important 











Figure 4.7: Binding of ghA, ghB and ghC to (a) DC-SIGN Tetramer and (b) DC-SIGN 
Monomer: Different concentrations of DC-SIGN Tetramer (a) and DC-SIGN Monomer (b) 
(5, 2.5, 1.25µg/well) was coated on microtitre wells in carbonate buffer and incubate overnight 
at 4°C. Wells were blocked in 2% BSA in PBS, following washing. ghA, ghB, ghC and MBP 
(2.5µg/well) were added and incubated. Wells were washed again and bound protein was 
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Figure 4.8: Binding of ghA, ghB and ghC to (a) SIGN-R Tetramer and (b) SIGN-R  Monomer: 
Different concentrations of  SIGN-R  Tetramer (a) and SIGN-R Monomer (b)  (5, 2.5, 
1.25µg/well) was coated on microtitre wells in carbonate buffer and incubated overnight at 4 
degrees. Wells were blocked in 2% BSA in PBS for 2 hours at 37 degrees. Following this, wells 
were washed 3 times in PBS + 0.05% Tween and ghA, ghB, ghC and MBP (2.5µg/well) were 
added  to each well and the plate was incubated at 37 degrees for 1.5 hours and at 4 degrees for 
























































Figure 4.9: Far western blot of ghA, ghB and ghC with DC-SIGN: 15µg of ghA, ghB and ghC 
was loaded on a gel in three wells and run. The gel was transferred onto PDV membrane for 1 
hour. The membrane was then blocked with 5% non-fat milk in PBS for 2 hours. 50µg of DC-
SIGN in PBS was added to the membrane and incubated overnight at room temperature. The 
membrane was then washed 3 times in PBS-Tween 0.02% for 15 minutes each and 10µl of mAb 
anti-MBP in 2% non fat milk was added and incubated for 2 hours at 37 degrees. Following 
repeated washing, 10µl of IgG-HRP in 2% non fat milk was added and incubated for 1 hour at 
room temperature. The bands were developed using DAB tablets dissolved in water.    
 
4.4.5 Examining the ability of DC-SIGN and SIGN-R to bind to the ghA substitution 
mutants   
The ability of R162E and R162A to bind to gC1qR was assessed by ELISA. Both 
substitiution mutants bound DC-SIGN and SIGN-R in a dose dependent manner (figure 
4.10 and 4.12). It appeared that SIGN-R was able to interact with the ghA substitution 
mutant R162E nearly as efficiently as it did with Wild Type ghA (Figure 4.13) showing a 
reduction in binding of only 15%. R162A, on the other hand, bound SIGN-R with much 
less affinity showing a drop of 33% (figure 4.13). Considering DC-SIGN and SIGN-R are 
both highly conserved, R162E was able to interact with DC-SIGN reasonably weaker 
than it did with SIGN-R (figure 4.11), showing a 40% reduced binding as opposed to 
15% (seen with SIGN-R.) The mutant R162A bound DC-SIGN in a similar manner as it 
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Figure 4.10: Binding of ghA, ghA-R162E and R162E to SIGN-R Tetramer: Different 
concentrations of SIGN-R tetramer (5, 2.5, 1.25µg/well) were coated on microtitre wells in 
carbonate buffer and incubated overnight at 4 degrees. Wells were blocked in 2% BSA In PBS 
for 2 hours at 37 degrees. Followig this, wells were washed  3 times in PBS + 0.05% Tween and 
ghA, ghA-R162A, ghA-R162E and MBP (2.5µg/well) were added  to each well and the plate was 
incubated at 37 degrees for 1.5 hours and at 4 degrees for 1.5 hours. Wells Were washed again 
and bound protein was detected using mAb MBP following IgG-HRP. 
 
 
Figure 4.11: Percentage binding of ghA mutants to SIGN-R: To qualitatively asses binding 
inhibitory properties of the ghA mutants R162A and R162E, the percentage binding was worked 
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Figure 4.12: Binding of ghA, ghA-R162E and R162E to DC-SIGN Tetramer: Different 
concentrations of DC-SIGN tetramer (5, 2.5, 1.25µg/well) were coated on microtitre wells in 
carbonate buffer and incubated overnight at 4 degrees. Wells were blocked in 2% BSA In PBS 
for 2 hours at 37 degrees. Following this, wells were washed 3 times in PBS + 0.05% Tween and 
ghA, ghA-R162A, ghA-R162E and MBP (2.5µg/well) were added to each well and the plate was 
incubated at 37 degrees for 1.5 hours and at 4 degrees for 1.5 hours. Wells Were washed again 



















Figure 4.13: Percentage binding of ghA mutants to SIGN-R: To qualitatively asses binding 
inhibitory properties of the ghA mutants R162A and R162E, the percentage binding was worked 
































4.4.6 The contributions of ghB substitution mutants to DC-SIGN and SIGN-R 
binding 
Using ELISA, we examined the ability of DC-SIGN to bind to the ghB substitution 
mutants R114Q, R114Q, R163E, R163A, R129A, R129E, H117D, T175L and L136G 
(Kojouharova et al 2004). Results showed that all the ghB substitution mutants bound 
both DC-SIGN and SIGN-R in a dose dependent manner (figure 4.14 and 4.16). 
Substituting Arg114 to Gln and Ala resulted in a reduction of 50% in DC-SIGN (figure 
4.15) and SIGN-R binding (figure 4.17), suggesting that the Arg residue at this point 
plays an important role in the C1q-DC-SIGN/SIGN-R interaction.  
 
Substituting the ghB mutant Arg129 with Glu and Ala caused a small reduction of ~20% 
binding with DC-SIGN (figure 4.15) with these mutants exhibiting similar binding ability 
to SIGN-R (10-25%) (figure 4.17). When Arg163 was replaced with the negatively 
charged Glu, its affinity for DC-SIGN and SIGN-R was reduced to 40% (figure 4.15 and 
4.17), whereas substitution with Ala resulted in 30% reduction for DC-SIGN (figure 
4.15) and 20% for SIGN-R (figure 4.17). A greater reduction in DC-SIGN binding of 60% 
was observed for the ghB mutant His117 substituted for Asp (figure 4.15), whereas the 
ability of H117D to interact with SIGN-R was knocked down by 30% (figure 4.17).  For 
the ghB module the Tyr175 substitution to Leu had the most significant effect showing a 
dramatic decrease of 70-75% in binding to both DC-SIGN and SIGN-R (figure 4.15 and 
4.17). Similarly, L136G bound less to DC-SIGN showing a drop of 50-60% (figure 4.15). 
 
4.4.7 Residue L136 and T175 of the ghB module is important for IgG binding is 
also involved in DC-SIGN and SIGN-R binding  
Given that DC-SIGN binds to ghB (this study) as well as that DC-SIGN binds to C1q at the 
IgG binding site (Hosszu et al, 2012) we sought to identify the complementary binding 
sites. Via a series of ghB substitution mutants (Kojouharova et al., 2004), the interaction 
between the ghB chain of C1q and DC-SIGN revealed two important substitution 
mutants; T175L and L136G (Figure 4.14 and 4.15). As reported previously, L136 and 
T175 residues are important in maintaining the gC1q structure as well as having a 
pivotal role in IgG binding. Therefore, we examined the C1q-DC-SIGN interaction with 
Lys136 substituted for Glu and Tyr175 substituted for Lys. DC-SIGN and SIGN-R for ghB 
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with L136G resulted in nearly 60% of binding abolished (figure 4.15 and 4.17), 
suggesting that DC-SIGN binding to ghB overlaps with IgG. When DC-SIGN and SIGN-R 
were incubated with T175L, binding was reduced to 60-75% (figure 4.15 and 4.17) 







Figure 4.14: Binding of ghB mutants L136G, T175L, R114Q,  R114A, R163A, R163E, 
R129E, R129A and H117D  to  DC-SIGN: Different concentrations of  DC-SIGN Tetramer  (5, 
2.5, 1.25µg/well) was coated on microtitre wells in carbonate/bicarbonate buffer and incubated 
overnight at 4°C. Blocking was performed in 2% BSA for 2 h at 37°C and microtitre wells were 
washed. 2.5µg/well of ghB, T175L, L136G, R114A, R114Q, R163E, R163A, R129A, R129E and 
H117D were diluted in Calcium buffer and added in each well. Following incubation and washes, 

















































Figure 4.15: Percentage binding of ghB mutants to DC-SIGN: To qualitatively asses binding 
inhibitory properties of the ghB mutants, the percentage binding was worked out by using WT 
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Figure 4.16: Binding of ghB mutants L136G, T175L, R114Q, R114A, R163A, R163E, R129E, 
R129A and H117D  to  SIGN-R: Different concentrations of  DC-SIGN Tetramer  (5, 2.5, 
1.25µg/well) was coated on microtitre wells in carbonate buffer and incubated overnight at 4 
degrees. Wells were blocked in 2% BSA in PBS for 2 hours at 37 degrees. Following this, wells 
were washed  3 times in PBS + 0.05% Tween and (2.5µg/well) of ghB, T175L, L136G, R114A, 
R114Q, R163E, R163A, R129A, R129E and H117D  were added  to each well in Calcium buffer  
and the plate was incubated at 37 degrees for 1.5 hours and at 4 degrees for 1.5 hours. Wells 
were washed again and bound protein was detected using mAb MBP following IgG-HRP (1:5000 














































Figure 4.17: Percentage binding of ghB mutants to SIGN-R: To qualitatively asses binding 
inhibitory properties of the ghB mutants, the percentage binding was worked out by using WT 




4.4.7 The contributions of ghC substitution mutants to DC-SIGN binding 
ELISA to examine the interaction between ghC mutants and DC-SIGN showed that the 
substitution mutants H101A, R156E and L170E bound to DC-SIGN in a dose-dependent 
manner (figure 4.18). It appears that replacing Arg156 with Glu of the ghC chain slightly 
strengthened binding to DC-SIGN witb an increase in 15% (figure 4.19) suggesting that 
a Glu residue at this point is effective in attracting DC-SIGN. The ghC mutants H101A 
and L170E reduced binding to ghC by 15-20% (figure 4.19), suggesting that the 
contributions of His101 and Leu170 are comparable in the DC-SIGN-C1q interaction. 
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Figure 4.18: Binding of ghC mutants H101A, R156E and L170E to DC-SIGN: Different 
concentrations of DC-SIGN Tetramer (5, 2.5, 1.25µg/well) was coated on microtitre wells in 
carbonate buffer and incubated overnight at 4 degrees. Wells were blocked in 2% BSA in PBS 
for 2 hours at 37 degrees. Following this, wells were washed  3 times in PBS + 0.05% Tween and 
(2.5µg/well) of ghC, H101A, R156E and L170E  were added  to each well in Calcium buffer  and 
the plate was incubated at 37 degrees for 1.5 hours and at 4 degrees for 1.5 hours. Wells were 
washed again and bound protein was detected using mAb MBP following IgG-HRP (1:5000 
dilution in PBS). Colour was developed using OPD and the plate was read at 415mm Percentage 
binding of ghC mutants to DC-SIGN: To qualitatively asses binding inhibitory properties of the 
ghC mutants, the percentage binding was worked out by using WT ghC as a 100% positive 






































Figure 4.19: Percentage binding of ghC mutants to DC-SIGN: To qualitatively asses binding 
inhibitory properties of the ghC mutants, the percentage binding was worked out by using WT 
ghC as a 100% positive control at each concentration 
 
4.4.8 The contributions of ghC mutants to SIGN-R 
The ghC substitution mutants bound to SIGN-R in a dose dependent manner (figure 
4.20). The substitution mutants H101A and R156E appeared to bind to SIGN-R as 
efficiently as its WT counterpart, whereas L170E showed a slight decrease in binding of 
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Figure 4.20: Binding of ghC mutants H101A, R156E and L170E to SIGN-R: Different 
concentrations of DC-SIGN Tetramer (5, 2.5, 1.25µg/well) was coated on microtitre wells in 
carbonate buffer and incubated overnight at 4 degrees. Wells were blocked in 2% BSA in PBS 
for 2 hours at 37 degrees. Following this, wells were washed  3 times in PBS + 0.05% Tween and 
(2.5µg/well) of ghC, H101A, R156E and L170E  were added  to each well in Calcium buffer  and 
the plate was incubated at 37 degrees for 1.5 hours and at 4 degrees for 1.5 hours. Wells were 
washed again and bound protein was detected using mAb MBP following IgG-HRP (1:5000 
dilution in PBS). Colour was developed using OPD and the plate was read at 415mm Percentage 
binding of ghC mutants to SIGN-R: To qualitatively asses binding inhibitory properties of the 
ghC mutants, the percentage binding was worked out by using WT ghC as a 100% positive 





































Figure 4.21: Percentage binding of ghC mutants to SIGN-R: To qualitatively asses binding 
inhibitory properties of the ghC mutants, the percentage binding was worked out by using WT 
































Figure 4.22) a) ELISA to show binding of ghB to DC-SIGN, b) ELISA to show binding of DC- 
SIGN to gC1qR. Different concentrations (5, 2.5, 1.25, 0.625µg/well) of either A) DC-SIGN or B) 
gC1qR were coated on microtitre wells in carbonate buffer and incubated overnight at +4°C. 
Contents were discarded and wells were washed in PBS + Tween 0.05%. 2.5µg of A) ghB or B) 
DC-SIGN in calcium buffer was added and the plate was incubated for 1.5 hours at 37°C and 1.5 
hours at +4. Following repeated washing, plate A was detected using anti MBP followed by a 
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Figure 4.23: ELISA to assess whether gC1qR and ghB directly compete for the same 
binding site on DC-SIGN: (a) DC-SIGN was coated at 5µg/well overnight at +4. Following 
morning contents were discarded and wells were blocked with 2% BSA in PBS for 2 hours at  37 
degrees. Wells were then washed with PBS 0.05% tween 3 times and 5µg/well of gC1qR and 
different concentrations of ghB (5, 2.5, 1.25, 0.625µg/well) were added in buffer containing 
5mM Calcium, 50mM Tris  and 100mM NaCl . The plate was incubated at 37 degrees for 1.5 
hours and +4 for 1.5 hours. Following repeated washes, bound gC1qR was probed using pAb 
rabbit anti-gc1qR and PA-HRP. Colour development was detected using OPD substrate. (b) 
Same concentrations of ghB were incubated with 5µg of gC1qR for 1 hour at 37 C and 30 
minutes at +4 C prior to adding to wells. 
 
4.4.9 gC1qR and ghB compete for the same binding site on DC-SIGN 
Direct Binding ELISA determined that To further explore the possibility of gC1qR, C1q 
and DC-SIGN forming a trimeric complex, as shown on iDCs by Hosszu et al, we sought 
to see whether DC-SIGN holds a complimentary site for its two ligands. Since ghB is the 
preferential binder to DC-SIGN out of the three chains, we used this globular head 
protein to perform competitive assays. By incubating different concentrations of ghB 
and a steady concentration of gC1qR with DC-SIGN, probing with anti-gC1qR enabled us 
to see that as the concentration of ghB decreases, more gC1qR was able to bind to DC-
SIGN (figure 4.23), thereby implying an overlapping site between the two ligands. 
Figure 4.22a shows that at a concentration of 5µg of DC-SIGN, 5µg is able to bind 
efficiently showing an OD of 0.8. However this binding appeared to drastically reduce 
when 5µg of gC1qR was added to compete with 5µg of ghB, as figure 4.23 shows the 
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C1q is a charge pattern recognition protein that binds to a variety of ligands via its gC1q 
domain. Due to already being identified to interact with SIGN-R, Hosszu et al very 
recently has showed that C1q also recognizes its homologue DC-SIGN (Hosszu et al 
2012). The availability of individual ghA, ghB and ghC modules has given us the 
opportunity to undertake structure-function studies and define whether individual 
globular head regions function as autonomous modules in this interaction with DC-SIGN 
and SIGN-R or whether a heterotrimeric structure of the gC1q domain is needed. 
We have performed a series of experiments involving both the tetrameric forms of DC-
SIGN and SIGN-R (comprising of the extracellular domain and CRD region) as well as the 
monomeric forms which only consists of the CRD region. We asked the question 
whether DC-SIGN and SIGN-R’s binding site for C1q (and its globular head modules) lies 
within their CRD region or the α-helical neck region also plays a important role in these 
interactions. Both proteins have been shown to have an increased affinity for 
glycoproteins containing high mannose oligosaccharides, such as mannose (Appelmelk 
et al., 2003), gp120 (Geijtenbeek et al 2000) and ICAM-3 (Geijtenbeek et al., 2000a) with 
this CRD-mediated binding. Our results show that the individual globular head modules 
bind better to the tetrameric forms of DC-SIGN and SIGN-R as opposed to just the CRD 
region alone, indicating that the neck region is need to facilitate binding.  It also 
suggests that you need a tatrameric structure for interaction. The neck region of DC-
SIGN and SIGN-R interestingly differ from most α helical structures (Mitchell et al 2001) 
as the 23 amino acid repeats only show the first half of each repeat presenting a pattern 
of hydrophobic residues spaced at intervals, a feature that is abundant in most dimer 
and trimer coiled-coils (Mclachlan and Stewart, 1975). Therefore, this novel form of a 
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Figure 4.24: Schematic diagram to show structure of DC-SIGN: A) DC-SIGN Tetramer 
comprises of the extra cellular domain made up of the cytoplasmic tail, transmembrane region 









Our data also show that ghB out of the three globular domains binds preferentially to 
both DC-SIGN and SIGN-R.  Previous studies have also identified ghB as a key module of 
the gC1qR domain in binding to ligands PTX3 and CRP (Roumenia et el 2006). Based on 
the 77% sequence similarity between these two homologues it is not surprising that the 
specificity within the globular domain is similar between the two. Physical studies also 
show that the specificity of these c-type lectins to identify glycoproteins lie largely 
within their CRD regions affinity to recognise specific oligosaccharides, as well as 
requiring calcium dependence (Stoiber et al., 1995), which is supported through their 
capacity of having similar ligand binding characteristics due to their almost identical 
structure (Soilleux et al., 2000). Another interesting feature made evident in our studies 
is that C1q as well as ghB is shown to bind with a greater affinity to SIGN-R than DC-
SIGN. This is interesting as it reflects on the way the oligomers within the CRD region 
interact. The physical structure of SIGN-R employs a close spacing of two 
oligosaccharides which is remarkable as Mitchell et al has highlighted that this 
substantially leads to a higher increase in affinity for SIGN-R to binds ligands in 
comparison to DC-SIGN, which is clearly evident in this study. Our results clearly display 
that ghA, ghB and ghC all possess a greater binding affinity to SIGN-R tetramer in 
comparison to DC-SIGN Tetramer as well as SIGN-R monomer to DC-SIGN monomer. 
Moreover this confirms that the binding between this ligand (i,e C1q) and receptor is 
mediated via the CRD region. 
The opportunity to express individual domains of ghA, ghB and ghC has allowed us to 
assess the modular nature of the gC1q domain. Furthermore, we were also able to 
express and purify globular head mutants (Gadjeva et al 2004) where single amino acid 
residues have been substituted which would help in identifying key residues that 
facilitate C1q’s relationship with its ligands. These mutants were designed by analyzing 
the crystal structure due to their position within the domain and known residues to be 
important in binding. By performing ELISA with DC-SIGN and SIGN-R, we examined the 
interaction of ghB residue Arg163, which was substituted with Glu and Ala, Arg114 
substituted with Ala and Glutamine, Arg129 with Ala and Glu, His117 with Asp, Leu136 with 
Gly and Thr175 with Leu. The role of Arginine residues have previously been shown to be 
important for the C1q-IgG interaction  (Burton et al 1980), which is of great interest as 
Hosszu et al has suggested that DC-SIGN binds to C1q via its IgG binding site. In addition 
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to this, recent epitope mapping analysis has identified additional Arg residues of the 
ghB chain, Arg108 and Arg109 to be involved in the initial stage of recognizing IgG, as well 
as contributing to its final binding (Gadjeva et al 2008). Our results also support the 
significance of Arg residues, clearly showing that Arg114, which is implicated as a vital 
residue in IgG binding is also important in DC-SIGN and SIGN-R binding, with figure 4.17 
shows a in 60% reduction in binding when compared to WT ghB at the highest 
concentration of 2.5µg/well. Our data shows that substitutions of Arg129 and Arg163 with 
either Glu or Ala did not make a significant difference in binding to DC-SIGN when 
comparing both mutants capacity to interact. Both mutants showed a decrease in 30% 
(figure 4.17). The same was observed when substituting Arg114 with the polar residue 
Glutamine and hydrophobic residue Ala, binding between the two mutants was both 
abolished at the same maximum ability of 80%. This, in turn, highlights a very 
important role for Arginine114 of human C1q ghB chain in maintaining the C1q-DC-SIGN 
interaction. This is consistent with Kojouharova et al 2004 who showed that residue 
Arg114 is the most important residue in C1q-IgG binding. 
Our mutantional studies have indicated, that residue Tyr175 is also critical for C1q-DC-
SIGN/SIGN-R binding. Figure 4.17 displays a dramatic reduction (82% for DC-SIGN and 
90% for SIGN-R) following substituting of Tyr for Leu. This is not the first time Tyr175 
has been shown to be a critical residue in gC1q binding, Gadjeva et al (2006) have 
shown that this residue mainly constitutes C1q binding to IgM. Over all our binding 
studies suggest that Tyr175 of ghB is critical for the C1q-DC-SIGN and C1q-SIGN-R 








Figure 4.25: Structural representation of DC-SIGN: DC-SIGN is a C-type lectin consisting of a 
CRD involved in binding carbohydrate residues in highly glycosylated ligands. The carbohydrate 
ligands are able to interact with Ca2+ through hydroxyl groups with amino acids Glu and Asn 
assisting this binding. The CRD region is made up of 12 β strands, 2 α helices and 3 disulphide 
bridges. A loop protruding from the protein surface forms two Ca+ sites. One of the Ca+ sites is 
essential for the conformation of the CRD whereas the other domain contains Glu347, Asn349, 
Glu354 and Asn365 which are involved in recognizing specific carbohydrate structures. Mutation 
of these sites leads to a loss in ligand binding (Geutenbeek et al, 2002). The CRD of DC-SIGN is 
separated from the transmembrane region by a neck comprised of 7 repeats. The neck is 
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gC1qR is increasingly being recognized as a major pathogen-associated molecular 
pattern recognition receptor (PRR). A wide range of bacterial and viral ligands, which 
bind gC1qR, are able to use it to either suppress the host’s immune response for their 
survival, or to gain access into cells to initiate viral-specific disease. Of the extensive 
array of viral ligands that have affinity for gC1qR, the HIV-1 envelope glycoprotein gp41 
and the core protein of HCV, are of major interest as they are known to contribute to the 
high morbidity and mortality caused by these pathogens. While the HCV core protein 
uses gC1qR on T cells to suppress their proliferation resulting in a significantly 
diminished immune response, gp41 employs gC1qR to induce surface expression of the 
NK cell ligand, NKp44L, on uninfected CD4+ T cells, thus rendering them susceptible to 
autologous destruction by NKp44R expressing NK cells. Because of the potential for the 
design of peptide-based or antibody-based therapeutic options, this chapter examines 
gC1qR interaction sites for these pathogen-associated molecular ligands. The binding of 
each viral ligand to wild type gC1qR and 10 gC1qR deletion mutants was examined in a 
ELISA. The results identify two major HCV core protein sites on a domain of gC1qR 
comprising of residues 144-148 and 196-202. Domain 196-202 in turn, is located in the 
last half of the larger gC1qR segment encoded by exons IV-VI (residues 159-282), which 
was proposed previously to contain the site for HCV core protein. The gC1qR site for 
gp41 on the other hand, was found to be in a highly conserved region encoded by exon 
IV and comprises of residues 174-180. Interestingly, gC1qR residues 174-180 also 
contain the cell surface-binding site for soluble gC1qR (sgC1qR), which can bind to the 
cell surface in an autocrine/paracrine manner. The identification of the precise sites for 
these important pathogen associated ligands could provide additional targets for the 




The receptor for the globular heads of C1q, gC1qR/p33, (also referred to as a C1q 
binding protein; gC1qBP) is a ubiquitously distributed highly acidic (pI 4.15), 
multifunctional cellular protein, which modulates a number of immunological functions 
including infection, inflammation, autoimmunity, and cancer. In addition to its known 
plasma ligands (C1q, High Molecular weight Kininogen (HK), fibrinogen, thrombin and 
vitronectin), gC1qR is able to bind a diverse range of bacterial (Nguyen et al., 2000) 
(Ghebrehiwet et al., 2007) and viral-associated molecular ligands (Wang et al., 1997, Yu 
et al., 1995) (Luo et al., 1994, Szabo et al., 2001, Fausther-Bovendo et al., 2010, Bruni 
and Roizman, 1996, Matthews and Russell, 1998, Kittlesen et al., 2000, Mohan et al., 
2002, Choi et al., 2009, Watthanasurorot et al., 2010). Thus gC1qR is being considered 
an important PRR. The core protein of the HCV and the envelope glycoprotein of the 
HIV-1 gp41 are two examples of viral associated molecular ligands that employ gC1qR 
to induce immunosuppression by targeting CD4+ T cells. The HCV core protein binds 
gC1qR on T cells and inhibits their proliferation (Kittlesen et al., 2000) in a manner that 
is similar to the C1q mediated anti-proliferative response (Chen et al., 1994). 
Suppression of the host immune response contributes to a high rate of viral persistence 
and disease progression (Kittlesen et al., 2000, Yao et al., 2004). Similarly, the HIV-1 
glycoprotein gp41, not only binds to the globular head domain of C1q via the 3S motif of 
gp41 (GIFGCSGKLICTT), but this interaction leads to activation of the classical pathway 
(Thielens et al, 1993; Quinkal et al, 1999). gp41 is also known to modulate T cell 
destruction thereby contributing to the persistently low level of T cells seen during the 
late phase of HIV-1 infection (Fausther-Bovendo et al., 2010; Caffrey, 2001). The 3S 
motif of HIV-1 gp41 corresponding to residues 601-620 (PWNASWSNKSLDDIW) has 
been shown to bind to gC1qR on uninfected bystander CD4+ T cells and induce surface 
expression of NKp44L, a cellular ligand for the NK receptor, NKp44, rendering them 
susceptible to autologous NK killing (Fausther-Bovendo et al., 2010).  Because 
molecules or peptides that inhibit the interaction between PAMPs and gC1qR can 
potentially be used as targets for therapeutic interventions, the present studies were 
undertaken to map out and refine the precise gC1qR interaction sites for these 
important molecules.   
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5.2.1 Interaction of Gp41 with complement 
Gp41 is also shown to bind to C1q. The loop region of gp41 at residues 601-613 is 
involved in this interaction (Thielens et al., 1993; Ebenbichler et al., 1991). It is known 
that retrovirus isolates from animals are able to undergo lysis by complement proteins 
in an antibody-independent manner (Bartholomew et al., 1978). However HIV-1 does 
not behave in the same manner when bound to C1q. Instead of undergoing complement 
mediated lysis of the infected cell, this interaction results in the deposition of C3b on the 
infected cell surface, which aids in the recruitment of immune cells such as phagocytes. 
However, it is not known yet whether this mechanism lessens the intensity of infection 
HIV (Solder et al., 1989). The behaviour of complement receptor bearing cells with HIV-
1 has been studied by Reisinger et al (1990). Experiments performed on the monocytic 
cell line U937 showed that HIV-1 in fact uses complement receptors as a port of entry. 
Low doses of HIV-1 enhanced infection of these U937 cells in the presence of 
complement. This observation has been further supported by the fact that addition of 
the mAbs (anti-CD4) and (anti-CR3) reduced HIV infection (Reisinger et al, 1990) 
 
The inability of complement to lyse the virus could be due to certain factors abundant in 
an individual that work to separate ‘self’ from ‘non-self’.  Such factors include decay 
accelerating factor (DAF; CD55), which serves to protect the body’s host tissue against 
the complement by binding  C3b, thereby disassembling the C3 convertase complex and 
inhibiting activation of the membrane attack complex (MAC), (Caras et al., 1987). Such 
factors could be embedded in the HIV membrane which would effectively provide a 
protective mechanism against complement mediated lysis. 
 
The HIV  loop region possesses many properties, which support the above mentioned 
interaction with C1q. Firstly, the loop region displays a lack of charged residues which is 
evident in literature that charged residues are less involved in protein-protein 
interactions (Zhao et al., 2011). It has been proposed that C1q recognises gp41 through 
hydrophobic interactions (Quinkal et al., 1999). The loop region is rich in hydrophobic 
clusters (Caffrey, 2001) (Only 4 hydrophilic residues are present out of 30 residue 
sequence) (Caffrey, 2001). Another striking feature observed in the loop region is the 
formation of a cleft, which is the likely docking site for the gC1q domain (Caffrey 2001).  
It has been shown that the ghA module from the gC1q region is specific to the loop 
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region of HIV-1 gp41 protein (Kishore et al., 2003). Quinkal et al 1999 used synthetic 
peptides corresponding to residues 601-613 of the gp41 loop and a mutational form by 
substituting a single amino acid in each sequence. As the wild-type peptide 601-613 was 
able inhibit binding of gp41 to C1q, the mutant peptides lle602, Trp603, Lys608 and 
lle610 failed to inhibit the binding of gp41 to C1q, thereby implying that these residues 
are key in the interaction between gp41 and C1q, (Quinkal et al,1999). 
5.2.2 Role of gp41 & gC1qR in HIV infection 
Recently, it has been established that gp41 brings about its insertion of viral genome 
into its target cell via binding to gC1qR, which is expressed on the surface of CD4+ T 
cells (Fausther-Bovendo et al., 2010). The 3S motif of gp41 consisting of 6 sequences 
(SWSNKS) located on residues 618-623 is central to this interaction (Vieillard et al., 
2005).  Initially the CD4+ T cell loss was thought to arise from cytotoxic killing of the 
cells infected with the HIV-1 virus. However, research has evidently exploited that death 
of these T cells is not in fact due to their infection by cytotoxic killing (Finkel et al., 
1995) but bought upon by the activation of signaling pathways to initiate apoptosis in 
uninfected cells (Alimonti et al., 2003).  
 It has emerged that such a signaling cascade results with the cell surface translocation 
of the Natural Killer (NK) ligand NKP44L , which binds to its counterpart cytotoxic 
receptor NKP44 causing T cells to become susceptible to NK lysis (Ward et al., 2007). 
NK lysis involves the cells releasing small cytoplasmic granules of proteins that initiate 
the target cell for death by apoptosis. 
 
Binding of the 3S motif with gC1qR activates class I phosphatidylinositol 3-kinase PI3Ks, 
a group of enzymes involved in regulation of cell growth (Engelman et al., 2006). These 
indirectly activate the Rho GTPase family member Rac. This, in turn, triggers the 
membrane bound enzyme complex NADPH Oxidase, whose activation is dependent 
upon the action of a Rac protein (Heyworth et al., 1993). NADPH oxidase stimulates T 
cells to release H202 which induces GTP hydrolysis of TC10, another member of the Rho 
family of GTPases,  into its active form. TC10 is then involved in bearing the exocytosis 
of NKP44L within its vesicles to the cell surface. It is by this mechanism that gp41 is able 
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to initiate the translocation of NP44L, which predisposes healthy CD4 T cells to NK 
mediated lysis, leading to the depletion of T-cells observed in HIV infection. 
 
It has also been proposed that the involvement of the 3S Motif with NKP44L lies solely 
within the expression of this ligand on the cell surface, not its synthesis. CD4-T  cells 
unstimulated by the 3S motif were shown to retain NKP44L in their cytoplasm with the 
inability to translocate it which illustrates that the 3S motif is only able to stimulate the 
translocation of pre-existing NKP44L from the cytoplasm to the cell surface (Fausther-
Bovendo et al., 2010) 
 
Fausther et al have confirmed that gC1qR is the receptor for the 3S Motif. In addition, 
CD4+ T cells pre-treated with anti gC1qR mAbs were sufficient to inhibit the binding of 

























Figure 5.1: Structure of gp41: HIV-1 gp41 is composed of a trimeric configuration of two 
peptides, N36 and C34 derived from the N and C terminal regions of the ectodomain of gp41. 
These peptides come together to form a 6 helical bundle. The N36 helix are packed interiorly, 
aligned in a coiled manner parallel to each other, whereas the C-terminal helix is packed anti-
parallel to the N36 peptides, on the surface of this trimer (Chan et al., 1997) A) Axial view 
looking down the 3-fold axis of the trimer, the N terminal helix is packed inside surrounded by 







5.2.3 Gp41 structure and relevance in host-pathogen interaction 
Gp41 and gp120 are held together by non-covalent interactions, the importance of this 
weak contact between the two molecules provides gp120 with its flexibility in order to 
undergo its change in shape, as well as arrest gp41 transitions after binding to its target 
cell (figure 5.4) (Pancera et al., 2009).  The structural elements that make up gp120 
include the β sandwich, the outer domain, and the V1/V2 loops (figure 5.2). The gp120 





Figure 5.2:  gp41-gp120 interaction: Three monomers of gp120 make up the trimeric 
structure represented in purple and bind to 3 molecules of gp41 to form a trimeric complex 
(Burton et al, 2004)  
 
 
Structurally, the gp41 subunit is composed of 3 domains consisting of an ectodomain, a 
cytoplasmic domain, and a membrane spanning domain (figure 5.3) (Long et al., 2011). 
The ectodomain is composed of a N-terminal and C-terminal region (figure 5.1). The N-
terminal contains the fusion peptide which inserts into the target membrane at the start 
of the membrane fusion process, (Stegmann et al., 1991)a polar region and a MPER 
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(Membrane Proximal External Region). The MPER is a highly conserved sequence made 
up of 24 amino acids and participates in promoting fusogenicity and virus infectivity 
(Munoz-Barroso et al., 1999).  
 
a)  
b)    
 
 
Figure 5.3: Model of gp41 domains: a) three domains are present in gp41, the ectodomain, the 
MSD (Membrane Spanning Domain) and the Cytoplasmic domain within which are the lentiviral 
lytic peptides (LLP). Left of the vertical dashed line indicates the N-terminal whereas to the left 
of it represents the C terminal. b) Composition of ectodomain shows N-terminal region 
containing MPER and C-terminal consisting of Heptad repeats regions 1 and 2 held together by 
the loop (Frey et al., 2010) 
 
The C-terminal is composed of 2 coiled heptad repeat regions called HR1 and HR2 
(figure 5.3) (Munoz-Barroso et al., 1999) that form an α-helical structure that is 
hydrophobic in nature and held together by a disulphide bridge within a hydrophilic 
loop (Melikyan, 2008). Three HR1 helices are present which are aligned in parallel to 
one another and fold over a hydrophobic groove. Positioned anti-paralell to this are 3 
motifs of HR2, binding of the fusion peptide to the host cell causes HR2 to bind back, 
creating a hair-pin structure, which together gives rise to a six helical bundle that 
creates close enough contact between the viral membrane and cell membrane. It is this 
interaction that allows fusion to occur. The cytoplasmic domain contains 3 amphipathic 
α-helical sequences, known as lentivirus lytic peptide 2 (LLP2), LLP-3 and LLP-1, all of 
which are membrane interacting (Yang et al., 2010). Both LLP1 and LLP2 contain Arg 
residues on one face of their α-helix which makes them positively charged. LLP 
segments have been associated with envelope fusogenicity (Kalia et al., 2003), stability 
of the envelope protein (Lee et al., 2002) and multimerisation, where it was shown that 
LLP1 and LLP2 play a vital role in assembling the cytoplasmic domain into a multimeric  
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structure, which is in confluence with previous findings stating that the multimeric form 
of the cytopplasmic domain is key in virus infectivity (Lee et al., 2000). It has also been 
demonstrated that the LLP segments bind membranes (Chen et al., 2001) and induce 
cytolytic activity (Miller et al., 1993). Substituion of Arg residues in LLP-1 with Glu 
disrupts cell lysis activity. It has recently been proposed that LLP2 becomes exposed on 
the cell surface during fusion of the virus with the host cell (Lu et al., 2008). The 
cytoplasmic region also contains two cysteine residues that have been implicated in 
targeting the Envelope to the lipid rafts (Rousso et al., 2000) and in association with 
this, LLP-1 has also been suggested to play a part in this anchorage, as a mutated form of 
LLP-1 reduced attachment of the envelope to the lipid rafts. 
 
Lastly the MSD is composed of a membrane spanning α- helix made up of 25 amino acid 
residues (Haffar et al., 1988) that anchor the envelope into the lipid bilayer. The highly 
conserved arrangement of the MSD implys that it plays a role in the envelope function 
and this statement has been supported by experiments showing that the insertion of 
mutations in the core region of this domain affected Envelope mediated fusion (Shang et 
al., 2008). 
 
Figure 5.4: Structure of gp41 interacting with host cell membrane: As the fusion peptide 
binds to the host cell membrane, the three motifs of HR2 are able to bind back bringing the viral 
membrane in close proximity to the host cell membrane to assist fusion of viral content (Miller 
et al., 2005) 
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5.3 Materials and Methods  
5.3.1 Chemicals and general reagents 
The following reagents and chemicals were purchased or obtained from the sources 
indicated: Dulbecco’s PBS (D-PBS) with and without calcium and magnesium 
(Mediatech Inc, Manassas, VA); Dulbecco’s Modified Eagles Medium (DMEM); RPMI 
1640, 100x Penicillin/Streptomycin, (GIBCO-Invitrogen, Grand Island, NY); heat 
inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT); human serum albumin 
(HSA) (Immuno-US, Rochester, MI); p-nitrophenyl phosphate (pNPP) (Pierce, Rockford, 
IL); and Immu-Mount (Thermo Fisher, Waltham, MA). Alexa 488- or Alexa 594-
Streptavidin, Alexa 488- or Alexa 594-F(ab’)2, goat anti mouse or anti rabbit; FITC-
conjugated goat anti-mouse IgG F(ab’)2 or sheep anti-rabbit IgG F(ab’)2 (Invitrogen, 
Carlsbad, CA); and alkaline phosphatase (AP)–conjugated rabbit anti-goat IgG (Pierce), 
and C1q (CompTech), D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone 
(PPACK)—a specific thrombin inhibitor (Sigma-Adlrich).  
5.3.2 Expression of various versions of recombinant gC1qR proteins 
The strategy for the construction of plasmids containing the glutathione-S-transferase 
(GST)-gC1qR wild type (WT), as well as several important deletion (∆) mutants lacking 
highly charged domains selected on the basis of their prominent position in the crystal 
structure (Jiang et al., 1999) have been described. (Ghebrehiwet et al., 2002; 
Ghebrehiwet et al., 2001) . In addition, a point mutation that projects from the S face in 
the crystal structure has also been generated with the idea that its conspicuous 
projection might signify its biological relevance (Ghebrehiwet et al., 2001). The fusion 
products were purified on glutathione-Sepharose 4B column, then cleaved by thrombin 
(3.2 µg /ml), and the GST-free gC1qR proteins purified on fast protein liquid 
chromatography (FPLC, Pharmacia) using a Mono-Q ion exchange column.  After 
verification by ELISA and Western blotting, the single peak containing the gC1qR 
protein was pooled, concentrated to 1-2 mg/ml and stored at –800 C in the presence of 
50 nM PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone)—a specific 
thrombin inhibitor (Sigma Adlrich). To estimate the organization and integrity of each 
recombinant protein, gel filtration of purified gC1qR (wild Type, WT) as well as the 
various deletion mutants was carried out by analytical gel filtration Superose column of 
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(Ghebrehiwet et al., 2001). With the exception of those lacking residues 74-95, 204-218, 
and 212-223, all of the deletions mutants displayed a properly folded trimer (Figure 
5.5).  
5.3.3 Expression and purification of gC1qR deletion mutants 
The plasmids generated for expressing the WT gC1qR used in these studies as well as 
the gC1qR deletion mutants were constructed as GST-fusion product in the vector pGex-
2T by Ghebrehiwet et al 1994. The GST-gC1qR fusion products were cleaved by 
thrombin (3.2µg/ml) and the gC1qR was purified using a Mono-Q ion exchange column. 
The single peak was pooled and frozen at -20 
5.3.4 Purification of recombinant WT gC1qR and gC1qR deletion mutants 
T he cDNAa of WT gC1qR and the deletion mutants were subcloned to the gluthathione 
S-transferase gene in the plasmid pGex-2T to be expressed as fusion products with the 
GST part at the N terminus and the gC1qR at the C terminus. The plasmid was 
transformed in e.coli and purified on a glutathione-Speharose column. The purified 
gC1qR fusion proteins were than cleaved by thrombin and the released gC1qR proteins 
were purified on a Mono-Q ion-exchange column 
5.3.5 Single point mutagenesis 
The solution face of gC1qR in the crystal structure displays a domain made up of a single 
residue Trp 233 that project conspicuously. A single residue mutation was carried out 
on Trp 233 where the codon TGG was mutated by a single base change to GGG (Gly) by 
double strand mutagenesis and transformed into E.coli and purified as the other 
deletion mutants. 
5.3.6 Trimer Formation 
The organization and ability of each gC1qR deletion mutant as well as WT to form a 
trimer was analysed using gel filteration. A  superpose beads column (1.4cm x 30cm) 
was equilibrated in a buffer made up of  50mM Tris-HCL buffer pH 7.4 and 1mM EDTA 
(Ghebrehiwet et al 1994). The flow rate was adjusted to 0.2ml/min and the column was 
caliberated with two proteins Carbonic Anydrase (29kDa) and BSA (65Kda) due to them 
having similar molecular weight to the monomeric and trimeric forms of gC1qR. The 
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peak elution of these two proteins was noted and used as the control to compare, 
against the elution time of each gC1qR recombinant protein.  
5.3.7 SDS-PAGE and Western blot analysis 
SDS-PAGE was performed on a 1.5 mm thick slab gels according to the method of 
Laemmli (Laemmli, 1970) with samples being run unreduced or reduced and alkylated 
by boiling for 5 min in the presence of 0.1 M dithiothreitol and 0.2 M iodoacetamide. 
After electrophoresis, the gels were stained either with Coomassie Briliant Blue or silver 
stain, destained and dried. Samples for Western blot analysis were first run on SDS-
PAGE as, and above then electrotransferred to polyvinyl difluoride (PVDF) 
nitrocellulose membranes, blocked with 5% non-fat milk containing TBST (20 mM Tris-
HCl, 150 mM NaCl and 0.05% Tween 20). The bound proteins were probed with an 
appropriate dilution of target-specific antibodies. The bound antibodies in turn were 
visualized by chemiluminescence horseradish peroxidase-conjugated species-specific 
antibody followed by reaction with 4-chloro-1-naphthol substrate. 
5.3.8 Proteins and antibodies  
Purified recombinant gp41, CD4 as well as monoclonal antibodies to gp41 and CD4 
were obtained from the NIH AIDS repository Program (Germantown, MD).  HCV core 
protein was purchased from Abcam (Cambridge, MA) and   rabbit anti-fibrinogen 
antibodies were a generous gift from Dr. Dennis Galanakis (Stony Brook University, NY). 
Antibodies to recombinant human gC1qR represent part of the anti-gC1qR antibody 
databank in the laboratory (Cummings et al., 2009). Affinity purified rabbit anti-gC1qR 
peptide 174-180, and a synthetic peptide corresponding to the 3S motif of gp41 were 
purchased (GenScript, Piscataway, NJ). Monoclonal antibodies to E. coli MBP (maltose 
binding protein) were purchased from Sigma. MBP -fused- recombinant globular head 
regions of human C1q: ghA, ghB, and ghC, were expressed and purified as experiments 
described previously (Kishore et al 2003). The ghA substitution mutants of globular 
head modules were generated as described earlier (Kojouharova et al 2004). 
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5.3.9 ELISA to examine binding of HCV core protein and HIV-1 gp41 to gC1qR 
deletion mutants 
The ability of the various gC1qR proteins to bind to HCV core protein or HIV-1 gp41 was 
assessed by ELISA. Microtiter wells were coated in duplicate (90 min, room temp or 
overnight, 4°C) with 100 µl of either 1µg/ml HCV core protein, gp41, or BSA, in 
carbonate/bi-carbonate buffer, pH 9.6 (15 mM Na2CO3 and 35 mM NaHCO3). The 
unbound protein was removed; the wells washed twice with TBST (20 mM Tris-HCl pH 
7.5, 150 mM NaCl, and 0.05% Tween -20), and the unreacted sites blocked by 
incubation (30 min, room temp) with 300 µl of 5% non-fat dry milk or blotto (10 mg/ml 
casein in TBS, pH 8.0).  After washing (2 x with TBST), the microtiter plate bound HCV 
or gp41 was incubated (60 min, room temp.) with various concentrations of 
biotinylated wild type gC1qR ranging from 0-5 µg/ml. This was followed by sequential 
reaction (60 min each, room temp) with alkaline-phosphatase conjugated streptavidin 
and pNPP. After firmly establishing dose-dependent binding (n=3), experiments were 
repeated as above to compare the binding of either 5 µg/ml biotinylated WT gC1qR or 
deletion (Δ) mutants followed by sequential reaction with alkaline-phosphatase 
conjugated streptavidin and pNPP as described.  
5.3.10 ELISA to examine binding of gp41 3S motif to gC1qR 
Microtitre wells were coated in duplicates with 100µl per well of 2µg/ml of gC1qR in 
carbonate buffer and incubated overnight at 4°C. The following morning the contents 
were discarded and wells were blocked with 5% non-fat milk in TBS for 1 hour at 37°C. 
Wells were then washed with TBS + 0.05% Tween 20 and different concentrations (1 
.2.5 and 5µg/ml) of the gp41 3S motif peptide. The plate was incubated at 37°C for1 
hour and the wells were repeatedly washed. Bound protein was detected using affinity 
purified rabbit anti-3S IgG which was incubated for a further hour at 37°C. The 
secondary antibody used was alkaline phosphatase conjugated anti-goat and wells were 
developed using PNPP. Another identical ELISA was performed, with the exception of 
the proteins coated in the reverse order. Wells were first coated with 100µl per well of 
100µg/well of the gp41 3S motif and different concentrations (1, 2.5, 5µg/well) of 




5.4 Results  
5.4.1 Location of deletions based on the crystal structure of gC1qR 
After purity of the gC1qR deletion mutants was assessed by SDS-PAGE, it was 
determined to see whether the deletion of specific residues affects the ability of the 
protein to form a trimer (figure 5.5). This was assessed by gel filteration on a superose 
column. As shown in table, the deletion mutants 74-95, 204-218 and 212-223 were 
unable to maintain a trimeric structure. Crystal analysis reveals that the N-terminal 
residues 74-95 make up the α-helical coiled coil region of each monomer and plays a 
role in forming extensive intermolecular contact in maintaining the trimeric structure 
(Jiang et al, 1999, Ghebrehiwet et al, 2002). Residues 204-218 cover the β6 structure of 
each monomer and residues 212-223 span the entire loop connecting β6 and β7 as well 
as covering the 20-A donut hole of the trimer (Jiang et al, 1999; Ghebrehiwet et al, 
2002). 
As the HCV core protein has been identified to bind to gC1qR, preliminary experiments 
were performed by a direct binding assay to confirm this interaction. The binding of 






Figure 5.5. Location of deleted residues. The deleted residues and their effect on 
trimerization are as described (Ghebrehiwet et al., 2001) and are reproduced here together 
with the ribbon structure of a gC1qR monomer (Jiang et al., 1999) to show the position of the 







                       
Figure 5.6.  Dose–dependent binding of gC1qR to HCV core protein. Microtiter wells were 
first coated with 1 µg/ml HCV core protein (1 h, 37º C). After washing and blocking with 5% 
non-fat dry milk for 1 hour at 37 degrees, the bound HCV was reacted (overnight, 4 º C) with 
different concentrations of biotinylated WT gC1qR ranging from 0-5 µg/ml to 5µg/ml  followed 
by sequential reaction with alkaline-phosphatase conjugated streptavidin and pNPP following 
the standard procedure for ELISA. Each data point is a mean of duplicate experiments and the 
figure is a representative of three such experiments.  
 
5.4.2 Identification of the gC1qR site for HCV core protein using gC1qR deletion 
mutants  
 As shown in Figure 5.6, the binding of HCV core to gC1qR is reproducible, specific, and 
dose-dependent. Previous studies (Kittlesen et al., 2000) have suggested that the 
binding site for HCV core protein resides on a long stretch of gC1qR that is encoded by 
exons IV-VI (residues 159-282). Therefore in order to verify and accurately define the 
HCV core protein interaction site on gC1qR, we used a solid-phase microtitre plate 
binding assay to test the interaction of a range of highly purified gC1qR deletion 
(Ghebrehiwet et al., 2001). When the binding of these deletion mutants was assessed 
using HCV coated microtitre wells, two mutants lacking residues 144-148 and 196-202 
respectively, showed significantly reduced interaction with HCV core protein when 
compared to the WT-gC1qR (Figure 5.7).  Furthermore, the HCV core protein was found 
to bind both synthetic peptides (residues 144-148 and 196-202) but not to other 
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Figure 5.7.  Interaction of gC1qR and gC1qR deletion mutants with HCV core protein. 
Microtiter plate wells were first coated with 1 µg/ml of HCV core protein and incubated for 1 
hour at  37º C. Wells were  washed three times with TBS + 0.05% tween and blocked with 5% 
non-fat dry milk for 1 hour at 37°C. The bound HCV was reacted (O/N, 4 º C) with 5 µg/ml of 
either biotinylated WT gC1qR or gC1qR deletion (Δ) mutants Δ204-218, Δ212-223, Δ144-148 
and Δ196-202. The reaction was developed using alkaline phosphotase- streptavidin and PNPP. 
Data shown are representative of three separate experiments run in duplicates and includes 
data of only the deletion mutants that reacted weakly with HCV core protein.  
 
 
5.4.3 Binding of gC1qR to gp41 
When different concentrations of gC1qR were added to coated gp41, gC1qR bound gp41 
in a dose dependant manner. The amount of bound gC1qR increased by 12% when the 
concentration was increased from 0.25µg to 0.5µg, and 28% when increased from 0.5µg 
to 1µg. BSA was used as a negative control. 1µg is the optimum concentration for the 










Figure 5.8.  Binding of gC1qR to gp41:  ELISA plate wells were first coated with 100 µl per 
well of 2 µg/ml of gp41 (1 h, 37º C).  Following blocking with 2% BSA for 1 h, wells were 
washed (3x with TBS-T) and incubated with different concentrations of gC1qR (1µg, 0.5 µg and 
0.25 µg/ml) in TBS, (1 h, 37º C). Bound gC1qR was then detected using mAb 74.5.2 anti-gC1qR 
(0.5 µg/ml) followed by sequential reaction with alkaline phosphatase goat anti-mouse IgG and 
pNPP. The absorbance of the color developed after 30 min was measured 
spectrophotometrically at 405 nm. Each data bar is a mean of each experiment run in duplicates 
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Figure 5.9. Identification of gp41 site on gC1qR: Microtiter plate wells were first coated with 
1 µg/ml HIV-gp41 (1 h, 37°C) and after washing and blocking with 5% non-fat dry milk, the 
bound gp41 was reacted (O/N, 4°C) with 2.5 µg/ml of biotinylated WT gC1qR or gC1R deletion 
(Δ) mutants and the reaction developed by standard ELISA procedure. Data shown are 
representative of three separate experiments run in duplicates. 
 
5.4.4 Binding of gp41 to gC1qR deletion mutants 
Since gC1qR does bind to gp41 in a dose dependant manner, we examined which 
residues on gC1qR are important for this interaction. As the 3S motif of gp41 located on 
residues 618 – 623 is identified as a gC1qR binder, we wanted to map the binding site 
on gC1qR that is complementary to this complex. Different concentrations of the 
deletion mutants of gC1qR , 174-180, 74-96, w233g and 204-218 were challenged with 
gp41 to assess binding. The deletion mutants of gC1qR were truncated due to the 
deletion of several residues from the full length sequence. The ELISA results showed 
binding was preferentially reduced when gp41 was challenged with the deletion mutant 
174 – 180.  Using WT gC1qR as a positive control, the results were compared against 
this point. gp41 bound 2 fold less to 174 – 180 in comparison to WT gC1qR. Deleting 
residues 204 –218 reduced gp41 binding to gC1qR by 45% whereas deletion mutant 
76-96 decreased binding to 75%. W233g is a truncated version of gC1qR with one 
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comparison to wild type gC1qR.  Thus, residues 204-18 are not very critical in 
facilitating the interaction between gC1qR and gp41 as deleting these residues did not 
have as much of an effect as Δ174-180, 74-96 and w233g did. The finding that only the 
deletion of residues 174-180 in gC1qR reduced gp41 binding dramatically to 33%, 
suggests that these 6 residues are involved in this interaction with gp41. Interestingly, 
the deletion of 6 residues had greater effect than the deletion of 22 residues (Δ74-96) 
and 14 residues Δ204 – 218. 
 
a)                                                                                  b) 
 
 
Figure 5.10. Interaction between HIV-1 gp41 3S motif and gC1qR.  a) Duplicate wells of a 
microtiter plate were coated with 100 µl of 2µg/ml gC1qR and incubated (O/N, 4 º C). Then, 
after blocking the unreacted sites with 5% non-fat dry milk, the bound gC1qR was reacted (1 h, 
37º C) with concentrations of synthetic gp41 3S peptide and the bound peptide detected using 
an affinity purified rabbit anti- S IgG.  In b) the reaction sequence was reversed in that the wells 
were first coated with 100 µl of 100 µg/ml 3S peptide, reacted with increasing concentrations of 
gC1qR and the bound gC1qR detected using rabbit anti-gC1qR IgG.  
 
5.4.5 Identification of the gC1qR site for the HIV-1 gp41  
Similarly, the binding of gC1qR to gp41 coated microtitre wells is also dose-dependent 
Figure 5.8. Subsequent binding assays comparing WT-gC1qR and its deletion mutants 
showed (figure 5.9) that only gC1qRΔ174-180 had a significantly reduced binding to 
gp41 (n=3). Furthermore, since the 3S motif of gp41 (residues 601-620) has been 
reported to be the binding site for gC1qR (Fausther-Bovendo et al., 2010), we generated 
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a synthetic peptide spanning the putative 3S residues (PWNASWSNKSLDDIW), and 
tested the ability of this peptide to bind to gC1qR coated wells. As shown in figure 5.10 
there was a strong and dose-dependent interaction over a wide-range of concentrations. 
Conversely, gC1qR was also able to bind to 3S-coated plates, which was inhibited by 
anti-3S antibody (data not shown). 
 
 
Figure 5.11: Interaction of ghA mutants with gC1qR: Microtiter wells were coated with 1.0, 
0.5 or 0.25  µg/well of gC1qR in carbonate buffer and the plate incubated at 4º C overnight. The 
next morning, contents were discarded and wells were blocked for 2 h with 2% BSA at 37º C. 
After washing with PBS + 0.05% Tween, 2.5 µg/well of ghA wild type, R162A, R162E and MBP 
was added and the plate was incubated 1.5 h, 37º C and 1.5 h at 4º C. Wells then were washed 
and anti-MBP (1/5000) was added, incubated for 1 h 37º C and the bound protein was detected 
using horseradish peroxidase conjugated IgG. After addition of OPD buffer, the colour developed 
was read at 450 nm.  
 
5.4.6 The ghA domain of C1q is the binding site for both gC1qR and gp41 
 Previous studies using both ligand blot and peptide mapping analyses have shown that 
gC1qR binds to gC1q predominantly via the A chain (ghA residues 155-164) and that 
the two adjacent Arg residues at positions 162 and 163 are critical for this binding 
(Ghebrehiwet et al., 2001). This conclusion was further substantiated by the finding that 
gC1qR binding to this A chain peptide was abolished when the two Arg residues were 
substituted with Gln residues (Ghebrehiwet et al., 2001).  In the present study, the 
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binding of gC1qR to recombinant ghA module was compared to ghA mutants in which 
the Arg at position 162 was substituted with either Ala (R162A) or Glu (R162E). As 
shown in figure 5.11 while gC1qR binds well to recombinant ghA, there was no binding 
with either ghA R162A or R162E. Similarly, the HIV-1 gp41 glycoprotein also binds to 
C1q to the same domain in the A-chain of gC1q (data not shown). 
 
Figure 5.12. The 3S motif carries the C1q and gC1qR binding sites. Schematic 
representation of the interaction between gC1qR, the 3S domain of HIV-1 gp41, and 





Figure 5.13. gC1qR shares  3-D structural similarity with gp41. Dimensional alignment of 
gp41 and gC1qR reveals that gC1qR shares a 3-D structural similarity with transmembrane 
protein gp41, with a p-value of 8.72E-6. One monomer of gC1qR (C chain, 176 residues) is 











5.5 Discussion  
As discussed earlier (Ghebrehiwet et al., 2001), the gC1qR molecule is targeted by a 
wide range of pathogenic microorganisms and as such is considered to be an emerging 
receptor for pathogen-associated molecular ligands. Among these important pathogens 
are: HCV and HIV-1, both of which suppress T cells via gC1qR (Yao et al 2004). HCV is a 
major cause of chronic hepatitis worldwide, and is the leading cause of hepatocellular 
carcinoma, and to date there is no effective treatment (Cummings et al., 2009).  
Similarly, the mortality and morbidity caused by HIV infection is staggering, with more 
than 34 million people infected presently and over a million-and half deaths worldwide 
in 2011 alone. Therefore, understanding at the molecular level, the virus-host cell 
interaction and, in particular, identification of novel molecular targets by which these 
pathogens cause pathology will not only give us insight into how they escape the 
onslaught of the innate immune defense mechanism, but may provide us with 
alternative approaches for designing better therapeutic targets  
 
Previous studies have shown that the 22 KDa non-glycosylated HCV core protein binds 
gC1qR on CD4+ T cells and induces an anti-proliferative response (Kittlesen et al., 2000). 
Suppression of T cells is considered to contribute to an extremely high rate of viral 
persistence and severe disease progression. Although the binding of HCV core protein 
has been identified to be in a domain within a long stretch of gC1qR comprising of 
residues 188-259, the precise binding site has not been identified. In this study, we not 
only confirmed that the interaction site is within this segment but also, using several 
gC1qR deletion mutants refined and mapped the HCV core protein site(s) on two gC1qR 
domains comprising of residues 144-148 and 196-202. These residues make up the 
loops in each monomer that connect 3 to 4 and 5 to 6, respectively, in the structure 
of the protein (figure 5.5). These prominent loops, which cover up much of the 
doughnut hole of the gC1qR homotrimer, are highly charged and probably form a 
binding cluster in space. Interestingly, the doughnut hole covered by these residues also 
overlaps with the binding site for HK (Ghebrehiwet et al., 2002). 
 
Similarly, the envelope glycoprotein gp41 of HIV-1 interacts with gC1qR on CD4+ T cells. 
This interaction is considered to enhance the destruction of uninfected T cells by 
activated NK cells thereby contributing to the persistently low level of T cell count seen 
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in the late phase of the disease (Fausther-Bovendo et al., 2010). While the gC1qR 
interaction site on gp41 has been mapped to the 3S motif and comprises of residues 
601-620 (Fausther-Bovendo et al., 2010), the complementary binding site for gp41 on 
gC1qR has not been identified.  
 
After preliminary experiments confirmed that gC1qR does bind to gp41 in a dose 
dependant manner, we were able to use several deletion mutants of gC1qR (74 – 86, 
174 – 180, w233g and 204 – 218) and challenge them with gp41 to observe for changes 
in affinity binding.  
 
Here, we have identified gC1qR residues 174-180 as the major binding site for HIV-1 
gp41. Domain 174-180, which has recently been shown to contain the cell surface-
binding site for soluble gC1qR, is a highly conserved loop, which connects 4 to 5 in 
the 3D structure of gC1qR (Figure 5.5). Previous studies by others have also shown that 
C1q, the natural ligand for gC1qR, binds to gp41 and the binding site was mapped to a 
complement site intact on a domain (residues 586-598), which is adjacent to the 3S 
motif of gp41 residues 601-620) (Thielens et al, 1993; Quinkal et al, 1999). Although the 
biological significance of this remains to be assessed, it is intriguing to find that the 
binding sites for both gC1qR and C1q are localized in the same stretch of the gp41 3S 
domain, and may therefore overlap (Figure 5.2). The biological implications of the 
simultaneous binding of gp41 and C1q to CD4+ T cells remain to be ascertained. Viral 
envelope proteins such the outer envelope protein gp120 of HIV-1 share certain 
structural  and functional similarities with C1q (Szabo et al., 2001). Three -dimensional 
alignment (Fig 5.13) of the gC1qR monomer with gp41, for example, reveals structural 
similarity between the two proteins. Therefore, it was predicted that proteins like 
gC1qR that are able to interact with C1q may also interact with isolated gp120 or even 
with the whole HIV-1 virus. Thus, gC1qR has been shown to effectively and dose-
dependently inhibit the production of one T-lymphotropic (X4) and one macrophage-
tropic (R5) strain in human T cell lines (MT-4 and H9) and human monocyte-derived 
macrophage cultures, respectively (Szabo et al., 2001). Interestingly, the extent of this 
inhibition was enhanced when gC1qR was first incubated with, and then removed from 
the target cell cultures before virus infection, compared to when the cells were infected 
with gC1qR-HIV mixtures (Szabo et al., 2001). Furthermore, these experiments showed 
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that although gC1qR did not bind to a solid-phase recombinant gp120, it showed a 
strong and dose-dependent binding of gC1qR to solid-phase CD4 (Szabo et al., 2001). 
Since gp120 within the gp120/gp41 complex determines viral tropism and the role of 
gp41 is to mediate fusion between viral and cellular membranes (Caffrey, 2001), gC1qR 
may prevent the latter process by binding to gp41 within the complex in the early phase 
of viral infection. While these results imply a beneficial role of gC1qR for the host, a 
darker side to this interaction is when gp41, potentially released during infection, 
interacts with cell surface gC1qR to favor viral survival through destruction of CD4+ 
cells (Stocker et al., 2000) (Vieillard et al., 2005). Since the great majority of dying cells 
during the later phase of HIV-1 infection are the uninfected CD4+ T cells, the interaction 
of gp41 and gC1qR can play a significant role in perpetuating the disease process by 
enhancing the autologous destruction of these cells (Fausther-Bovendo et al., 2010, 
Vieillard et al., 2005). The destruction of uninfected T cells is, therefore, postulated to be 




               a)     
                b)                 
Figure 5.14: Structural image to highlight the structure of gC1qR indicating hypothesised 
gp41 binding region: a) gC1qR in its solution face b) gC1qR in its membrane face. This 
structural image was constructed to highlight and visualise the suggested gp41 binding site 
which is shown in blue. The green regions represent the binding site for HK corresponding to 
regions 204-219 and yellow regions for C1q binding site being 74-96. 
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The identification of gC1qR domain 174-180 as the major binding site for gp41, 
therefore presents an alternative opportunity for the design of either peptide-based or 
antibody-based therapy that salvages CD4+ T cells from gp41 mediated destruction. This 
postulate is further substantiated by the fact that a synthetic peptide corresponding to 
domain 174-180 is able to block the interaction between gp41 and gC1qR. In addition to 
this, residues 174 – 180 appears to be a highly conserved sequence evident in a range of 
homologues, as shown in the table below 
 
gC1qR peptide MF-1 (aa 174-180)     I K N D D G K K A 
Trichomonas vaginalis G3 I K N D D L K K A 
Borrelia valaisiana  I K N D D G K K I 
Borrelia burgdorferi B31      I K N E D G K K V 
[Translation initiation factor (IF-2)] 
 
I K N D D G R K A 
Zebrafish    
 
Table 5.1: List of homologues that contain the sequence 174-180: A range of species share 
the highly conserved sequence 174-180 found in gC1qR  
 
The fact that such a wide range of organisms hold such a similar sequence, and present 
data supports the identification of this motif as a binding site, makes it extremely 












Endothelial Cell gC1qR and its effect on 
vascular permeability via bradykinin 
receptor 1 (B1R) 
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6.1 Abstract  
The endothelial cell (EC) receptor complex for high molecular weight kininogen (HK) 
involves two-component system: cytokeratin 1-uPAR (urokinase-type plasminogen 
activator receptor), and gC1qR-cytokeratin 1, required for the assembly and activation 
of the coagulation/KKS. FXII preferentially binds to the cytokeratin 1-uPAR complex 
while gC1qR is a high affinity receptor for HK and contributes to KKS activation leading 
to the generation of BK. BK, a potent vasodilator agonist, belongs to the kinin family of 
proinflammatory peptides, which induce their activity via two G-protein-coupled 
receptors: bradykinin receptor 1 (B1R) and B2R. B2R is constitutively expressed on a 
range of normal cells including ECs. However, B1R is induced and expressed by IL-1. 
We hypothesized that soluble gC1qR (sgC1qR) can serve as an autocrine/paracrine 
signal for the induction of B1R expression based on the evidence that (1) gC1qR is 
secreted by activated ECs at sites of inflammation, and (2) sgC1qR can bind to cells in a 
specific and dose-dependent manner. In this chapter it is being shown that (1) gC1qR 
binds to microvascular ECs predominantly via a gC1qR domain (residues 174-180); (2) 
sgC1qR induced enhancement of B1R expression by ECs dose-dependently; (3) The 
effect of gC1qR on B1R expression was greatly diminished by gC1qR lacking residues 
174-180 (gC1qR174-180) and by gC1qR154-162. Furthermore, (4) a synthetic 
peptide comprising of residues 174-180 mimicked the effects of the parent molecule. 
Although ECs normally express detectable amount of B1R, this base level expression 
increases slightly in the presence of gC1qR even after 2 hr incubation, indicating 
translocation of stored B1R. Finally, the binding of soluble gC1qR was predominantly 
through surface-expressed fibrinogen, which is inhibited by anti-fibrinogen antibodies. 
Thus, at sites of activation and inflammation, ECs secrete soluble gC1qR, which binds to 
a fibrinogen-like surface molecule. This interaction can enhance vascular permeability 
through upregulation of B1R de novo synthesis as well as rapid translocation of 






6.2 Introduction  
The EC receptor for HK involves two complexes: uPAR-cytokeratin 1 and gC1qR-
cytokeratin 1  (Joseph et al., 1996, Herwald et al., 1996, Hasan et al., 1998, Colman et al., 
1997, Pixley et al., 2011, Mahdi et al., 2001, Joseph et al., 2004). gC1qR serves as a zinc-
dependent high affinity receptor for HK. It is critical for the assembly and activation of 
the plasma KKS system leading to the generation of BK (Joseph et al., 1996, Pixley et al., 
2011). The KKS consists of three components (Kaplan, 2002): coagulation factor XII 
[FXII (or Hageman Factor, HF)], prekallikrein (PK), and HK. HK is known to release TNF-
α, IL-1β, IL-6 and IL-4 from human mononuclear cells (Khan et al., 2006). While FXII 
preferentially binds to the uPAR-cytokeratin 1, HK, which circulates in complex with PK, 
binds to gC1qR through residues located in its domain 5 (Kaplan, 2002).  Once factor XII 
is activated to factor XIIa, it converts prekallikrein to kallikrein, a process that is 
enhanced by heat shock protein 90 and/or the enzyme carboxypeptidase released by 
ECs (Joseph and Kaplan, 2005). Kallikrein digests HK to generate the first kinin 
produced from kininogens, the nonapeptide BK (NH2-Arg-Pro-Pro-Gly-Phe-Ser-Pro-
Phe-Arg-OH) (Kaplan, 2002). Kinins are potent vasoactive pro-inflammatory peptides 
that are generated in response to pathological stimuli by their kininogen precursors 
(Bhoola et al., 1992). BK belongs to the kinin family of proinflammatory peptides and is 
among the most potent vasodilator agonists known (Regoli and Barabe, 1980, Bhoola et 
al., 1992). Once generated, it is rapidly converted to des-Arg9-BK via the removal of the 
C-terminal arginine. BK induces its activity via two G-protein-coupled receptor 
subtypes: bradykinin receptor 2 (B2R) and to a lesser extent, B1R. These kinin 
receptors are expressed on both peripheral and central ECs, where they couple to the G 
proteins Gq and Gi to induce an increase levels of intracellular Ca2 and nitric oxide, which 









                                
Figure 6.1: The Kinin System: HK is able to bind to gC1qR and activate the vasoactive peptide 
BK causing the vessel wall to become more permeable, leading to an influx of tissue fluid 
causing inflammation (Valdes et al., 2009). 
 
While B2R is constitutively expressed on a number of normal cells including ECs, B1R is 
expressed at low levels but induced rapidly following tissue damage by IL-1 and 
responds to the carboxypeptidase product desArg9-BK (Leeb-Lundberg et al., 2001). BK 
has a higher affinity for B2R, des-Arg9-BK is a selective ligand for B1R. This BK receptor 
activation of both receptors is known to contribute to a number of acute and chronic 
diseases including hypotension, bronchoconstriction, pain and inflammation (Menke et 




During the inflammatory response, activated cells including ECs are known to 
overexpress and secrete soluble gC1qR (sgC1qR). Soluble gC1qR can bind to intact cells 
in an autocrine/paracrine manner (Peterson et al., 1997).  gC1qR can bind HK on ECs 
activate the kinin pathway (Kaplan et al., 2001). Ghebrehiwet et al (2013) have thus 
identified additional HK binding sites on gC1qR using gC1qR deletion mutants. In 
solution, BK is generated when mixed with HK, PK and FXII and incubated for hours. 
However, with the addition of gC1qR, this process can be completed within minutes. 
Thus, BK can be generated in the presence of soluble gC1qR. Therefore, once gC1qR is 
secreted into the pericellular milieu by activating cells, gC1qR can potentially bring 
upon BK generation in the presence of circulating PK, HK and FXII (Kaplan et al., 2001). 
Soluble gC1qR from culture supernatants of proliferating cells binds to U937 and ECs. 
Blocking gC1qR and B1R inhibits BK-induced angioedema (Bossi et al., 2009), which 
suggests that gC1qR could potentially behave as an autocrine signal to induce B1R 
expression. Therefore, blocking gC1qR could prove helpful in inhibiting the generation 
of BK, pointing a way forward to peptide based therapies to control vascular 
permeability and inflammation. Here, we show that gC1qR upregulates B1R on ECs via 
its interaction with surface expressed fibrinogen.  
6.3 Materials and Methods  
6.3.1 Chemicals and reagents 
 The following reagents and chemicals were purchased or obtained from the sources 
indicated: D-PBS with and without calcium and magnesium (Mediatech Inc, Manassas, 
VA); Dulbecco’s Modified Eagles Medium (DMEM); RPMI 1640, 100x 
Penicillin/Streptomycin, (GIBCO-Invitrogen); heat inactivated fetal bovine serum 
(FBS) (Hyclone); human serum albumin (HSA) (Immuno-US); p-nitrophenyl phosphate 
(pNPP) (Pierce); and Immu-Mount (Thermo Fisher). Alexa 488- or Alexa 594-
Streptavidin, Alexa 488- or Alexa 594-F(ab’)2, goat anti mouse or anti rabbit; FITC 
conjugated goat anti-mouse IgG F(ab’)2 or sheep anti-rabbit IgG F(ab’)2 (Invitrogen); 
and alkaline phosphatase (AP)–conjugated rabbit anti-goat IgG (Pierce), and C4d-EIA 
test kit (Quidel). 
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6.3.2 Expression of recombinant gC1qR and its deletion mutants 
The strategy for the construction of plasmids containing the full length as well deletion 
mutants lacking highly charged domains has been described in Chapter 5. 
6.3.3 Cultured cells 
Human brain microvascular endothelial cells (HB-MVECs) were cultured in EC Growth 
Medium-2 (EGM-2MV; Lonza,) containing 5% heat inactivated FBS as described 
previously (Yin et al., 2007). Cells grown to confluence on 2 % gelatin were first treated 
with 0.25 % trypsin, 0.01 % EDTA to dissociate cells from the gelatin matrix by 
incubation (30 min, 370 C) in 0.01 M Tris-buffered saline. The cells were then washed 
and sub-cultured in Dulbecco’s Modified Eagles Medium. Experiments were done with 
cells between passages 3-15. The U937 cell line was grown in suspension in RPMI1640 
containing 10% heat inactivated fetal bovine serum and 100 units/ml penicillin and 
100µg/ml streptomycin and maintained in a humidified air consisting of 5% CO2 and 
95% air as described (Randazzo et al., 1988). Prior to each experiment, the viability of 
cells was verified by trypan blue exclusion. 
6.3.4 Proteins and antibodies:  
Fibrinogen and rabbit anti-fibrinogen IgG were a generous gift from Dr. Dennis 
Galanakis (Stony Brook University). Purified rabbit IgG antibodies to bradykinin 
receptor 1 (B1R) and B2R were purchased from Abcam Inc. (Cambridge, MA) and 
affinity purified rabbit IgG (designated pAb UN-15) to a synthetic gC1qR peptide was 
generated commercially (GenScript, Piscataway, NJ).  
6.3.5 SDS-PAGE and Western blot analysis 
Analyses on SDS-PAGE was performed on a 1.5 mm thick slab gels according to the 
method of Laemmli (Laemmli et al 1970) with samples being run unreduced or reduced 
and alkylated by boiling for 5 min in the presence of 0.1 M dithiothreitol and 0.2 M 
iodoacetamide. After electrophoresis, the gels were stained either with Coomassie 
Briliant Blue, or silver stain, then destained and dried. Samples for Western blot 
analysis were first run on SDS-PAGE as above, then electrotransferred to PVDF 
nitrocellulose membranes, blocked with 5% non-fat milk containing Tris Base Saline 
201 
 
(TBS)-T (20 mM Tris-HCl, 150 mM NaCl and 0.05% Tween 20), and the bound proteins 
probed with the appropriate and specific antibodies. The bound antibodies in turn were 
visualized by chemiluminescence horseradish peroxidase-conjugated species-specific 
antibody followed by reaction with 4-chloro-1-naphthol substrate. 
6.3.6 Biotinylation of U937 cells 
A total culture of 125ml of U937 cells grown in FBS were used (25ml in 5 tubes), which 
corresponded to 125 x 108. The cells were first checked for viability. This involved 
adding 10µl of trypan blue to 1ml of cells and observing the cells under a microscope. 
Once the cells were verified for viability, the cells were spun down at 1400rpm for 8 
minutes. The supernatant was discarded and 3ml of DPBS was added to each pellet in 
each tube. The pellets were resuspended and pooled together and further DPBS was 
added to bring the volume up to 50ml. This mixture was then spun down at 1400rpm 
for 8 minutes. Once again, the DPBS was discarded and the pellet was resuspended in 
5ml DPBS and 100µl of NHS-LC-Biotin mix in DMSO at a concentration of 3mg/ml was 
added to the pellet mixture and left on a tumbler in the cold room for 2 hours. After this 
incubation, the mixture was spun down at 1400rpm for 5 minutes. The supernatant was 
discarded and 4ml of solubilisation buffer was added and the tube was left on ice for 1 
hour. Following this, the mixture was centrifuged at 1400rpm for 15 minutes and the 
supernatant was collected and transferred to separate eppendorf tubes. These tubes 
were spun down in a high speed centrifuge for 30 minutes and the supernantent was 
collected, aliquoted and stored at -20. 
6.3.7 Identification of membrane proteins by antigen capture assay 
U937 cells were first grown in either RPMI 1640 with heat inactivated FBS or serum-
free (without FBS). After the cells reached confluence (~1x106/ml), the contents of each 
culture flask (100 ml) were separately washed 3 x by centrifugation (800g, 4º C, 10 
min). Then, each cell pellet was re-suspended in 5 ml of 5 mM DPBS, pH 7.5 containing 
0.5 mM EDTA, 10 mM EACA, and 0.5 mM phenyl methyl-sulfonyl fluoride (PMSF). Cell 
membranes were then prepared by freeze thawing (five times) in liquid nitrogen 
followed by centrifugation (1 h, 45.000g, 4º C). The supernatant containing the cytosolic 
fraction was removed and the pellet containing the cell membrane was used to prepare 
membrane proteins by solubilization in DPBS containing 1% NP-40. The solubilized 
202 
 
membrane proteins were freed from insoluble material by centrifugation (1 h, 30,000g, 
4º C) after which the total protein concentration was determined by the detergent 
compatible Cultures with ≥95% viability were used for experiments. 
6.3.8 Protein Capture Assay 
Microtitre wells were coated with 100µg/well in coating buffer, pH 9.6 of the gC1qR 
peptide 174-180. As a positive control, the wells of gC1qR were coated at a 
concentration of 2µg/ml. This was coated to clarify that any protein(s) observed to bind 
to the peptide sequence of gC1qR would clearly have to bind to the full length protein 
itself if this binding is true. Once the plate was coated, it was incubated at 37°C for 2 
hours to ensure thorough binding. After this, the contents were discarded and the wells 
were blocked with 3% v/w Non-fat milk powder in TBS for 1 hour at 37°C. After this the 
wells were washed 3 x in TBS-T and 100µl of biotinylated and solubilised U937 
membrane lysates were added to each well. This was left at 37°C for 2 hours following 
overnight incubation at 4°C.  
6.3.9 Protein Precipitation 
Following overnight incubation with the U937 cell lysate, the wells were washed 3x 
with TBS-T and 100µl of glycine pH 2.6 was added to each well and left at room 
temperature in a shaker for 30’–1 hour. While this incubation was taking place, the 
required volume of Acetone needed was frozen. 1ml of each protein sample was to be 
pooled from the wells, thus 2 tubes with 4ml of acetone were labelled ‘174-180 peptide’ 
and ‘gC1qR’, and were both frozen at -20 for 30’–1 hour. Once the glycine incubation 
was over, each 100µl of glycine from the 174-180 peptide coated wells were pipetted 
out and pooled together in an eppendorf tube to give a total sample volume of 1ml (10 
wells at 100µl each). Whilst pipetting was performed to remove the glycine, the pipette 
tip was scraped against the well to ensure removal of all bound protein. The same 
procedure was performed for the gC1qR sample. Next, the cooled acetone was removed 
from the freezer and 1ml of each protein sample dissolved in glycine was added to their 
respective acetone tubes to give a new volume of 5ml. The tubes were then incubated at 
-20°C for up to 2 hours to allow complete precipitation. Next, the samples were 
centrifuged at 14,000xg for 10 minutes. The supernatant was discarded carefully 
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without disturbing the pellet. Next, the tubes were left uncapped at room temperature 
to allow any remaining acetone to evaporate.  
6.3.10 Silver Staining  
50µl of sample buffer was added to the pellet and resuspended and the samples were 
boiled at 100°C for 10 minutes. After spinning, the 50µl samples were loaded in a 12% 
SDS gel and 1µl of Biorad precision marker as standard. Silver staining method was 
used to visualise the proteins. The gel was placed in a clean plastic dish and washed in a 
generous amount of ultrapure dH20 2 times for 5 minutes each. Next, the gel was 
washed 2 x for 15 minutes in fixing solution (30% ethanol and 10% acetic acid). The gel 
was then washed 2 x for 5 minutes each in 10% ethanol. Following this, the gel was 
washed 2 x for 5 minutes in dH20. During this incubation, the sensitizer working 
solution was prepared by mixing 1 part Silver Stain Sensitizer with 500 parts dH20, 
(50µl Sensitizer with 25ml water). The gel was then sensitized for 1 minute and then 
washed 2 x for 1 minute each with dH20. During this incubation the Stain Working 
Solution was prepared by mixing 1 part Silver Stain Enhancer with 50 parts Silver Stain, 
(500µl Enhancer with 25ml Stain). The gel was incubated in this Stain Working Solution 
for 30 minutes. While the gel was being stained, the developer working solution was 
made by mixing 1 part Silver Stain Enhancer with 50 parts Silver Stain Developer, 
(500µl of Enhancer with 25ml Developer). Once the 30 minutes of staining was over, the 
gel was washed 2 x for 20 seconds each with dH20. Next, the developer working solution 
was added and the gel was developed for 2-3 minutes until the bands appeared. Once 
the desired band intensity was reached, the developer working solution was discarded 
and the stop solution, (5% acetic acid) was added to the gel for 10 minutes. Following 
this, the gel was washed briefly in water and covered in plastic. . 
6.3.11 Protein capture assay of solubilised membranes of U937 cells grown in 
serum free media 
U937 cells grown in serum free media this time were solubilised to form membrane 
lysates following the solubilising steps as described.  Following this, capture assay as 
mentioned in figure 6.7 was performed, along with the protein precipitation and Silver 
Staining procedure.  
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6.3.12 Western Blot of 174-180 peptide pull down assay from biotinylated, 
solubilised U937 membrane lysates grown in serum free media 
A 12% SDS-PAGE was prepared using the biorad rainbow marker. 50µl Sample buffer 
was added to the protein pellet and the sample was heated at 100°C for 10 minutes. 
Following a quick centrifuge the whole sample was loaded into the well and the gel was 
run at 120V and transferred onto PDVF membrane 
6.3.13 Western blot detection using Chemi-immunofluorescence 
Once the transfer was finished, the nitrocellulose membrane was carefully placed into a 
plastic cassette using tweezers and blocked for 1 hour at room temperature in blocking 
solution made up of 3% Non-fat milk powder in PBS. Following this, the membrane was 
incubated in HRP-Strepavidin at a concentration of 1:1000 in 1ml of 3% milk powder. 
This incubation was performed overnight at 4°C. The next morning the membrane was 
washed 5 x in TBS-T for 20 minutes each to ensure removal of any background. Next the 
membrane was placed in an open plastic wallet and sprayed with HyGLO Quick Spray 
which is a mixture of two reagents (Luminol enhancer and peroxide buffer) which 
allows a Chemiluminescene signal on HRP conjugated antibodies. The membrane 
immersed in the mixture was covered with the plastic wallet, and kept on for 1 minute. 
Following this, the excess substrate was blotted out with a paper towel and the 
membrane was transferred using tweezers to a fresh plastic wallet, which was taped to 
the Western Blotting Cassette and closed. The cassette and the Kodak films, which the 
bands would be lit up on, were taken to the dark room for developing. Once in the dark 
room, any handling of the films was carried out in darkness, the cassette was opened 
and the film was carefully placed on top. The first exposure was performed for 10 
seconds and the film was carefully removed and processed through the machine to 
visualise the transferred protein bands. 
6.3.14 Flow cytometry 
U937 cells were collected following trypsinisation, and washed in PBS-A buffer (PBS 
containing 1% BSA and 0.01% NaN3). Non-specific binding was blocked with 1 mg/ml 
human IgG or Fc fragments in PBS-A per 1x106 cells (30 min, 4°C) and primary Abs or 
the appropriate isotype-matched controls were added to the cells (30 min, 4°C). Cells 
were washed twice in PBS-A, and further incubated with FITC-labeled secondary Abs 
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(30 min, 4°C). The cells were washed in PBS-A, fixed in 10% formalin and analyzed by 
flow cytometry using FACSCalibur (Becton-Dickinson, Mountain View, CA). For each 
analysis, 5,000 events were collected. The data was analyzed using CellQuest Pro 
software (Beckton-Dickinson, BD).  
6.3.15 immunofluorescent microscopy  
Immunofluorescence studies were performed on either U937 cells or Human Brain 
Micro Vascular Endothelial Cells (HBr-MIVECs). The cells were grown on glass cover 
slips and the attached monolayer of cells incubated first with PBS containing 0.1% BSA 
and 1% heat inactivated human serum or 1mg/ml Fc fragments to block Fc receptors, 
followed by incubation with biotinylated gC1qR and FITC-conjugated secondary 
reagents, as described above. After fixing for 10 min with 10 % (v/v) formalin, the cover 
slips were air-dried and placed face-down onto microscope slides, sealed using 
mounting solution (Immuno-mount), and then examined by three-dimensional imaging 
using deconvolution microscopy. Staining with anti-von Willebrand factor (vWF) was 
included to ensure the authenticity of the EC phenotype.  
6.3.16 Solid-phase binding to microplate-fixed U937 cells  
The ability of gC1qR and its deletion mutants to bind to U937 cells was tested using a 
microtitre plate assay with fixed cells as described (Kennet et al 1980). Briefly, intact 
U937 cells (2 x 105 cells/well) were first attached (30 min, 22°C) onto poly-L lysine (10 
µg/ml in PBS, pH 7.4) coated duplicate ELISA wells. Subsequently, the cells were fixed 
(30 min, 22°C) by addition of an equal volume of glutaraldehyde (0.5 % solution in PBS), 
and the unreacted sites quenched with glycine-BSA (100 mM Glycine, 0.1% BSA in PBS, 
pH 7.4). Biotinylated gC1qR or deletion mutants ranging 0-5 µg/ml were added and 
incubated (60 min, 22º C) and the bound gC1qR proteins detected using AP-conjugated 
Neutravidin, followed by pNPP substrate.   
6.3.17 Effect of gC1qR on B1R and B2R surface expression  
To test the effect of gC1qR on the expression of B1R or B2R, ECs were first grown 
overnight, fibronectin coated 6-well plates in a volume of 1 ml of EGM-2MV medium to 
ensure that cell attachment was complete. After blocking with Fc receptors, gC1qR or its 
deletion mutants were added and incubated for either 2 hr or 24 hr. The supernatant 
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was then removed, cells washed in fresh medium, and incubated with 5 µg/ml of either 
anti-B1R or anti-B2R antibody (1 h, room temp). After removing the unbound antibody, 
the cells were washed and further incubated (1 h, room temp) with FITC-conjugated 
goat anti-rabbit IgG fixed with 10% formalin and analyzed by deconvolution 
microscopy. 
6.3.18 Statistical analysis  
Student t-tests were performed using statistical software (Excel; Microsoft, Redmond, 
WA, USA). A value of p=0.05 was considered to be a significant difference. (n  represents 
separate experiments performed in duplicates) 
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6.4 Results  
6.4.1 The full-length gC1qR (a1-282 residues) is located on the cell surface  
Previous studies have shown that the “mature form” of gC1qR (residues 74-282) was 
present on the cell surface. However, the presence of the full-length gC1qR (residues 1-
282) was not studied on the assumption that the full-length was synthesized as a “pre-
pro” protein in the mitochondria and then cleaved to generate the membrane associated 
“mature” protein. To determine if the full-length gC1qR was localized on the membrane, 
immunofluorescence studies were performed using a monospecific polyclonal IgG (pAb 
UN15) recognizing a synthetic peptide derived from the N-terminal residues 1-74. As 
shown in Figure 6.1, this antibody was able to stain the EC cell surface, and this staining 
was found to colocalize with that of mAb 74.5.2, which recognizes the HK site located 
within residues 204-218 of gC1qR  
 
gC1qR, being a membrane associated protein, can also be secreted into the pericellular 
milieu by proliferating stressed cells. It has been shown previously that this soluble 
gC1qR is capable of binding U937 cells (Peterson et al, 1997) in a dose dependent 
manner. We performed a series of cell staining experiments to examine whether sgC1qR 
also binds to ECs. When biotinylated sgC1qR was incubated with ECs, it was able to bind 
to the ECs dose dependently as the concentration of gC1qR increased.  Confirmation of 
this binding prompted us to see whether this cell attachment is mediated via residues 
174-189. Hence the cells were incubated with the gC1qR deletion mutant 174-180. The 
results revealed that the deletion mutant 174-180 bound poorly to the ECs (figure 6.3) 
suggesting that it is this domain that is involved in the cell attachment. Unbiotinylated 










Figure 6.2: Co-localization of the mature and full-length gC1qR on the cell surface of ECs. 
Human brain microvascular cells were grown on glass cover slips and the attached monolayer 
of cells were incubated first with PBS containing 0.1% BSA and 1 mg/ml Fc fragments to block 
Fc receptors, followed by incubation with either Mouse IgG1, kappa monoclonal (MOPC-21), 
mAb 74.5.2, or pAb UN15.  The bound antibodies were then probed with either Alexa-488-
F(ab’)2 anti mouse (B) or Alexa 594-F(ab’)2, anti-rabbit antibodies (C). The merged picture (D) is 
that of the staining with mAb 74.5.2, and pAb UN15. The image is a representative of 3 such 
experiments. The control staining with rabbit non-immune IgG, was similar to that in (A), and is 










Figure 6.3. Soluble gC1qR binds to ECs. a) Cells were first stained with biotinylated gC1qR 
ranging from 0-5 µg/ml) and the fluorescence intensity of each staining (n=2) was plotted to 
show dose-dependence. b) The comparative immunofluorescence staining between biotinylated 
gC1qR (5µg/ml), and biotinylated gC1qR deletion mutant lacking residues 174-180 (Δ174-180) 








Figure 6.4: Soluble gC1qR induces the expression of B1R. Endothelial cells were first grown 
for 24 h as described in the legend to Figure 6.1, until full attachment and cobblestone 
formation was achieved. The cells were then cultured with or without either 5µg/ml gC1qR for 
an additional 24 h. The expression of either B2R or B1R was then examined by incubation of the 
cells with the corresponding antibodies and analyzed by deconvolution immunofluorescence 
microscopy 
 
6.4.2 gC1qR binds to endothelial cells and induces the expression of B1R 
Activated cells or cells undergoing proliferation are known to secrete a soluble form of 
gC1qR, which is structurally and functionally similar to gC1qR purified from cell 
membranes (Peterson et al., 1997). However, the role of the soluble gC1qR is not 
completely understood. We have shown previously that soluble gC1qR, purified from 
culture supernatants of U937 cells, can bind to intact U937 cells and this binding was 
similar to that obtained with recombinant gC1qR (Peterson et al., 1997). Here, we have 
used immunofluorescence staining and deconvolution microscopy to show that 
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recombinant and biotinylated gC1qR can also bind to ECs (Figure 6.3) in a manner that 
is specific and dose-dependent and can be blocked by 10 molar excess of its unlabeled 
counterpart (data not shown).  In order to assess the biological implications of this 
binding, we first determined the optimal concentration for saturation, which was in the 
range of 2.5 to 5µg/ml. Then, experiments were performed to examine what effect such 
binding has on B2R and/or B1R expression.  While B2R is constitutively expressed, and 
ECs cultured alone therefore stained very strongly with anti-B2R as expected, there was 
nonetheless, a modest and quantifiable increase (~1.5-2 fold) in B2R surface expression 
when the ECs were cultured for 24 h in the presence of gC1qR (Figure 6.4). In contrast, 
while ECs have normally small amounts of B1R on their surface and is reflected by a 
very weak staining, the staining with ant-B1R increased considerably by increasing 
concentrations of gC1qR, reaching maximal staining at 5 µg/ml gC1qR (Figure 6.4).   
 
gC1qR was able to bind to the ECs in a dose-dependent manner. ECs cultured with 
gC1qR led to the induction of B1R. This prompted us to determine the sites/domain on 
gC1qR that are involved in binding to ECs and inducing B1R expression.  Biotinylated 
gC1qR deletion mutants were incubated with ECs and probed with AP-streptavidin. All 
the deletion mutants were able to bind at different degrees to fixed ECs. However, 
174-180, 154-162 144-162 and 196-202 bound poorly compared to WT gC1qR, 
suggesting that these domains are involved in binding to ECs and triggering B1R 
expression. Figure 6.5 displays the deletion mutants mentioned above bound to ECs 
with the same intensity as no gC1qR implying that they these residues are key players in 
B1R expression. The microscopy results revealed that deletion mutant 144-148 and 
212-223 bound to ECs the strongest out of the variants. However, none of the domains 
appeared to engage with the ECs as well as WT gC1qR, suggesting that the overall 






Figure 6.5: Comparison of the effect of WT gC1qR and its deletion mutants on B1R expression. The binding of biotinylated (2 µg/ml) gC1qR 
and various deletion mutants () to ECs was assessed by immunofluorescence microscopy (top figure). The mean intensity of each staining is plotted 





Figure 6.6: Protein(s) captured from U937 cell lysate using 174-180 peptide. ELISA-based 
antigen capture assay in which duplicate wells of a microtiter plate were first coated with 100 µl 
(100 µg/ml) of either gC1qR peptide MF-1 174-180 or peptide SF-1 144-162. After blocking 
with 1% BSA the wells were incubated (overnight, 4º C) with 100 µl of surface biotinylated 
U937 membrane proteins and the captured protein(s) subsequently detected with alkaline 
phosphatase-conjugated Neutravidin and developed following standard ELISA procedures.  
 
6.4.3 ELISA to capture proteins from Biotinylated U937 membrane cell lysate 
MF-1 peptide corresponding to the sequences 174–180 of gC1qR was coated on 
microtitre plates. When biotinylated U937 membrane lysates were added to the wells 
and probed with AP-Streptavidin. MF1 bound greatly compared to its control sample 
SF-1 (a peptide sequence extracted from the solution face of gC1qR). BSA was used as a 
negative control. As shown in figure 6.6 MF-1 bound protein(s) from the U937 lysate at 
a remarkable rate of nearly 6 folds greater than the control peptide indicating MF-1 was 











ELISA to capture proteins from U937 Cell 
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Figure 6.7: Intact gC1qR and gC1qR peptide 174-180 recognize the same membrane 
protein.  a) Proteins expressed from Cells grown in Serum, b) Proteins expressed from Cells 
grown in Serum free media. (Capture assay run on a 10% SDS gel under reducing conditions.) 
Each lane represents 41,000,000 cells) 125 x 108 were washed and resuspended in 3ml 
solubilisation buffer. 100ug/well of 174-180 peptide was coated on 10 wells, and 5ug/ml of 
gC1qR on another 10 wells and left at 37 degrees for 1.5 hours. Contents were discarded and 
wells were blocked with 3% BSA for 1 hour. Wells were washed 3 x in TBS-T and 100ul of cells 
were added to each well and incubated overnight at +4.  After the contents were discarded and 
wells  were washed 3x in TBS-T, 100ul of glycine was added to each well and left on a shaker for 
1 hour at room temperature. The glycine was pooled to give a total volume of 1ml for each 
protein sample, and this was added to 4ml cold Acetone, (4x Acetone to protein sample 
required). The mixture was left at -20 for 1 hour to allow precipitation of the proteins. Next, the 
samples were spun at 13,000 RPM for 10 minutes. Sample buffer was added to the pellet and 
run on a SDS-GEL. A) Lane 1: 174-180 peptide capturing protein from U937 cells grown in 
Serum. Lane 2: gC1qR used as a control to capture protein from U937 cells grown in Serum. . B) 
Lane 1: 174-180 peptide capturing protein from U937 cells grown in Serum free media. Lane 2: 




6.4.4 U937 Cell line used to identify proteins binding to 174-180 sequence of 
gC1qR 
The U937 cell line is derived from a histiocytic lymphoma male patient and displays 
many monocytic characteristics.  It can be used as a model to study the differentiation of 
monocytes to macrophages. The cell line produces a range of cytokines and growth 
factors including IL-1β, a pro-inflammatory cytokine, which is involved in inflammation 
and works to recruit leucocytes to fight infection. GM-CSF (Granulocye Macrophage 
Colony Stimulating Factor) is a growth factor expressed by U937 cells. It stimulates the 
proliferation and differentiation of precursors of monocytes.  GM-CSF has also shown to 
stimulate the production of the anti-inflammatory cytokine IL-10 in U937 cells. Another 
protein expressed by U937 cells includes VPF (Vascular Permeability Factor), which is a 
protein secreted by tumor cells that provides a blood supply that supports the 
metastasis of tumors. MDSF (Monocyte derived scattering factor) is also released by 
U937 cells which increases the motility of the cell 
6.4.5 Proteins captured from U937 Cell lysate using 174-180 peptide 
Once the ELISA performed using the 174 – 180 peptide to capture from the U937 lysate 
showed indication of a pull down (Figure 6.6), the next step was to identify what 
molecule(s) this conserved sequence was capturing.  Using glycine to break the bonds 
between the peptide and the captured protein(s), the sample of interest was eluted into 
acetone to allow precipitation of the protein(s). Once run on a 12% SDS gel and 
visualised using Silver Stain gel, 3 bands were observed corresponding between the 50 
and 75kDa marker. A doublet was also seen which appeared to be above the 25kDa 
marker.  Figure 6.7a shows the capture assay performed on U937 cells cultured in 
serum media. After confirmation of the 3 bands, it was proposed to ensure that any 
proteins being captured were not picked up from the serum. Such a possibility could 
occur due to serum proteins binding to proteins expressed by U937 cells, therefore 
enabling them to remain in the membrane lysate. To eliminate this possibility, the cells 
were grown in serum free media. As figure 6.7b 18 shows, the same 3 bands were 
expressed, which confirmed that the captured proteins were not serum-derived. The 
bands in figure 6.7, lane 1 (174 – 180) were much more abundant than the protein 
bands captured by gC1qR in lane 2, this was probably due to other proteins in the lysate 
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binding to gC1qR which could have masked the 174 – 180 binding site, therefore 
resulting in a lower amount of protein being pulled down. The gel was subjected to 
mass spectromic analyses. However, due to high keratin contamination, the bands were 
not able to be detected. The next mode of action was to have the pellet itself digested 
which would greatly reduce keratin contamination. However, this produced many 
protein hits (see appendix) which could have again been masking the protein(s) of 
interest, indicating that the sample was not pure enough. Both gels were run under 
reducing conditions, therefore it was interesting to see how the protein(s) behaved 
under non reducing conditions on a 6% gel. However after such a experiment was 
performed, no bands were seen on the gel (data not shown) which suggested the point 
that the protein exists as a trimer and that under non reducing conditions, is too large to 




                                                
 Figure 6.8:  Western Blotting to show 174-180 capturing U937 cell surface proteins 
grown in Serum free media. U937 cells were washed and resuspended in 5ml DPBS, to which 
100ul of DMSO-LC Biotin Mixture (3mg/ml) was added and left on a shaker for 1-2hrs at +4. 
Cells were solubilised. Protein capture assay and protein precipitation was carried out as 
described previously and samples were run on a 10% SDS gel. The captured proteins were 







6.4.6 Western Blotting to visualise 174- 180 peptide capturing proteins from 
biotinylated U937 membrane lysate 
Once the Silver Staining of the precipitated captured protein(s) confirmed the presence 
of a trimer between 50 -75kDa and a doublet above the 25kDa marker, we wanted to 
confirm that these identified proteins were essentially expressed on the surface of U937 
cells. As the cell lysate was biotinylated, western blotting and probing with a 
streptavidin conjugate would verify the surface location of these proteins. As shown in 
figure 6.8, the western blotting detected the same trimeric bands between the 50 and 
75kDa marker, as well as the doublet corresponding above the 25kDa marker. This 
validated that the proteins being captured from the lysate were on the surface of these 
U937 cells.  
  
 
Figure 6.9: Western blotting to detect fibrinogen: Protein capture assay and protein 
precipitation was carried out as described previously of the U937 cell lysate and samples were 
run in duplicates run on a 10% SDS gel with the addition of Fibrinogen (FGN) in duplicates too . 
The gel was transferred onto PDVF membrane as described and blocked in 5% non fat milk in 
TBS for 1 hour at room temperature. The blot was cut to separate the transferred bands and one 
strip was probed with rabbit anti-Fibrinogen and the other strip with Non Immune Rabbit IgG. 
Following three washes with TBS-T for 10 minutes each, the secondary antibody used was 
rabbit anti goat. The bound antibodies in turn were visualized by chemiluminescence 
horseradish peroxidase-conjugated species-specific antibody followed by reaction with 4-
chloro-1-naphthol substrate The three bands between 75 and 50 kDa in lanes 1 and 2 in (B) are 
the , , and  chains of fibrinogen, and are recognized by anti-FGN IgG and not by non-immune 





The protein capture assay analysed by SDS-PAGE and Western blotting revealed three 
bands corresponding between 50-75kDa. Such a three-chain molecule and its molecular 
weight suggested that this could potentially be fibrinogen. gC1qR is known to bind to 
fibrinogen (Lu et al, 1999) specific to the D domain and the γ chain also contributing to 
the interaction. The fact that this gC1qR/FGN interaction was possibly occurring on the 
cell surface, encouraged us to identify this three chain protein. We performed a western 
blot in duplicates, identical to the one mentioned with the addition of FGN as a positive 
control.  The one transferred lysate was probed with anti-FGN IgG and the other one 
with Non Immune Rabbit IgG (NIRG) as a negative control and. As shown in figure 6.9, 
anti-FGN Ab was able to pick FGN as well as all three chains, α, β and γ of FGN from the 
U937 membrane cell lysate. NIRG, as expected, was not able to pick up either of the 
transferred bands confirming that three bands observed in figure 6.9 are the α, β and γ 
chains of FGN. 
6.4.7 Anti-fibrinogen IgG inhibits gC1qR binding to U937 cells  
To further validate the gC1qR binding to cell surface FGN, we performed a standard 
ELISA using microtitre fixed U937 cells to see if anti-FGN was able to inhibit the binding 
of gC1qR to FGN. gC1qR binding to FGN was reduced in the presence of anti-FGN Ab 
when compared to NIRG and PBS, which were used as positive controls further 









Figure 6.10: Anti-fibrinogen IgG inhibits gC1qR binding to U937 cells. The binding of 
biotinylated gC1qR to microtiter plate-fixed U937 cells was assessed by standard ELISA to 
examine the ability of gC1qR to bind U937 cells in the presence or absence of anti-fibrinogen IgG 
or non-immune rabbit IgG as control. U937 cells were first attached to 96-well microtiter plates 
using poly-L-Lysine and fixed as described (Kennet, 1984; Ghebrehiwet et al., 1996). Anti-FGN 
IgG in PBS, NIRG and PBS were added to the wells and incubated at 37°C for a hour. The wells 
were washed three times in TBS-T and 3µg of biotinylated gC1qR was added to each condition 











Figure 6.11. Fibrinogen and gC1qR are co-localized on the surface of U937 cells. U937 cells that were grown to confluence in serum-free 
medium, were first incubated with either 5 µg/ml rabbit non-immune IgG (RbIgG) or MOPC-21 (MsIgG) or rabbit anti-fibrinogen or mAb74.5.2 anti-
gC1qR. The bound antibody was then visualized using Alexa-488-(green) or Alexa 594 (red)-conjugated F(ab’)2 secondary antibody. After fixing, the 













Figure 6.12. Co-localization of gC1qR and fibrinogen on the endothelial cell surface. (A) 
ECs were grown on cover slips and incubated with either ant-FGN (anti-FGN), biotinylated-
gC1qR (Biot.gC1qR) or both (merge). Cells incubated without primary antibody (No 1eAb) were 




Figure 6.13: Co-localisation of FGN and gC1qR:  Cells showing co-localization of FGN and gC1qR (merge) were subjected to 3D rotation to show 
staining of cells as seen from the front (or top), the side (90º rotation), or back (360º rotation) views. 
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6.4.8 Co-localisation of gC1qR and FGN on the cell surface of U937 cells and ECs 
We sought to visualize the colocalisation of FGN and gC1qR on the cell surface of U937 
cells and ECs. We first verified the presence of FGN and gC1qR individually by 
incubating the cells with anti-fibrinogen and biotinylated gC1qR followed by anti-gC1qR 
74.6.2. Probing of the antibodies using Alexa-488-(green) or Alexa 594 (red)-conjugated 
F(ab’)2 secondary antibody and visualizing using deconvolution microscopy showed the 
clear prescence of both FGN and gC1qR on the cell surface of U937cells and ECs (figure 
6.11 and 6.12). To verify the interaction of these two proteins on the cell surface, we 
also investigated the colocalisation of FGN and gC1qR using immunoflurorescnt 
microscopy. The analysis of this colocalisation was confirmed by the merging of anti-
FGN and gC1qR (figure 6.11 and 6.12) clearly showing the interaction between gC1qR 
and FGN. The staining on both types of cells appeared to be robust implying that cell 
surface FGN is the ligand for soluble gC1qR. The negative control used in both 
experiments was NIRG which showed no binding (figure 6.11 and 6.12). The staining of 
FGN and gC1qR together was also subjected to rotation to visualize the staining from 





Figure 6.14: Comparison of the expression of fibrinogen and von Willebrand factor on EC surface. Cells were grown on cover slips and 
incubated with either 5 µg/ml anti-fibrinogen (C), anti-von Willebrand factor (B) or species-matched IgG (A). The bound antibody was visualized 
using Alexa-488-F(ab’)2 secondary antibody as described in Methods.  
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6.4.9 Domain 174-180 is the primary attachment site for soluble gC1qR 
Soluble gC1qR is able to bind to various cell types including U937 (Peterson et al., 
1997)and ECs. However, neither the domain of gC1qR that allows for such binding nor 
the cellular entity that is the site for gC1qR binding is known. In an effort to identify the 
gC1qR domain that is the potential biding site, we compared the binding of wild type 
gC1qR with 10 gC1qR deletion () mutants lacking highly charged surface exposed 
domains. As shown in Figure 6.5, gC1qR lacking residues 174-180 or 144-162 and 154-
162 consistently showed diminished binding to ECs suggesting that at least two sites 
exist: one at 174-180 and another in an overlapping site between 144-162 and 154-162. 
Because subsequent binding studies using microtitre plate fixed U937 cells showed 
consistently a diminished binding with gC1qR174-180, we generated two synthetic 
peptides: one corresponding to residues 174-180 and another to 144-162. These 
peptides were then used in an antigen-capture ELISA to pull down solubilized 
membrane protein(s) from surface biotinylated U937 cells. As shown in Figure 6.6, only 
peptide 174-180 was able to pull down a biotinylated membrane protein(s). To identify 
of the captured protein, pull down experiments were performed using intact gC1qR and 
peptide 174-180. When the captured U937 membrane proteins were analyzed by 
Western blotting under denaturing and reducing conditions (Figure 6.9), a molecule 
with a chain structure and molecular weight that resembled fibrinogen (FGN) was 
visualized.  
6.4.10 Cell surface expressed fibrinogen is the ligand for soluble gC1qR  
 The presence of FGN on cell surfaces has not, to our knowledge, been reported before. 
Therefore to examine the presence of FGN on the cell surface, we used ant-FGN to 
examine the presence of FGN on U937 using microplate–fixed U937 cells grown either 
in complete medium containing fetal bovine serum or serum-free growth medium. 
Results showed a strong anti-FGN binding when compared to isotype- and species-
matched IgG (data not shown). Then experiments were done to determine if anti-FGN 
antibodies could inhibit gC1qR binding to microplate-fixed U937 cells. As shown in 
Figure 6.10, a statistically significant inhibition (p=0.032) was observed when cells 
were pretreated with anti-FGN prior to incubation with gC1qR.  Subsequent 
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immunofluoresence experiments confirmed the presence of FGN on U937 cells (Figure 



































gC1qR is synthesized as a full-length protein of 282 residues, which is then cleaved at 
position 73-74 to generate the membrane-bound mature form (residues 74-282) 
(Ghebrehiwet et al., 1994). However, when a monospecific polyclonal antibody 
recognizing a peptide (residues 50-63) in the gC1qR region covered by residues 1-73 
was used in immunofluorescence studies, a robust membrane staining was observed 
(Figure 6.1) indicating the presence of either the full-length protein or a fragment that 
contains residues 1-73. This staining was comparable to the staining observed with 
mAb 74.5.2, which recognizes residues 204-218. Thus, in addition to its localization 
inside the cell, the full-length molecule is localized on the membrane (Kim et al., 2009) 
probably via a CRAC (cholesterol recognition amino acid consensus) motif present on 
gC1qR.  
 
Most proliferating or activated cells are known to overexpress and secrete gC1qR that 
can potentially modulate a diverse range of biological functions including angiogenesis 
(Bossi et al., 2011), vascular permeability (Joseph and Kaplan, 2005) (Ghebrehiwet et al, 
2013) and inflammation (Ghebrehiwet et al 2013) through complement activation and 
the kinin/kallikrein systems (KKS). This is partly due to the susceptibility of gC1qR to 
proteolytic cleavage by enzymes in plasma, or membrane-associated enzymes such as 
Membrane type 1 metalloprotease (MT1-MMP) as shown earlier (Rozanov et al., 2002).    
Soluble gC1qR (either recombinant or purified from cell cultures), can bind to U937 
cells (Leeb-Lundberg et al., 2001). Here, we wish to (a) examine if gC1qR also binds to 
ECs; (b) identify the surface molecule(s), which serves as the gC1qR site; and (c) assess 
whether gC1qR can serve as an autocrine/paracrine signal for the induction of B1R, 
which, unlike B2R, is induced by IL-1 (Menke et al., 1994; Hess et al., 1992; Mceachern 
et al., 1991; Marceau and Regoli, 2004).    
 
Here, we show that gC1qR binds to ECs in a dose-dependent manner (Figure 6.2 and 
6.3), enhances B2R expression, and induces B1R expression on ECs (Figure 6.4). When 
binding of wild type gC1qR to U937 cells or ECs was compared with a range of gC1qR 
deletion mutants each lacking in a highly charged region exposed on the surface of the 
molecule (Jiang et al., 1999; Ghebrehiwet et al 2002), the binding of gC1qR deletion 
mutants lacking in residues 174-180, 144-162 and 154-162 were significantly reduced 
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when compared to wild type gC1qR (Figure 6.5).  However, only peptide 174-180, and 
not 144-162, was able to recognize a membrane protein from U937 cells. Thus, initial 
gC1qR interaction site may be located on the domain 174-180 with subsequent multiple 
interactions via other sites including residues 144–62. While both gC1qR- and peptide 
174-180 captured a membrane protein from U937 cells, peptide 144-162 did not. The 
captured protein(s), in turn, appears to be surface bound fibrinogen. In the pull-down 
experiments (Figure 6.7), a three-chain molecule similar to fibrinogen appeared on SDS-
PAGE. In addition, anti-fibrinogen antibodies inhibited binding of gC1qR to U937 cells. 
Both U937 (Figure 6.11) and ECs (Figure 6.12 and 6.13) stained strongly for fibrinogen 
(Figure 6.14). Recombinant gC1qR has previously been shown to bind human 
fibrinogen and interfere with its polymerization (Lu et al., 1999). The binding site for 
gC1qR was found to be on the D domain of fibrinogen/fibrin, with the carboxy-terminal 
segment of fibrinogen/fibrin γ chain being important for this interaction, suggesting a 
potential role for gC1qR in modulating fibrin formation at the site of injury or 
inflammation (Lu et al., 1999). Therefore, the gC1qR/finrinogen interaction taking place 
on the EC surface represents a novel biological function for soluble gC1qR in regulating 
local inflammation.  
 
Thus, soluble gC1qR can bind ECs (Guo et al., 1999). Highly activated cells such as tumor 
cells or cells at inflammatory sites overexpress gC1qR on their surface, as well as 
release a soluble form of the molecule into the pericellular milieu. Each form of the 
gC1qR molecule (surface expressed or soluble) has been shown to play a role in the 
induction of inflammation by activation of the KKS as well as classical pathway of the 
complement system (Peterson et al., 1997). Thus, activation of the KKS leads to the 
generation of BK (residues Arg–Pro–Pro–Gly–Phe–Ser–Pro–Phe–Arg), which acts on the 
B2R to trigger vascular permeability. In humans, the half-life of BK is extremely short. It 
is rapidly degraded by three kininases: angiotensin-converting enzyme, aminopeptidase 
P, and the carboxypeptidases N (CP-N), or M, (membrane bound enzyme), which cleave 
the 7-8, 1-2, and 8-9 positions, respectively (Dendorfer et al., 2001, Kuoppala et al., 
2000). The first degradation product of BK–des-Arg9-BK–is more stable and possesses a 
high affinity for B1R. Although a detectable amount of B1R exists on the cell surface, 
B1R is induced by IL-1β produced by monocytes recruited to the inflammatory site. 
Soluble gC1qR is capable of inducing B1R expression, and thus enhances BK-mediated 
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vascular permeability. It is also able to recruit C1q, a powerful chemoattractant (Leigh 
et al, 1998), which like activated HK (HKa), is also able to generate proinflammatory 
cytokines such as TNF-α, IL-1β, IL-6, and the chemokines IL-8 and MCP-1 (Khan et al., 
2006; Van den Berg et al., 1998). Thus, at sites of inflammation or under pathological 
conditions such as angioedema, in which vascular permeability plays a central role, 
gC1qR can facilitate various pro-inflammatory cascades, and therefore, represents a 




















CHAPTER 7:  




7.1 Conclusions and future perspectives 
Since its discovery from Raji cells in 1994, gC1qR has undergone numerous 
nomenclatures including C1q binding protein (C1BP), mitochondrial protein p33, etc. 
starting as a C1q binder via the gC1q domain, gC1qR has been now established as a 
multi-ligand binder and multi-functional protein. This aspect has been dealt with n 
great details in the Introduction of this thesis. There are continued debates about the 
localisation of gC1qR-mitochondial, intracellular, cell surface, and extracellular? Like 
many proteins, the celluar localisation of these candidate receptor molecules is a 
subjective matter dependent on the cell type, local environment, techniques used, and 
the context of health and disease. The gC1qR counterpart, CRT, also went through this 
debate from being endoplasmic reticulum resident protein to trapped in lipd raft, and 
then from being on the cell surface (anchored to CD91) to being secreted. However, the 
fact that gC1qR is exclusive in binding to the globular head domain of C1q remains 
interesting and intriguing. With the availability of the recombinant forms of individual 
globular head modules (ghA, ghB and ghC) and a number of single residue substitution 
mutations, it became possible to re-examine the nature of interaction between gC1qR 
and gC1q domain of C1q. In addition to establishing ionic interaction between gC1q and 
gC1qR, the current study highlighted a central role for A chain and residue Arg162 in the 
protein-protein interaction. The biphasic upregulation of expression of gC1qR and C1q 
in adherent monocytes appears to suggest their autocrine/paracrine relationships. The 
downregulation of gC1qR in response to LPS challenge appears to suggest that gC1qR 
involvement in processes involving direct interaction with LPS is not required although 
C1q remains a crucial innate immune component. Experiments have been set up and are 
being carried out currently in our laboratory to examine if individual gobular head 
modules, on their own, exrert anti-lymphoproliferative effect or have additive effects of 
C1q-mediated effect on PHA-stimulated PBMCs. We are also asking the question if this 
effect of glubular head modules or C1q can be modulated by soluble form of 
recombinant gC1qR. These studies are being carried out to establish a clear biological 
link between C1q functions and gC1qR in the regulation of inflammation and immune 
activation. 
The novel finding of a tripartite interaction between C1q, gC1qR and DC-SIGN needed 
further exploration. Having established the nature of interaction between these three 
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crucial molecules that are associated with the HIV-1 infection of dendritic cells, 
experiments are in progress to examine how DC-SIGN mediated HIV-1 infection is 
modulated by recombinat globular head modules independently as well as in concert 
with gC1qR, given that both gC1qR and C1q are gp41 binders. We are culturing HEK293 
and U937 cells transfected with lentivirus construct that expresses full-length DC-SIGN 
on the cell surface. The ability of C1q, recombinant ghA, ghB and ghC modules, and 
gC1qR to enhance or inhibit viral entry via DC-SIGN and viral replication in vitro is 
being examined.  HIV-1 induced cytokine storm in the transfected U937 cell line in these 
assays will be monitored via qPCR analysis and cytokine array. This will be followed up 
by examining phosphorylation of key kinases p38, Erk1/2 and AKT, which contribute to 
HIV-1 induced immune activation using commercially available antibodies.  
 
An indicator anti-HIV-1 assay is also being carried out that relies on the generation of 
blue foci of infection in the cellular background. HIV-1 infection is quantified using TZM-
bl cells, which express luciferase as well as β-galactosidase genes under the control of 
the HIV-1 LTR promoter. TZM-bl cells (6 X 103) are grown in a 96-well tissue culture 
plate for 24 h. In separate tubes, 100 TCID50 units of HIV-1 (strains: HIV-1LAI, HIV-1 
IN93/905, HIV-1 98/IN/017 and HIV-1 96USNG31) are pretreated with indicated 
concentrations of C1q, globular head modules and gC1qR and the opsonised virus is 
allowed to infect TZM-bl cells. After 4 h, excess virus is washed with 50mM PBS, fresh 
medium was added, and then cells are incubated for an additional 48 h. Next, cells are 
washed twice with PBS, fixed in 1% glutaraldehyde for 10 min at room temperature 
followed by staining with X-gal staining solution (10ml PBS with 1mg/ml X-gal 
dissolved in DMF, 100mM potassium ferricyanide, 100mM potassium ferrocyanide and 
1mM MgCl2) for 24 h at 37°C. The blue stained (β-gal expressing) foci are counted under 
the microscope. 
 
Quantitation of p24 levels as a marker of viral replication is being carried out in culture 
supernatants. Different concentrations of soluble recombinant proteins will be pre-
incubated with 100 TCID50 of HIV-1 96USNG31 for 1h before addition to HEK-DC-SIGN 
cells. After 4h, residual virus is removed, cells are washed and fresh medium added. On 
day 3, 6, 9 and 12, 100 µl supernatant was collected. Viral replication will be determined 
by the HIV-1 p24 Antigen Capture Assay ELISA (XpressBio). The cytokine and groth 
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factor analysis will be done using Cytokine Array 1 kit for IL-1α, IL-1β, IL-2, IL-4, IL-6, 
IL-8, IL-10, IFN-, TNF-α, MCP-1, VEGF, and EGF. These experiments will help us 
understand the roles played by C1q and gC1qR in association with DC-SIGN in HIV-1 
infection of dendritic cells and perhaps by-stander cells. Having established gC1qR as a 
pattern recognition receptor of viral proteins using HCV core protein and HIV-1 gp41 as 
a model system, the identification of complementary binding sites may have 
implications in therapeutic strategies. Again, after optimising the infection assays, these 
therapeutic peptides can be used in the HIV-1 infection assay, as described above. 
 
The identification of a role for gC1qR as an inducer of B1R on the endothelial cells is 
very interesting. Since tumour cells overexpress gC1qR which are secreted as well as 
surface-bound, they can give rise to basal level of inflammation that can promote 
tumourogenesis and metastasis involving activation of KKS as well as the classical 
pathway. Bradykinin mediated initiation of vascular permeability via B2R, and 
subsequently via B1R offers an excellent target for therapeutically controlling these 
inflammatory processes. Thus, IL-1mediated upregulation of B1R surface expression 
is acted upon in concert by gC1qR. This paves the way to identify agonists and 
antagonists. It will be worth examining if adherent monocytes overexpress gC1qR and 
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